2013N165256_06 CONFIDENTIA L
The GlaxoSmithKline group of companies FGF117360
1TITLE PA GE
Division: Worldwide Development
Retention Category: GRS019
Information Type: Protocol Amendment
Title: Multi -arm, Non- randomized, Open- Label Phase IB Study  to 
Evaluate [COMPANY_004]3052230 in Combination with Paclitaxel and 
Carboplatin, or Docetaxel or as Single Agent in Subjects with 
Solid Malignancies and Deregulated FGF Pathway  Signaling
Compound Number: [COMPANY_004]3052230
Effective Date: 14-DEC -2015
Protocol Amendment Number:  [ADDRESS_471692]: squamous non-small cell lung cancer, FGFR, [COMPANY_004]3052230, HGS1036, FP1039, 
paclitaxel, carboplatin, docetaxel, FGFR1, FGF2, permetrexed, cisplatin
Author:
Oncology  Clinical Development, [LOCATION_003]
Precision Medicine and Diagnostics, Oncology , [LOCATION_003]
Quantitative Sciences -Oncolo gy, [LOCATION_003]
Biotransformation and Drug Disposition, PTS, [LOCATION_003]
Global Clinical Safety  and Pharmacovigilance, [LOCATION_003]
Cancer Research, [LOCATION_003]
Clinical Pharmacology  Modeling & Simulation, U SA
Quantitative Sciences -Genetics, [LOCATION_003]
Clinical I mmunology , [LOCATION_003]
GMP Operations Biopharm R&D, [LOCATION_003]
Oncology  Clinical Development, [LOCATION_003]
Copy right [ADDRESS_471693] been revised.
2013N165256_02 2013 -NOV-07 Amendment No. 2
Amendment No.2: This amendment applies to all sites. Sponsor medical monitor 
information was updated, the inclusion criterion for FGFR gene amplification was 
modified, clarifications were made to the Time and Events Table, vital sign 
measurements, and permitted concomitant medications; and contraceptive requirements 
were corrected.
2013N165256_03 2014 -FEB-03 Amendment No. 3
Amendment No.3: This amendment changed Arm C of the protocol from [COMPANY_004]3052230 
monotherap y of subjects with solid tumors to combination chemotherap y ([COMPANY_004]3052230 
plus pemetrexed and cisplatin) of subjects with mesothelioma. Asso ciated additions to 
the protocol include safety  precautions for pemetrexed and cisplatin, use of modified 
RECI ST for evaluation of clinical response, assessment of forced vital capacity . Patient 
reported outcomes using the L ung Cancer S ymptom Scale (L CSS) was added for 
subjects with lung cancer and L CSS-meso for subjects with mesothelioma. Additional 
background and rationale were added. Stoppi[INVESTIGATOR_377012]. 
Translational research objectives were clarified
2013N165256_04 2014 -FEB-03 Amendment No. 3
Amendment No.3 version 2: A minor correction to Amendment [ADDRESS_471694] -15 Amendment No. 4
Amendment No.4: The protocol medical monitor contact [CONTACT_377075].  Additional information on preclinical studies in mesothelioma was 
added in the background section, and clarifications were provided for modified RECI ST, 
the time & event tables, concomitant medications and Cockcroft -gault formula 
description.  In Arm B, the criteria for entry  has been broaden to greater than two prior 
lines of therap y.  The protocol was expanded to allow intra -subject dose escalation or de -
escalation.  This allows subjects who receive benefit during the d ose escalation to 
transition to the recommended expansion dose.  In addition, additional wording has been 
added to allow alternative dosing and schedules to be explored.   
2013N165256_06 CONFIDENTIA L
The GlaxoSmithKline group of companies FGF117360
32013N165256_06 2015 -DEC -14 Amendment No. 5
Amendment No.5: Changes including (1) the medical monitors contacts, (2) sy nopsis 
wording clarified to be consistent with the changes in Amendment 4 regarding confirmed 
diagnosis being Stage IIIB or IV for subjects in Arm A or B; (3) provide additional 
wording that chemotherapy  such as cisplat in should be administered per local standards, 
(4) providing additional guidance for [COMPANY_004]3052230 dosing with extended infusion 
timings and pre -medication per local institutional standard practice, (5) providing more 
flexible timing for subjects in Arm A scr eening who desire to start chemotherap y prior to 
[COMPANY_004]3052230 first dose, (6) providing new PK sampling for cisplatin for Arm C subjects, 
and (7) requiring total calcium instead of total calcium and ionized calcium at selected 
sites in the [LOCATION_006].
[COMPANY_003]
[COMPANY_003]
2013N165256_06 CONFIDENTIA L
FGF117360
5MEDICA L MONITOR INFO RMATION PA GE
Medical Monitor and Sponsor Contact [CONTACT_7171]:
Role Name [CONTACT_301229] -hours 
Phone/Cell/
Pager 
NumberFax 
Numb er[COMPANY_004] Address
Medical 
Monitor 
MD, PhDGlaxoSmithKline
[ADDRESS_471695]
[PO_BOX]
Collegeville, PA [ZIP_CODE] -0989, 
[LOCATION_002]
Email: 
Secondary 
Medical 
Monitor MDGlaxoSmithKline
[ADDRESS_471696], 
Collegeville, PA [ZIP_CODE] -0989, 
[LOCATION_002]
Email:  
Additional medical monitor or sponsor contacts may be provided in a letter to investigator during the course 
of the study conduct without involving a protocol amendment.   
Sponsor Registered Address:
GlaxoSmithKline Research & Development Limited
[ADDRESS_471697]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinic al trial sponsor may  be the local GlaxoSmithKline affiliate 
compan y (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_131980].
Regulatory  Agency  Identify ing Number(s):  
Compound Number IND Number EudraCT Number
[COMPANY_004]3052230 IND# [PHONE_7786] -000354 -21
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N165256_06 CONFIDENTIA L
FGF117360
6INVESTIGA TOR PROTOCOL AGREEMENT PA GE
For protocol number FGF117360:
Iconfirm agreement to conduct the study  in compli ance with the protocol, as amended b y 
this protocol amendment.
I acknowledge that I am responsible for overall study  conduct. I agree to personall y 
conduct or supervise the described stud y.
I agree to ensure that all associates, colleagues and employ ees assisting in the conduct of 
the study  are informed about their obligations. Mechanisms are in place to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782]
2013N165256_06 CONFIDENTIA L
FGF117360
7TABLE OF CONTENTS
PAGE
LIST OF ABBREVIATION S................................................................
........................... [ADDRESS_471698] in Cancer ....................................................................... 17
1.2. Lung Cancer ............................................................................................... 17
1.3. Mesothelioma ............................................................................................. 18
1.4. [COMPANY_004]3052230 .............................................................................................. 18
1.4.1. Background ................................................................................. 18
[IP_ADDRESS]. Preclinical data on [COMPANY_004]3052230 ................................ [ADDRESS_471699]-time-in-human study FP1039 -001........................................ 19
[IP_ADDRESS]. Clinical Pharmacokinetics of [COMPANY_004]3052230 ................. 20
[IP_ADDRESS]. Clinical Safety of [COMPANY_004]3052230 .................................. 20
[IP_ADDRESS]. Anti-tumor Activity with [COMPANY_004]3052230 ......................... 21
1.5. Chemotherapy (Paclitaxel, Carboplatin, Docetaxel, Pemetrexed, 
Cisplatin) ..................................................................................................... 21
1.5.1. Paclitaxel/Carboplatin .................................................................. 21
1.5.2. Docetaxel ..................................................................................... 22
1.5.3. Pemetrexed/Cisplatin ................................................................... [ADDRESS_471700] Dose Escalation or Dose De -escalation .................. 37
[IP_ADDRESS]. Alternative Dosing and Schedule Cohorts .................. 37
4.3. Rationale .................................................................................................... 37
4.3.1. Rationale for Evaluation of [COMPANY_004]3052230 in Chemotherapy 
Combinations ............................................................................... 37
4.3.2. Rationale for Dose of [COMPANY_004]3052230 ............................................. 37
4.3.3. Rationale for Endpoints ................................................................ 38
4.4. Study Treatment Assignment ...................................................................... 38
2013N165256_06 CONFIDENTIA L
FGF117360
84.5. Dosage and Administration of Study Treatments ........................................ 38
4.5.1. [COMPANY_004]3052230 ............................................................................... 38
[IP_ADDRESS]. Study treatments: Alternative Dosing and 
Schedule cohorts ........................................................ 38
4.5.2. Paclitaxel + Carboplatin ............................................................... 39
4.5.3. Docetaxel ..................................................................................... 40
4.5.4. Pemetrexed and Cisplatin ............................................................ 40
4.6. Safety Management Guidelines .................................................................. 41
4.6.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 41
[IP_ADDRESS]. Liver Chemistry Follow -up Procedures ....................... 41
4.6.2. QTc Stoppi[INVESTIGATOR_2121] .................................................................. 43
4.6.3. Left Ventricular Ejection Fraction (LVEF) and Valvular 
Toxicity Stoppi[INVESTIGATOR_2121] ............................................................. 44
[IP_ADDRESS]. LVEF Stoppi[INVESTIGATOR_2121] ............................................... 44
[IP_ADDRESS]. Cardiac Valve Toxicity Stoppi[INVESTIGATOR_2121] ..................... 44
4.6.4. Management of Diarrhea ............................................................. 45
4.6.5. Management of Fluid Retenti on................................................... 45
4.7. Dose Modifications ..................................................................................... 46
4.7.1. Dose Delays ................................................................................ 46
4.7.2. Hematologic Toxicity Related to Chemotherapy ........................... 46
4.7.3. Non-hematologic Tox icity Related to Chemotherapy ................... 47
4.7.4. [COMPANY_004]3052230 Dose Modifications ................................................ 49
[IP_ADDRESS]. [COMPANY_004]3052230 Dose Modifications regarding 
infusion related reactions ............................................ [ADDRESS_471701] ............................................................................. 50
5.1. Description of Investigational Products ....................................................... 50
5.1.1. [COMPANY_004]3052230 ............................................................................... 50
5.1.2. Chemotherapeutic Agents ........................................................... 50
5.2. Preparation/ Handling/Storage of [COMPANY_004]3052230 ........................................... [ADDRESS_471702] Completion Criteria ........................................................................ 52
6.3. Permanent Discontinuation from Study Treatment ...................................... 52
6.4. Study Completion ....................................................................................... 53
6.5. Treatment after the End of the Study .......................................................... 53
7.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 53
7.1. Time and Events Table ............................................................................... 54
7.2. Demographic/Medical History and Baseline Assessments .......................... 60
7.2.1. Critical Baseline Assessments ..................................................... 60
7.3. Safety Evaluations ...................................................................................... 60
7.3.1. Physical Examinations ................................................................ .61
7.3.2. ECOG Performance Status .......................................................... 61
7.3.3. Vital Signs .................................................................................... 61
7.3.4. Forced Vital Capacity ................................................................... 61
7.3.5. Electrocardiogram ........................................................................ 61
7.3.6. Echocardiogram ........................................................................... 61
2013N165256_06 CONFIDENTIA L
FGF117360
97.3.7. Ophthalmologic Examinations ...................................................... 62
7.3.8. Laboratory Assessments ............................................................. 62
7.3.9. Pregnancy Testing and Reportin g................................................ 63
7.4. Evaluation of Anti -Cancer Activity ............................................................... 64
7.4.1. Evaluation of Response in Arm A and Arm B (RECIST 
1.1).............................................................................................. 66
[IP_ADDRESS]. Evaluation of target lesions ......................................... 66
[IP_ADDRESS]. Evaluation of non- target lesions .................................. 67
[IP_ADDRESS]. New lesions ................................................................ 67
[IP_ADDRESS]. Evaluation of overall response .................................... 67
[IP_ADDRESS]. Evaluation of best overall response ............................ 68
7.4.2. Evaluation of Response in Arm C: Mesothelioma ........................ 69
[IP_ADDRESS]. Mesothelioma Tumor Imaging .................................... 69
[IP_ADDRESS]. Prior Scan collection ................................................... [ADDRESS_471703] Status 
and Translational Research ......................................................... 72
7.7.2. Peripheral Blood .......................................................................... 72
[IP_ADDRESS]. Plasma for Soluble Markers ........................................ 72
[IP_ADDRESS]. Circulating cell free DNA (cfDNA) Analysis ................. 73
7.8. Pharmacogenetics ...................................................................................... 73
8.ADVERSE EVENTS AND S ERIOUS ADVERSE EVENT S..................................... 74
8.1. Definition of an AE ...................................................................................... 74
8.2. Definition of a SAE ...................................................................................... 75
8.3. Disease -Related Events and/or Disease- Related Outcomes Not 
Qualifying as SAEs ..................................................................................... 76
8.4. Laboratory and Other Safety Assessment Abnormalities Reported 
as AEs and SAEs ....................................................................................... 76
8.5. Time Period and Frequency of Detecting AEs and SAEs ............................ 76
8.5.1. Method of Detecting AEs and SAEs ............................................. 77
8.5.2. Prompt Reporting of SAEs and Other Events to [COMPANY_004] .................. 77
8.5.3. Regulatory reporting requirements for SAEs ................................ 78
9.CONCOMITANT MEDICATI ONS AND NON -DRUG THERAPI[INVESTIGATOR_5165] ......................... 79
9.1. Permitted Medication(s) .............................................................................. 79
9.2. Prohibited Medications ................................................................................ 79
9.3. Permitted Non -Drug Therapi[INVESTIGATOR_014] ................................................................... 80
10.LIFESTYLE AND/OR DIE TARY RESTRICTIONS .................................................. [ADDRESS_471704] ATISTICAL CONSIDERAT IONS ................................... 82
2013N165256_06 CONFIDENTIA L
FGF117360
1012.1. Considerations of statistical design ............................................................. 82
12.2. Hypotheses ................................................................................................ .82
12.3. Sample Size Determination ........................................................................ 83
12.3.1. Arm A: [COMPANY_004]3052230 + Paclitaxel + Carboplatin .......................... 83
12.3.2. Arm B: [COMPANY_004]3052230 + Docetaxel ................................................ 83
12.3.3. Arm C: [COMPANY_004]3 052230 + Pemetrexed + Cisplatin ........................... 84
12.4. Sample Size Sensitivity ............................................................................... 84
12.4.1. Sample Size Re- estimation .......................................................... 84
12.5. Data Analysis Considerations ..................................................................... 84
12.5.1. Analysis Populations .................................................................... 84
12.6. Treatment Comparisons ............................................................................. 85
12.7. Interim Analysis .......................................................................................... 85
12.8. Key Elements of Analysis Plan ................................................................... 88
12.8.1. Anti-Cancer Activity Analyses ...................................................... 89
12.8.2. Safety Analyses ........................................................................... 89
[IP_ADDRESS]. Extent of Exposure ..................................................... 89
[IP_ADDRESS]. Adverse Events .......................................................... 89
[IP_ADDRESS]. Clinical Laboratory Evaluations .................................. 89
[IP_ADDRESS]. Other Safety Measures ............................................... 90
12.8.3. Patient Reported Outcomes ......................................................... 90
12.8.4. Pharmacokinetic Analyses ........................................................... 90
12.8.5. Pharmacokinetic/Pharmacodynamic Analyses ............................. [ADDRESS_471705] CONSID ERATIONS ............................................................... 92
13.1. Posting of Information on Clinicaltrials.gov .................................................. 92
13.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 92
13.3. Urgent Safety Measures ............................................................................. 92
13.4. Quality Control (Study Monitoring) .............................................................. 93
13.5. Quality Assurance ....................................................................................... 93
13.6. Study and Site Closure ............................................................................... 93
13.7. Records Retention ...................................................................................... 94
13.8. Provision of Study Results to Investigators, Posting of Information 
on Publicly Available Clinical Trials Registers and Publication .................... 94
14.REFERENCES ....................................................................................................... 96
15.APPENDICES ...................................................................................................... 102
15.1. Appendix 1: Pharmacogenetics (PGx) ...................................................... 102
15.2. Appendix 2: NYHA Functional Classification System ................................ 107
15.3. Appendix 3: COCKCROFT -GAULT FORMULA ........................................ 108
15.4. Appendix 4: ECOG Performance Status1.................................................. 109
15.5. Appendix 5: Liver Chemistry Monitoring, Interruption Stoppi[INVESTIGATOR_377013] w-up Criteria ...................................................................................... 110
15.6. Appendix 6: Urine Protein Creatinine (UPC) Ratio .................................... 111
15.7. Appendix 7: Country Specific Requirements ............................................. 112
15.8. Appendix 8: Protocol Amendment Changes .............................................. [ADDRESS_471706] OF A BBREVIATIONS
AE(s) Adverse Event(s)
ADA Anti- drug antibody
AIDS Acquired immunodeficiency  syndrome
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AML Acute m yeloid leukemia
ANC Absolute neut rophil count
AST Aspartate aminotransferase
AUC(0 -) Area under the concentration- time curve over the dosing interval
-HCG Beta-Human Chorionic Gonadotropin
BSA Body surface area
BUN Blood urea nitrogen
CAF Cytokines and Angiogenic Factors
Cav Aver age concentration
CBC Complete blood count
CfDNA Circulating cell free DNA
CL Systemic clearance of parent drug
CLCR Creatinine clearance
Cmax Maximum observed concentration 
CT Computed tomograph y
Cτ Pre-dose (trough) concentration at the end of the dosing interval
CO [ADDRESS_471707] observed quantifiable concentration
DLT Dose -limitin g toxicity
DNA Deox yribonucleic acid
EC Ethics committee
ECG(s) Electrocardiogram(s)
ECHO Echocardiogram
ECL Electrochemiluminescent
ECOG Eastern Cooperative Oncology  Group
eCRF Electronic case report form
EGF Endothelial growth factor
FDA Food an d Drug Administration
FGF Fibroblast growth factor
FGFR1 Fibroblast growth factor receptor [ADDRESS_471708] time in man
GCP Good Clinical Practice
GFR Glomerular filtration rate 
GGT Gamma glutamy ltransferase
2013N165256_06 CONFIDENTIA L
FGF117360
12[COMPANY_004] GlaxoSmithKline
HIV Human Immunodeficiency  Virus
h/hr Hour(s)
IB Investigator’s Brochure
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IgG1 Immunoglobulin G1
IHC Immunohistochemistr y
IND Investigational New Drug
INR International normalization ratio
IP Investigational Product
IRB Institutional Review Board
IU International Unit
IV Intravenous
kg Kilogram
L Liter
LDT/IUO Laboratory  developed test for investigational use only
LLN Lower limit of normal
LVEF Left Ventricular Ejection Fraction
MedDRA Medical Dictionary  for Regulatory  Activities
mg Milligrams
mL Milliliter
msec Milliseconds
MFD Maximum Feasible Dose
MPM Malignant pleural mesothelioma
MRI Magnetic resonanc e imaging
MTD Maximum tolerated dose
NSCL C Non-small cell lung cancer
NCI-CTCAE National Cancer Institute -Common Terminology Criteria for Adverse 
Events
NYHA [LOCATION_001] Heart Association
ORR Overall response rate
PD Progressive disease or pharmacod ynamics
PET Probability  of earl y termination
PFS Progression- free survival
PGx Pharmacogenetics
PK Pharmacokinetic
PO Per os, by [CONTACT_377076] b y Bazett’s formula
QTcF QT interval corrected for heart rate b y Fridericia’s formula
RAMOS Registration and Medication Ordering Sy stem
RAP Reporting and Anal ysis Plan
RBC Red blood cells
2013N165256_06 CONFIDENTIA L
FGF117360
13RECI ST Response Evaluation Criteria in Solid Tum ors
RNA Ribonucleic acid
SAE Serious adverse event(s)
SCCHN Squamous cell carcinoma of the head and neck
SD Standard deviation or stable disease
SMRP Soluble mesotheline -related peptides
SPM Study  Procedures Manual
t Time of last observed quantifiab le concentration
t1/[ADDRESS_471709] Upper limit of normal
[LOCATION_006] [LOCATION_008]
UPC Urine protein creatinine
US/[LOCATION_003] [LOCATION_002]/[LOCATION_002] of America
Vd Apparent volume of distribution after IV administration
WBC White blood cells
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_377077]
2013N165256_06 CONFIDENTIA L
FGF117360
14PROTOCOL SYNOPSIS
Title : Multi -arm, Non- randomized, Open- Label Phase IB Study  to Evaluate 
[COMPANY_004]3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single 
Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway  Signal ing
Protocol Number : FGF117360
Clinical Phase : IB
Compound: [COMPANY_004]3052230
Study Rationale : FGF receptor 1 ( FGFR1) amplification has been identified in 
approximately  20% of squamous non -small cell lung cancer (NSCLC) with suggested 
tumor dependence on fibrobla st growth factor (FGF) pathway  signaling in this subset. 
FGFR1 amplification has been associated with significantly  shorter disease free and 
overall survival in NSCLC [ Kim, 2013]. [COMPANY_004]3052230 inhibits the FGF pathway thro ugh 
binding and sequestering of FGF ligands and has demonstrated tumor growth inhibition 
in several tumor xenograft models [ Harding , 2013]. Carboplatin and paclitaxel can be 
used in first line therap y of metastatic N SCLC and docetaxel is a standard second line 
agent. Additive antitumor effect was demonstrated in tumor xenograft models treated 
with the combination of [COMPANY_004]3052230 and chemotherap y including paclitaxel and 
carboplatin as well as docetaxel. Based on the clinical and preclinical data, the 
combination of [COMPANY_004]3052230 in combination with chemotherap y will be investigated in 
patients with metastatic squamous NSCL C in Arms A and B.
FGF ligand -dependent signaling play s an important role in cancer development and 
tumor maintenance . [COMPANY_004]3052230 has been shown to inhibit tumor growth in non -
amplified FGFR1 tumor xenograft models where FGF2 mRNA was overexpressed 
[Harding , 2013]. Malignant pleural mesothelioma (MPM) is a tumor ty pe where FGF2 
ligand overexpression has been observed in a high percentage of primary  specimens and 
where [COMPANY_004]3052230 preclinical efficacy  has been observed in xenograft models. 
Pemetrexed and cisplatin are standard agents used in first line therap y of MPM. I nArm 
C, the combination of [COMPANY_004]3052230 and pemetrexed + cisplatin will be investigated in 
patients with MPM who are not surgically  resectable or have relapsed after surgery  or 
localized treatment.
Study Design : This will be a multi -arm, multicenter, non -randomized, parallel -group, 
uncontrolled, open -label Phase IB study  designed to evaluate the safet y, tolerability and 
preliminary  activity  of [COMPANY_004]3052230 in combination with paclitaxel + carboplatin in 
previously  untreated metastatic squamous NSCLC (Arm A), in combination with 
docetaxel in metastatic squamous NSCL C that has progressed after at least 1 line of 
chemotherap y(Arm B), or in combination with pemetrexed + cisplatin in MPM 
previously  untreated with chemotherap y or investigational agents (Arm C). 
Obje ctives and Endpoints:
The primary  objectives and endpoints are noted below. The full objectives and endpoints 
(primary, secondary  andexploratory ) are located in the main protocol in Section 2.
2013N165256_06 CONFIDENTIA L
FGF117360
15Primary Objective s:
To characterize the safety and tolerability  of [COMPANY_004]3052230 in combination with 
chemotherap y regimens.
To determine the regimen of [COMPANY_004]3052230 in combination with chemotherapy  for 
evaluation in future studies based on the maximum tolerated dose (or maximum
feasible dose).
To assess the overall response rate (ORR) in each treatment arm.
Primary Endpoints:
Measurements used to evaluate safety and tolerability  will include rate and severit y 
of adverse events (AEs), withdrawals due to AEs, dose interruptions an d reductions, 
treatment duration, and dose- limiting toxicities (DLTs) as well as change from 
baseline for the following: ph ysical examinations, vital signs,12- lead 
electrocardiograms (ECGs), echocardiograms (ECHO), clinical laboratory tests.
Maximum tolerated dose (MTD) or maximum feasible dose (MFD).
Best response defined as complete or partial response, stable disease or progressive 
disease according to Response Evaluation Criteria in Solid Tumors (RECI ST) 1.1. 
ORR defined as the proportion of subjects with investigator -assessed confirmed 
complete response or partial response per RECIST 1.1.
Hypotheses :
Arm A: H0: p≤25% versus HA:p≥45%
Arm B: H0: p≤10% versus HA:p≥25%
Arm C: H0:p≤40% versus HA: p≥60%
Number of Subjects : Approximately  70 subjects (minimum of 38 and up to 120, 
alternative dosing cohorts could potentially  add another 6 to ~40 subjects ).
Inclusion Criteria: A high level summary  of the inclusion and exclusion criteria are 
denoted below. The full details of inclusion and exclusion criteria are located in the main 
protocol Section 3.2.
1.Histologicall yor cy tologically  confirmed diagnosis:
Arms A and B: Stage IIIB or IV or recurrent metastatic squamous NSCL C (TNM 
Staging for NSCLC, 7thEdition) with FGFR1 gene amplification b y central 
laboratory  testing.
Arm C: recurrent after local treatment or unresectable MPM with measurable 
lesions .
For specific arms the following requirements:
Arm A: Subjects who have received no prior therapy  for Stage IV or recurrent 
metastatic disease. Note, to avoid any  undue delay of initiating sy stemic
chemotherap y for these s ubjects with newly  diagnosed metastatic disease, it is 
allowed to initiate the first cy cle of chemotherap y while eligibility for the study  is 
2013N165256_06 CONFIDENTIA L
FGF117360
16still being determined, as long as the first dose of [COMPANY_004]3052230 is given no later than 
Cycle 2 Day  1 of chemothera py.
Arm B: Subjects who have documented tumor progression (based on radiological 
imaging), or intolerability, after receiving onl y at least prior line of platinum 
containing combination chemotherap y for metastatic disease. 
Arm C: Subjects who have receive d no prior s ystemic therapy  for MPM.
2.Availability  of archival tumor tissue required. If archival tissue is not available, a 
fresh biops y is required.
3.Measurable disease per RECI ST version 1.1 for Arms A & B and by [CONTACT_377078] C .
4.Eastern Coopera tive Oncology  Group (ECOG) Performance Status of 0- 1 for Arm A
and C and 0 -2 for Arm B. 
Exclusion Criteria:
1.For Arms A,  C: Treatment with any FGFR inhibitor.
For Arm B: Treatment with any  anti-cancer therapy  (for biological anti -cancer 
therapi[INVESTIGATOR_377014] 2.) during the preceding [ADDRESS_471710] compression.
Study Treatment Dose/Route/Regimen : [COMPANY_004]3052230 will be administered via 
intravenous infusion (i.v.) once weekl y in each 21 -day cy cle. [COMPANY_004]3052230 will be 
diluted in a 250 mL  (nominal volume) i.v. bag containing either 5% dextrose solution or 
normal saline and administered over 30 minutes. Paclitaxel and carboplatin (Arm A), 
docetaxel (Arm B), and pemetrexed and cisplatin (Arm C) will be administered per 
product label on Day  1 of each cy cle.
Study Assessments : Prior to starting the stud y informed consent will be obtained from 
all subjects. Safet y assessments and study procedures include: medical history, review 
inclusion/exclusion criteria, phy sical exam, vital signs, w eight, height, ophthalmologic 
exam, ECHO, Eastern Cooperative Oncology  Group Performance Status (ECOG PS), 
laboratory  assessments (hematology , coagulation, pancreatic markers, chemistry , thyroid, 
pregnancy , urinal ysis), ECG, and immunogenicit y sampling. Ra diologic and disease 
assessments include brain scan and bone scan. Patient reported outcomes will be assessed 
using the Lung Cancer Sy mptom Scale or Lung Cancer S ymptom Scale Mesothelioma 
[LCSS( -meso)]. Additional samples (blood, plasma or tissue) will be obtained for 
pharmacokinetic, pharmacody namic, or translational research.  An optional 
pharmacogenetic blood sample may  be obtained if subject consents.
2013N165256_06 CONFIDENTIA L
FGF117360
171. INTRODUCTION
1.1. The FGF Pathway  in Cancer
Preclinically, the fibroblast growth factor (FGF) pathway  play s many roles in the 
development of cancer, including regulation of cell growth and differentiation, regulation 
of angiogenesis and participation in tumor -stroma interactions. FGFs can stimulate the 
proliferation of tumor cells and tumor cell lines. Blockade of FGF signaling can prevent 
tumor cell growth [ Lamont , 2011].
There are 22 known human FGFs (for a review on FGFs and their role in cancer see 
[Beenken , 2009]. The expression o f the FGFs is restricted to specific tissues, cell ty pes, 
and/or developmental stages with the exception of FGF -[ADDRESS_471711] genes producing FGF 
receptor subty pes termed FGFR1- 4.  Many  FGFs bind with high affinit y to multiple FGF 
receptors, and as such, each FGF receptor has a characteristic binding profile.  The FGF 
proteins trigger their 4 cognate receptor t yrosine kinases (FGFRs) to generate a range of 
cellular proliferation, survival, and differentiation responses [ Itoh, 2007].
FGFR1 is the best characterized of the [ADDRESS_471712] e 
mechanisms in the promotion of tumor cell growth and survival. FGFR1 signaling 
increases the mitotic rate of tumor cells, promotes tumor angiogenesis, and helps 
maintain the tumorigenicity  of tumor stem cells. Many  tumor cell lines are responsive to 
and dependent on FGFR1 signaling for growth in vitro, and tumor cell lines become 
resistant to cy totoxic agents when stimulated with FGF2 [ Song , 2000]. 
FGF ligand -dependent signaling occurs through autocrine production of FGFs directly  
from cancer cells or through paracrine production of FGFs from the local stroma [ Turner , 
2010]. FGF2 -FGFR1 autocrine feedback loops have been characterized in several tumor 
types and may  have a role in drug resistance upon exposure to chemotherapy  or targeted 
agents such as gefitinib [ Sharpe , 2011; 
Marek, 2009]. Overexpression of FGFs is readily  
detectable b y immunohistochemical approaches, as several studies have shown high 
levels of FGF2 protein in MPM tumor specimens [ Kumar -Singh , 1999; Davidson , 2004; 
Li, 201 1]. Further, overexpression or high sy stemic levels of FGF ligands correlate with 
tumorigenesis and poor patient outcome. These discoveries support the notion that 
specific treatments targeting FGF pathway  alterations may  provide benefit in this 
population .
1.2. Lung Cancer
Various in vitro studies utilizing non-small cell lung cancer (NSCLC) cell lines reveal 
that specific FGFs (FGF2 and FGF9) as well as FGFR1 and FGFR2 are frequently  co-
expressed [ Berger , 1999; Chandler , 1999; Fischer , 2008; Kono , 2009].  I n addition, 
frequent expression of FGF2, FGFR1 and FGFR2 mRNA and protein in primary  NSCLC 
specimens h ave been demonstrated [ Kono , 2009]. Further it has been shown that FGFR1
gene amplification is associated with sensitivity  to FGFR1 inhibition in non -small cell 
lung cancer (NSCL C) cell lines [ Dutt, 2011]. 
2013N165256_06 CONFIDENTIA L
FGF117360
18Increased expression of FGFRs, FGFR1 gene amplification, or production of FGFs 
correlates with poor prognosis in a variety  of tumor ty pes including NSCLC [ Nguyen, 
1994; Kim, 2013]. A focal amplification of the FGFR1 gene has been detected in 
approximately  20% of subjects with squamous NSCL C [Weiss, 2010], a histological 
subty pe of NSCL C which previously  had very  limited e vidence of molecular alterations 
amenable to targeted drug therap y. 
1.3. Mesothelioma
Malignant mesothelioma remains a deadl y disease with few effective therapi[INVESTIGATOR_014]. Although 
the incidence of mesothelioma is leveling off in the [LOCATION_002], the incidence in 
Western Europe, China, Russia, and I ndia continues to rise [ Ettinger , 2012]. The median 
overall survival ranges from 9- 17 months regardless of disease stage [ Tsao , 2009]. The 
stand
ard of care for the front-line treatment of mesothelioma remains cisplatin and 
pemetrexed with the combination regimen having a 41% response rate, a median time to 
progression of 5.7 months, a median overall survival of 12.1 months, and significant 
improve ments in quality  of life [ Vogelzang , 2003; Gralla , 2003]. There remains no 
widely  approved regimen for recurrent mesothelioma although pemetrexed (if not used in 
the front -line), vinorelbine, and gemcitabine are agents that have been used with limited 
success [ Jassem , 2008; Stebbing , 2009; 
Manegold , 2005]. A recentl y completed Phase III 
study  of vorinostat versus placebo in 660 patients with recurrent mesothelioma reported a 
median progression -free survival (PFS) of 6.3 versus 6.1 weeks and median overall 
survival (OS) of [ADDRESS_471713] Phase III stud y completed to date in recurrent mesothelioma 
[Krug , 2011]. These poor PFS and OS data underscore the need for more effective 
therapi[INVESTIGATOR_377015].
1.4. [COMPANY_004]3052230
1.4.1. Background
[COMPANY_004]3052230 was originally  developed as FP1039 and was also briefl y known as 
HGS1036. All three names refer to the same molecular entit y and differ only in the 
extinction coefficient used to calculate the concentration of drug. Please refer to the 
Investigators Brochure (IB) for additional details [GlaxoSmithKline Document Number
2013N160379_00].
[COMPANY_004]3052230 is a soluble fusion protein consisting of the extracellular domains of human 
fibroblast g rowth factor receptor 1 (FGFR1) isoform α- IIIc linked to the modified hinge 
and native Fc regions of human immunoglobulin G1 (IgG1).  [COMPANY_004]3052230 acts as a 
fusion protein “trap” that sequesters FGFs that may  be involved in the growth of tumor 
cells or the a ssociated vasculature mediated by  [CONTACT_169086]. In this manner, [COMPANY_004]3052230 
may have anti- tumor activity  either b y inhibiting tumor cell proliferation and/or by  
[CONTACT_377079]. 
[IP_ADDRESS]. Preclinical data on [COMPANY_004]3052230
Seventy -eight tumor -derive d xenograft models were treated with [COMPANY_004]3052230 (FP1039) 
as a single agent.  Twenty -eight models were found to show significant tumor growth 
2013N165256_06 CONFIDENTIA L
FGF117360
19inhibition (TGI ), including models of NSCLC, small cell lung cancer, mesothelioma, 
squamous cell carcinoma of the h ead and neck (SCCHN), endometrial, colon and breast 
cancer [ Harding , 2010; Harding , 2013].  I n lung cancer xenografts, [COMPANY_004]3052230- teated 
tumors harboring FGFR1 gene amplificati on display ed an average of 56% TGI compared 
to 22% TGI in non -amplified FGFR1 xenografts (p=0.03)[ Harding , 2013]. FGF2 mRNA 
levels display ed the highest ratio (247.7- fold) of median gene expression between 
[COMPANY_004]3052230 responder and nonresponder xenograft models and was the only marker 
that correlated with response in the subset of non -amplified FGFR1 lung cancer 
xenografts where significant tumor growth inhibition was observed [ Harding , 2013]. 
To further extend this observation, [COMPANY_004]3052230 was tested in models of mesothelioma, 
a tumor ty pe shown to express high levels of FGF2 mRNA in cell lines and in primary  
tumor specimens [ DeYoung , 2014]. [COMPANY_004]3052230 inh ibited MAPK signaling as 
evidenced b y decreased phospho- ERK levels in both NCI -H226 and MSTO -211H cells. 
When both cell lines were grown as tumor xenografts in mice, [COMPANY_004]3052230 inhibited 
tumor growth in a dose -dependent manner (NCI -H226: 16 –78% TGI; MSTO -211H: 20 
–50% TGI). Because FGFs also play  a key  role in angiogenesis, the effects of 
[COMPANY_004]3052230 on tumor vessel formation in NCI -H226 xenografts were explored 
[DeYoung , 2014
]. Dose -dependent and statistically- significant reductio ns in tumor vessel 
density  were observed in [COMPANY_004]3052230 -treated tumors compared to vehicle
-treated 
tumors using MECA -32 endothelial cell IHC staining. Therefore, FGFR1 amplification 
or FGF2 overexpression served as predictive markers of response to [COMPANY_004]3052230.
An additional thirty  tumor xenograft models were treated with [COMPANY_004]3052230 in 
combination with other anti- cancer agents including chemotherap y and targeted agents. 
In general, the combination of [COMPANY_004]3052230 and a second agent was more effective than 
eithe r [COMPANY_004]3052230 or the other agent when administered alone. In A549 lung 
xenografts, [COMPANY_004]3052230 treatment (15 mg/kg) alone resulted in 42% tumor inhibition 
(not significant). Carboplatin (25 mg/kg) plus paclitaxel (30 mg/kg) alone resulted in 
73% tumor inhibi tion (p < 0.001), and carboplatin plus paclitaxel and [COMPANY_004]3052230 
resulted in 86% tumor inhibition (p < 0.001) compared to vehicle treated animals. I n two 
prophy lactic models (A549 and NCI -H1703) the combination of [COMPANY_004]3052230 and 
docetaxel showed tumor growth inhibition of 58% (p < 0.01) and 97% (p < 0.001) 
compared to 46% and 26% with [COMPANY_004]3052230 alone (both not significant).  I n these three 
models, the addition of [COMPANY_004]3052230 did not confer additional toxicity  compared to 
chemotherap y alone [GlaxoSmithKline Document Number 2013N160379_00].
1.4.2. First -time- in-human study FP1039 -001
[COMPANY_004]3052230 has been studied in a Phase 1, open -label, dose -escalation study  (Protocol 
FP1039- 001, please refer to I nvestigator Brochure, GlaxoSmithKline Document Number 
2013N160379_00).  No maximum tolerated dose (MTD) was identified in this study  
exploring a dose range from 0.6 to 20 mg/kg/week of [COMPANY_004]3052230.  The 20 mg/kg once 
weekl y dosing schedule was determined to be safe and was declared the ‘maximum 
feasible dose’ (MFD) taking into account the high absolute dose of drug as well as 
achievement of the desired target concentration based on preclinical studies.
2013N165256_06 CONFIDENTIA L
FGF117360
[IP_ADDRESS]. Clinical Pharmacokinetics of [COMPANY_004]3052230
In stud y FP1039-001, the [COMPANY_004]3052230 PK profiles were assessed following the 1st and 
4th doses and were found to be ty pi[INVESTIGATOR_12340] a large protein, with an initial distribution phase 
and a terminal elimination phase.  The profile in humans is similar to that observed in 
rats, dog s, and chimpanzees.  After the 1st dose, the mean terminal phase half -life (t 1/2) 
ranged from 63 to 92 h, while after the 4th dose t 1/2ranged from 87 to 125 h. Sy stemic 
clearance (CL) ranged from 0.0648 to 0.101 L /h across the dose range and appears to be
independent of dose.  The maximum plasma [COMPANY_004]3052230 concentration (Cmax) and 
area under the plasma [COMPANY_004]3052230 concentration -time curve during a dosing interval 
(AUC (0-)) increased proportionally  to dose.  Some accumulation was observed after 4 
weekl y dos es; Cmax after the 4th infusion was 11% to 42% higher than Cmax after the 
1st dose, and AUC (0-)was 30% to 61% higher after the 4th dose compared to the 1st 
dose.  The pharmacokinetic anal ysis supports a weekly  IV dosing schedule of between 10 
and 20 mg/k g, when used as monotherapy, achieving the desired target concentration 
throughout the dosing interval.
[IP_ADDRESS]. Clinical Safety  of [COMPANY_004]3052230
[COMPANY_004]3052230 has been investigated as monotherapy  in a first -time-in-man (FTIM) study  
(FP1039 -001) including a total of 39 subjects with different tumor t ypes. It should be 
noted that the study  population was heavil y pretreated with a median of 4 prior anticancer 
therapi[INVESTIGATOR_014] (range 0 -11). [COMPANY_004]3052230 I V once every  week was considered tolerable over 
the dose range studied (0.6-20 m g/kg/week).  Mean duration of exposure was 54 day s 
(13-203 day s). One subject required a dose reduction (Grade 3 neutropenia event 
described below) and a total of 6 subjects experienced dose interruptions at any  timepoint 
during the stud y. 
A total of 4 do se-limiting toxicities (DL Ts) were reported over the course of the study  
and occurred at doses of 1.0 mg/kg (urticaria), 1.3 mg/kg (intestinal perforation and 
neutropenia each counted as an event), and 20 mg/kg (muscular weakness). After seeing 
2 DL Ts at 1 .3 mg/kg/week, 2 dose levels below 1.3 mg/kg were explored in 6 subjects 
each. Both these dose levels were considered tolerable.  Since the DLT of intestinal 
perforation was confounded by  [CONTACT_377080]305223 0 (see below) and the DLT of neutropenia was a brief Grade 3 event, further 
exploration of this dose -level for a total of 6 subjects was carried out. Since there were no 
further DLTs at this dose level, dose escalation continued.  No clear evidence of dose -
related toxicity  limiting the dose escalation was found, hence a MTD was not identified, 
rather, a ‘maximum feasible dose’ of 20 mg/kg was determined. 
The most common toxicities were diarrhea (44%), fatigue (44%) and nausea (26%), with 
no clear dose -related increases in frequency  of an y adverse events (AEs) except low 
grade nausea/vomiting seen at the highest dose -level.
The more commonl y reported Grade 3 (severe) AEs involved metabolism and nutrition 
disorders as reflected in abnormal clinical chemistry values, reported for 7 subjects 
(17.9%) and consisted of hy pergly cemia, hy pokalemia, and hy pophosphatemia (each 
reported b y 2 subjects [5.1%]).  Of note, h yperphosphatemia that has been previously 
reported with agents targeting the FGF pathway  was not iden tified in the study .  Other 
2013N165256_06 CONFIDENTIA L
FGF117360
21Grade [ADDRESS_471714] were abdominal pain and d yspnea (each 
reported b y 2 subjects [5.1%]).  A total of 2 subjects had Grade 4 and/or fatal AEs ([ADDRESS_471715] with Grade 4 leukopenia, Grade 
4 neutropenia, and Grade 5 respi[INVESTIGATOR_33078]).
A total of 12 serious adverse events (SAEs) were reported in 11 subjects during the 
course of this study.  Two SAEs, intestinal perforation and worsening bilateral leg 
weakness/peri pheral neuropathy, were considered at least possibly  related to 
[COMPANY_004]3052230.  I ntestinal perforation occurred in a subject with malignant liposarcoma of 
the retroperitoneum treated with several resections and abdominal radiotherap y, who died 
of intestinal p erforation [ADDRESS_471716] dose of [COMPANY_004]3052230.  The tumor mass 
involved the bowel at study  entry ; this was also a DL T event.  The second subject 
developed exacerbation of pre -existing bilateral leg weakness and died of acute 
respi[INVESTIGATOR_377016] y to pneumonia [ADDRESS_471717] was transferred to a rehabilitation facility  where he died 19 day s later.
A total of five deaths were reported in the study .  Please refer to the Investigator 
Brochure, GlaxoSmithKline Document Numb er 2013N160379_00, for further details.
[IP_ADDRESS]. Anti-tumor A ctivity  with [COMPANY_004]3052230
No activity  in terms of objective tumor responses were seen in the FTIM study  which 
was carried out in a population unselected for deregulation of FGF signaling pathway . 
For subjects with evaluable disease, the best overall tumor response (Response 
Evaluation Criteria in Solid Tumors [RECI ST] 1.0) was stable disease (SD) for 15/36 
subjects (41.7%) and progressive disease (PD) for 17/36 subjects (47. 2%). One subject 
with hormone resistant prostate cancer rapi[INVESTIGATOR_2478] y progressing on prior docetaxel, 
experienced a 20% reduction in tumor diameter and stable disease of 7 months duration.
1.5. Chemotherapy  (Paclitaxel, Carboplatin, Docetaxel, 
Pemetrexed, Cisplatin)
1.5.1. Paclitaxel/Carboplatin
Paclitaxel, a mitotic inhibitor originall y extracted from the pacific yew (Taxus 
brevifolia), has been shown to be active as a single agent and/or in combination with 
other chemotherapeutic drugs in subjects with ovarian cancer, brea st cancer, NSCL C, and 
Kaposi’s sarcoma.  Paclitaxel causes side effects that are generally  predictable and 
manageable. Neutropenia, the most frequent side effect, is generall y of short duration.  
Peripheral neuropath y, myalgia, and arthralgia are usually  noted with the administration 
of higher doses of paclitaxel ( ≥ 175 mg/m2) for several cy cles. Paclitaxel causes rapid 
and usually  complete alopecia.  Other toxicities include: mild to moderate nausea, 
vomiting, diarrhea, and mucositis [ Taxol USPI , 2011].
Carboplatin is an analog of cisplatin with an improved toxicity  profile. Bone marrow 
suppression is the major dose -limiting toxicity  of carboplatin. Carboplatin has been 
2013N165256_06 CONFIDENTIA L
FGF117360
22shown to be active as a single agent and/or in com bination with other chemotherapeutic 
drugs in subjects with ovarian cancer, NSCL C, bladder cancer, esophageal and other 
upper gastrointestinal cancer [ Paraplatin USPI, 2010]. Nausea, vomiting, and loss of 
appetite are usuall y mild to moderate.  The pharmacokinetics (area under the time 
concentration curve [AUC] and the pharmacod ynamic effects (hematologic toxicity ) of 
carboplatin are much better predicted b y glomerular filtration rate (GFR) based dosing as 
compared with t he more traditional body  surface area (BSA) dosing method [ Calvert , 
1994]. 
The combination of paclitaxel and carboplatin has been developed to avoid overlappi[INVESTIGATOR_377017].  Several Phase 
[ADDRESS_471718] shown that 
the drug combination is active in subjects with NSCL C, ovarian cancer, bladder cancer, 
esophageal cancers, SCCHN cancers and other tumor ty pes [ NCCN Guidelines, 2012]. 
1.5.2. Docetaxel
Docetaxel, a semi -synthetic analog of paclitaxel, acts by  [CONTACT_377081].  Docetaxel is used as a single agent in the 
treatment of NSCLC, breast cancer, and in combination with multiple other 
chemotherapi[INVESTIGATOR_377018], NSCL C, gastric cancer and SCCHN. 
The most common adverse events associated with the administration of docetaxel are 
infections, neut ropenia, anemia, febrile neutropenia, hy persensitivity , thrombocy topenia, 
neuropath y, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, 
asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia
, skin reactions and my algia 
[Taxot erePI, 2010]. 
1.5.3. Pemetrexed/Cisplatin
Pemetrexed is a folate analog inhibitor that disrupts folate -dependent metabolic processes 
essential for cell replication. In vitro studies have shown that pemetrexed inhibits
thymidy late sy nthase, dihy drofolate reductase, and gl ycinamide ribonucleotide 
formy ltransferase, which are folate -dependent enzy mes involved in de novo biosy nthesis 
of thy midine and purine nucleotides. Cisplatin is a heavy -metal complex containing a 
centr al platinum atom with 2 chloride atoms and 2 ammonia molecules in the cis 
position. Pemtrexed in combination with cisplatin is recommended for the treatment of 
mesothelioma [ Alimta PI, 2004].
The most common adverse reactions (incidence ≥20%) with single -agent use of 
pemetrexed are fatigue, nausea, and anorexia. Additional common adverse reactions 
when used in combination with cisplatin include vomiting, neutropenia, leukopenia, 
anemia, stomatitis/pharyngitis, thrombocy topenia, and constipation [ Alimta PI, 2004].
Common adverse reactions (incidence ≥20%) associated with cisplatin include 
nephrotoxicity, ototoxicity , myelosuppression, and nausea/vomiting. Other toxicities 
include vascular c omplications, serum electrol yte imbalance, Hy peruricemia, 
neurotoxicity , ocular toxicity , anaphy lactic -type reactions, and hepatotoxicity  [Platinol
PI, 2010].
2013N165256_06 CONFIDENTIA L
FGF117360
231.6. Summary  of Risk Management
Further information on these pote ntial risks can be found in the Investigator Brochure 
(IB) for [COMPANY_004]3052230 [ GlaxoSmithKline Document Number 2013N160379_00].
Based on preclinical data and experience from the clinical study , as well as the toxicity  
profile of the combination agents, the following are events of interest:
Infusion -related reactions/Edema/Hypersensitivity: 
Generalized edema of unknown cause (not associated with measurable increase in 
histamine or cy tokines) was a prominent observation in precl inical toxicology  
studies
Edema and h ypersensitivity  are potential overlappi[INVESTIGATOR_377019] 3052230 and taxanes such as paclitaxel and docetaxel.
Subjects will be closely  monitored for infusion -related reactions.
Subjects in the combination chemotherap y arms will alread y be receiving 
premedication with glucocorticoids (for the paclitaxel combination also 
antihistamines and H2 receptor antagonists) as part of the standard of care. 
Epi[INVESTIGATOR_41217], diphenhydramine for IV inject ion, and any  
other medications and resuscitation equipment for the emergency  management of 
anaph ylactic reactions must be available in the room where the infusions are being 
performed.
If infusion reactions are noted in subjects not already  premedicated wi th 
glucocorticoids, antihistamines and H2 receptor antagonists, appropriate 
premedication against hypersensitivity  reactions may  be initiated prior to the next 
infusions at the discretion of the investigator according to the institution’s standard 
practice .  All subjects who have experienced an infusion reaction should have 
[COMPANY_004]3052230 infused over [ADDRESS_471719] a reaction 
on re -challenge, the infusion of [COMPANY_004]3052230 may be prolonged for 90 minutes.
Anti -drug antibodies :
The antidrug antibod y response in study FP1039- 001 was generally weak with no 
apparent associated changes in drug exposure or clinical sequelae. Anti -drug 
antibodies will be moni tored throughout the study.
Anterior uveitis:
Bilateral acute anterior uveitis was seen in preclinical toxicology  studies. This is 
believed to be secondary  to anti -drug antibody  (ADA) immune complexes deposited 
in the ey es of the animals. No events of ante rior uveitis were reported in study  
FP1039-001.
Optic neuritis, papi[INVESTIGATOR_044], and cerebral blindness have been reported in patients 
receiving standard recommended doses of cisplatin.
2013N165256_06 CONFIDENTIA L
FGF117360
24An ophthalmologic exam will be performed at screening and at C ycle 4 
(Sect ion7.3.7 ). If at an y time the subject complains of photophobia, changes in 
vision, or ey e pain; the ophthalmic examination finding are abnormal; or visual 
acuity  has worsened by  [ADDRESS_471720].
Wound healing:
Abnormal wound healing is a theoretical risk associated with inhibition of the FGF
signaling pathway . No events of abnormal wound healing have been reported 
previously . Subjects with non- healing wounds that, in the opi[INVESTIGATOR_871], 
would pose a significant medical risk to the subject should wound healing be further 
impaired, will be excluded from participation in this study . 
Interruption of therap y is recommended in subjects undergoing surgical procedures; 
treatment with [COMPANY_004]3052230 should be stopped at least [ADDRESS_471721]’s notes. 
Bowel perforation :
One subject developed fatal bowel perforation in Study  FP1039- 001.The subject’s 
history  was notable for several risk factors for perforation.  However, [COMPANY_004]3052230 
may have a nti-angiogenic activity  that has previously  been associated with a risk of 
bowel perforation, so subjects with conditions with an increased risk for bowel 
perforation are excluded from participation in this study .
Heart valve fibrosis:
Heart valve thickeni ng due to fibrosis was noted at necrops y in 2 rats in a 4 -week 
toxicology  study . This finding was consistent with chronic persistent irritation and 
attributed to infusion catheter complications.
Subjects participating will undergo echocardiography  at scree ning and Cy cle 4 for 
evaluation of cardiac valve abnormalities and left ventricular ejection fraction 
(LVEF) changes (note, additional assessments may  be obtained as clinically  
indicated or if the subject discontinues prior to Cycle 4). 
Peripheral Neuropa thy 
One event of worsening bilateral leg neuropath y/muscle weakness was reported as a 
possibly  related SAE in a subject with pre -existing neuropathy  in Study  FP1039 -001.
Peripheral neuropath y is a potentially  overlappi[INVESTIGATOR_377020]3052230, 
taxan es such as paclitaxel and docetaxel, and cisplatin.
Complete phy sical exam will be performed at screening. Also, disease -oriented 
physical examination will be performed on Day  [ADDRESS_471722] visi t off treatment, and 30 day s after 
discontinuation of [COMPANY_004]3052230 therap y
2013N165256_06 CONFIDENTIA L
FGF117360
25Hypothyroidism:
Slightly  reduced weight of the thyroid gland was seen in preclinical toxicology  
studies. I n study  FP1039- 001, 2 events of h ypoth yroidism/increased th yroid 
stimulating hormone (TSH) were reported. 
Subjects participating in clinical studies with [COMPANY_004]3052230 will be assessed for TSH 
at baseline and periodically  during the study . If TSH is abnormal, additional thy roid 
assessments (total T3, total T4, free T4) along with ap propriate clinical assessments 
are warranted.
Hematologic toxicity :
Two events of neutropenia (Grade 3 and grade 4) were reported in Study  FP1039 -001 
for an overall rate of 5.1%. Furthermore, paclitaxel, docetaxel, and cisplatin have 
known bone -marrow toxi city. 
All subjects in the study  will have their blood counts monitored regularl y, and 
supportive therap y including blood transfusions and growth factor support is 
encouraged (Section 9.1).
Nephrotoxicity:
Dose -related and cumulative renal insufficiency , including acute renal failure, is the 
major dose -limiting toxicity  of cisplatin. Renal toxicity  has been noted in 28% to 36% 
of patients treated with a single dose of 50 mg/m2. It is first noted during the second
week after a dose and is manifested b y elevations in BUN and creatinine, serum uric 
acid and/or a decrease in creatinine clearance. Renal toxicity  becomes more 
prolonged and severe with repeated courses of the drug. Renal function must return to 
normal be fore another dose of cisplatin can be given.
One patient with severe renal impairment (creatinine clearance 19 mL /min) who did 
not receive folic acid and vitamin B12 died of drug- related toxicity  following 
administration of pemetrexed alone.
Ototoxicity :
Ototoxicity  has been observed in up to 31% of patients treated with a single dose of 
cisplatin 50 mg/m2, and is manifested b y tinnitus and/or hearing loss in the high 
frequency  range (4000 to 8000 Hz). Decreased ability  to hear normal conversational 
tones m ay occur. Deafness after the initial dose of cisplatin has been reported. 
Hearing loss can be unilateral or bilateral and tends to become more frequent and 
severe with repeated doses. Careful monitoring per standard of care should be 
performed.
2013N165256_06 CONFIDENTIA L
FGF117360
262. OBJECTIVES AND ENDPOINTS
2.1. Primary
Objectives Endpoints
Primary To characterize the safety and tolerability 
of [COMPANY_004]3052230 in combination with 
chemotherapy regimens.Measurements used to evaluate safety 
and tolerability will include rate and 
severity of AEs, withdra wals due to AEs, 
dose interruptions and reductions, 
treatment duration, and DLTs as well as 
change from baseline for the following: 
physical examinations, vital signs,:12 -lead 
ECGs, ECHO, clinical laboratory tests.
To determine the regimen of 
[COMPANY_004]3052230 in combination with 
chemotherapy for evaluation in future 
studies based on the maximum tolerated 
dose (or maximum feasible dose).Maximum tolerated dose (MTD) or 
maximum feasible dose (MFD).
To assess the overall response rate 
(ORR) in each treatment arm .Best response defined as complete or 
partial response, stable disease or 
progressive disease according to RECIST 
1.[ADDRESS_471723] (for MPM)
ORR defined as the proportion of subjects 
with investigator- assessed confirmed 
complete response or parti al response per 
RECIST 1.[ADDRESS_471724] (for 
MPM)
2.2. Secondary
Objectives Endpoints
Secondary To assess progression free survival 
(PFS) for each treatment arm. PFS is defined as the interval between first 
dose of [COMPANY_004]3052230 and the earliest date 
of disease progression or death due to 
any cause by [CONTACT_377082] 1.[ADDRESS_471725] (for 
MPM)
Secondary To characterize the population 
pharmacokinetics of [COMPANY_004]3052230 and 
identify important determinants of 
variability.[COMPANY_004]3052230 population pharmacokinetic 
parameters such as clearance (CL) and 
volume of distribution (Vd), and relevant 
covariates which may influence exposure 
(e.g. age, weight, or disease related 
covariates).
Secondary Assess improvement in Pulmonary 
Function Tests in Patients with MPMChange from baseline in  Forced Vital 
Capacity (FVC) in patients with MPM
2013N165256_06 CONFIDENTIA L
FGF117360
272.3. Exploratory
Objectives Endpoints
Exploratory To describe the kinetics of tumor growth 
in the presence of [COMPANY_004]3052230 for 
each treatment arm and investigate the
relationship between tumor growth 
kinetics and clinical activity. Tumor size over time, tumor growth rate 
constants, and time to tumor growth 
(TTG) predicted with the model 
parameters. Additional analysis will be 
performed utilizing volumetric analysis.
Exploratory To identify biomarkers that may predict 
response or resistance.Evaluate potential predictive/prognostic 
biomarkers (DNA, RNA, or protein) of 
response in circulation and/or in tumor.
Exploratory To evaluate the pharmacodynamic 
response in ci rculation following 
treatment.Changes in circulating biomarkers (eg, 
proteins) implicated in FGFR or disease 
biology signalling in pre and post dose 
blood samples. 
Exploratory To explore the relationship between PK, 
pharmacodynamic response, and 
clinica l endpoints.Predicted/observed exposure (AUC), 
trough concentrations ( C), or other PK 
endpoints as compared to 
pharmacodynamic and clinical endpoints.
Exploratory To develop and validate an assay to 
measure  FGFR1 gene amplification 
status such as, but not limited to, a 
Fluorescence in situ hybridization 
(FISH) -based assay ..Association of FGFR1 gene amplification 
with clinical response to support the 
development of an investigation use only 
test (IUO) and potential companion 
diagnostic for subject sel ection.
Exploratory To investigate additional measures of 
FGF signaling pathway deregulation as 
potential predictive biomarkers for 
[COMPANY_004]3052230 in tissue.Identification and validation of alternative 
measures of FGF signaling pathway 
deregulation retrospec tivelysuch as 
ligand or receptor overexpression for 
example but not limited to FGF2 or 
FGFR1 expression   FGF2 
overexpression) as predictive biomarkers 
for subject selection and potential 
development of a companion diagnostic.
Exploratory To evaluate chan ges in patient reported 
outcomesChange from baseline and association 
with ORR in observer and patient 
assessed components of the Lung 
Cancer Symptom Scale (LCSS) and 
LCSS -meso
Pharmacogenetics To investigate the relationship between 
genetic variants in t he host DNA and 
the pharmacokinetics of [COMPANY_004]3052230
and/or the relationship between genetic 
variants in the host DNA and the 
efficacy, safety and tolerability of 
[COMPANY_004]3052230.Refer to Appendix 1 . 
2013N165256_06 CONFIDENTIA L
FGF117360
283. STUDY POPULA TION
3.1. Number of Subjects
Approximately  70 subjects will be enrolled in the study  (minimum of 38 and up to 
approximately  120, alternative dosing cohorts could potentially  add another 6 to ~ 40 
subjects ). In addition to minimum and maximum sample sizes for each arm, s ample sizes 
that would be expected under the null and alternative hy pothesis rates are provided in 
Section 12.3.
3.2. Subject Selection Criteria
Specific information regarding warnings, precautions, contraindications , AEs, and other 
pertinent information on the [COMPANY_004] study  treatment or other study  treatment(s) that may  
impact subject eligibility  is provided in the Investigator Brochure [GlaxoSmithKline 
Document Number 2013N160379_00] an d the individual product labels [ Taxol PI, 2011 ], 
[Paraplatin PI, 2010 ], [Taxot erePI, 2010 ], [Alimta PI, 2004], [ Platinol PI, 2010].
Deviations from inclusion/exclusion criteria are not allowed because they  can potentiall y 
jeopardize the scientific integrit y of the study, regulatory acceptability or subject safet y. 
Therefore , adherence to the criteria as specified in the protocol is essential.
3.2.1. Inclusion Criteria
Subjects eligible for enrolment in the study  must meet all of the following criteria:
1. Signed written informed consent;
2.Histologicall y or c ytologically  confirmed diagn osis:
Arms A and B: Stage IV or recurrent metastatic squamous NSCL C [TNM 
classification of malignant tumors, 7thedition, 2009; Edge , 2010] with FGFR1 gene 
amplification by  [CONTACT_377083].
Arm C: recurrent after local therap y or unresectable malignant pleaural 
mesothelioma (MPM) with measurable lesions
.
For specific arms the following requirements:
Arm A: Subjects who have received no prior therapy  for Stage IIIB or Stage IV or 
recurrent metastatic disease. Note, to avoid an y undue delay  of initiating s ystemic 
chemotherap y for these subjects with newly  diagnosed advanced or metastatic 
disease, it is allowed to initiate the first cy cle of chemotherap y while eligibility  for 
the study  is still being determined, as long as the first dose of [COMPANY_004]3052230 is given 
no later than C ycle 2 Day 1 of chemotherap y. In addition, subjects with Stage IIIB or 
Stage IV disease and recurrence after previous NSCL C that has been treated with 
surger y and adjuvant chemotherap y or a radio -chemotherap y regimen with curative 
intent are eligible, provided 6 months has passed since this treatment ended[ TNM 
classification of malignant tumors, 7thedition, 2009; Edge , 2010].
2013N165256_06 CONFIDENTIA L
FGF117360
29Arm B: Subjects who have documented tumor progression (based on radiological 
imaging) or intolerability after receiving at least one prior line of platinum 
containing combination chemotherap y for Stage IIIB , Stage IV or recurrent 
metastatic disease [ TNM classification of malignant tumors, 7thedition, 2009; Edge , 
2010].. Note: Prior treatment should not include docetaxel but may  have included 
paclitaxel.
Arm C: Subjects who have received no prior s ystemic therapy  for MPM.
3.Availability  of archival tumor tissue required for assessment of deregulated FGF 
pathway  signaling eg, FGFR1 amplification or FGF2 or FGFR1 expression. If 
archival tissue is no t available, a fresh biopsy  is required. Please refer to Section 
7.7.1   
In Arms A and B , subjects will be prospectivel y screened for FGFR1 gene 
amplification using a FISH assay  (note, local testing is permitted for pre -screening 
of subjects prior to central testing) for the dose expansion and the MTD/MFD 
cohorts only . For inclusion in this study , based on the central laboratory  testing, 
FGFR1 gene amplification must meet one of the following criteria: a ratio of
FGFR1 /CEN 8 of ≥2; or average number of FGFR1 signals per tumor nucleus of ≥6; 
or the percentage of tumor nuclei containing  ≥5 FGFR1 signals is ≥50%. 
In Arm C , FGF2 expression by  [CONTACT_377084] y in tissue 
samples by a central laboratory  and is not a requirement for study  entry .
4.Measurable disease per RECI ST version 1.1 (Arm A and B) and modified RECI ST 
for Arm C .
5.Male or female [ADDRESS_471726] dose of chemotherap y, to allow for clearance of an y 
altered sperm.
8.Eastern Cooperative Oncology  Group (ECOG) Performance Status of 0- 1 for Arm s
A and C subjects and 0- 2 for Arm B. 
9.French subjects: In [LOCATION_009], a subject will be eligible for inclusion in this study  only 
if either affiliated to or a beneficiary  of a social security  category .
10.Must have a dequate organ function as defined b y the following baseline values:
2013N165256_06 CONFIDENTIA L
FGF117360
30Table 1 Inclusion Criteria: A dequate Organ Function
SYSTEM LABORATORY VALUES
Hematologic
ANC 1.5 x 109/L
Hemoglobin a 9 g/dL 
Platelets 100 x 109/L
Partial thromboplastin time (PTT) ≤ 1.[ADDRESS_471727].
Hepatic
Albumin 2.5 g/dL
Serum total bilirubin b 1.[ADDRESS_471728] (for Arm B: ULN ) 
AST and ALT 2.[ADDRESS_471729] (for Arm B: 1.[ADDRESS_471730])
Renal
Serum Creatinine
Or
Measured or Calculated Creatinine Cleara nce c1.[ADDRESS_471731]
Or
≥45 mL/min  (Arm A or B) ≥65mL/min (Arm C)
Cardiac
Left ventricular ejection fraction ≥50%by [CONTACT_18585]
a. Subjects should meet criteria in the absence of hematopoietic growth factors or transfusions.
b. If the serum total bilirubin is elevated at screening but the direct bilirubin is ≤ULN then the subject may be allowed to 
enter study.
c. Calculated by [CONTACT_99960].
NOTE: Laboratory  results obtained during Screening should be used to determine 
eligibility  criteria. In situations where laboratory  results are outside the permitted range, 
the investigator may  opt to retest the subject and the subsequent within range screening 
result may be used to confirm eligibility .
3.2.2. Exclusion Criteria
Deviations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y of the study, regulatory acceptability or subject safet y. 
Therefore, adherence to the criteria as specified in the protocol is essential.
Subjects meeting an y of the followi ng criteria must not be enrolled in the study :
1.For Arms A and C: Treatment with any  FGFR inhibitor .
For Arm B: Treatment with any  anti-cancer therapy  (for biological anti -cancer 
therapi[INVESTIGATOR_377021] 2) during the preceding [ADDRESS_471732] dose of [COMPANY_004]3052230.
3.Unresolved toxicity  of National Cancer Institute Common Terminology Criteria for 
Adverse Events, version 4.03 (NCI CTCAE v4.03) [ NCI, 2010] Grade [ADDRESS_471733] dose of study  drug.
7.Presence of an y non -healing wound, fracture, or ulcer.
8.Any prohibited medication(s) as described in Se ction 9.2.
9.Conditions likely  to increase the potential for abdominal perforation or fistula 
formation, including but not limited to:
Luminal intestinal cancers or bulky  abdominal disease.
Presence or history  of abdominal fistula, gastrointestinal perforation, peptic 
ulcer disease or intra -abdominal abscess within the six months prior to the first 
dose of [COMPANY_004]3052230.
Other risk factors for perforation, such as acute diverticulitis, obstruction or 
previous abdomina l or pelvic radiation.
10.Symptomatic leptomeningeal or brain metastases or spi[INVESTIGATOR_13377].
NOTE : Subjects previously  treated for these conditions are eligible if they  meet 
both of the criteria below:
(1) have had stable CNS disease for at least 4 we eks after local therap y as assessed 
by [CONTACT_9661] (contrast enhanced magnetic resonance imaging (MRI) or computed 
tomograph y (CT)) prior to Day  1, and
(2) are as ymptomatic and off corticosteroids, or are on stable dose of corticosteroids 
for at least [ADDRESS_471734] a known immediate or delay ed hy persensitivity  reaction or idiosy ncrasy  to 
drugs chemicall y related to study  drugs ([COMPANY_004]3052230, docetaxel, paclitaxel, 
carboplatin, pemetrexed, cisplatin) or their excipi[INVESTIGATOR_377022].
12.Known human immunodeficiency  virus (HIV) -positive serology , acquired 
immunodeficiency  syndrome (AIDS), or an AIDS -related illness.
13.Prior organ or allogeneic stem cell transplant.
14. The following cardiac abnormalities:
Corrected QT (QTc) interval 480 msecs
History  of acute coronary  syndromes (including unstable angina) within the past 
24 weeks
Coronary  angioplast y, or stenting within the past 24 weeks
Class II, III, or IV heart failure as defined b y the [LOCATION_001] Heart Association 
(NYHA) functiona l classification sy stem
Abnormal cardiac valve morphology  (≥ Grade 2) documented by  
[CONTACT_6751] (subjects with Grade 1 abnormalities [i.e., mild 
regurgitation/stenosis] can be entered on study ). 
History  of known arrhy thmias (except sinus arrhy thmia and atrial fibrillation 
that i s controlled) within the past 24 weeks
2013N165256_06 CONFIDENTIA L
FGF117360
3215.Presence or history  of hemopty sis (>½ teaspoon of red blood) [ADDRESS_471735] dose of [COMPANY_004]3052230.
16.Any serious and/or unstable pre -existing medical, psy chiatric disorder or other 
conditions that could interfe re with subject’s safety , obtaining informed consent or 
compliance to the stud y procedures.
17. Current active liver or biliary  disease (with the exception of Gilbert's sy ndrome or 
asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease 
per investigator’s assessment).
18.Pregnant, lactating or actively  breast feeding females.
19.French subjects: The French subject has participated in an y study using an 
investigational stud y treatment(s) during the previous 30 days.
4. INVESTIGA TIONAL PLA N
4.1. Discussion of Study  Design
This will be a multi -arm, multicenter, non -randomized, parallel- group, uncontrolled, 
open -label Phase IB study designed to evaluate the safet y, tolerability  and preliminary  
activity  of [COMPANY_004]3052230 in combination with paclitaxel + ca rboplatin (Arm A), in 
combination with docetaxel (Arm B), or in combination with pemetrexed + cisplatin 
(Arm C).
Figure 1 Study  Schema
Pemetr exed /Cisplatin +
[COMPANY_004]30522 30
3+3 design to deter mine
MTD  (MFD) in subj ects with MPMArm  CPaclitaxel/ Carbopl atin+
[COMPANY_004]30522 30
N=at least 12 and up to 30  sqNSCLC
Doce taxel + [COMPANY_004]3052230
3+3 design to deter mine MTD  (MFD) 
in subjects with sqNSCLCDocet axel+ [COMPANY_004]3052230
N=at least 14 and up t o 30 sqNSCLCArm  BPaclitaxel/ Carboplatin +
[COMPANY_004]30522 30
3+3 design to deter mine
MTD   (MFD) in subj ects with sqNSCLCArm  A
Pemetr exed /Cisplatin +
[COMPANY_004]30522 30
N=at least 12 and up to 30 MPM
Dose escalation will follow a 3+3 design as outlined in Section 4.2for determination of 
MTD (or MFD).  A cohort expansion of at least 12 subjects will be treated at the MTD 
(or MFD) in each arm, with the option of expanding to a maximum of 30 subjects. 
Stoppi[INVESTIGATOR_377023] -tumor activity  were d erived according to a predictive 
probability  design for each arm of the stud y and are detailed in Section 4.2.1 , Section 
4.2.2 , and Section 4.2.3.
2013N165256_06 CONFIDENTIA L
FGF117360
33[COMPANY_004]3052230 will be administered as a 30 -minute intravenous (i.v.) infusion once a week 
(Day  1, Day  8, Day  15) of each 21 -day cycle. Paclitaxel/carboplatin, docetaxel, and 
pemetrexed/cisplatin will be administered i.v. on Day  1 of each 21- day cycle. The 
number of cy cles of paclitaxel/carboplatin will be limited to 4 to 6 cy cles. Subjects may  
continue to receive docetaxel and pemetrexed/cisplatin until disease progression or as 
long as they  are considered to derive benefit from treat ment. Subjects on 
pemetrexed/cisplatin may have their cisplatin stopped after 4 cy cles per local clinical 
standards. Subjects who discontinue chemotherapy for reasons other than disease 
progression, may  continue to receive [COMPANY_004]3052230 as long as they  are considered to 
derive benefit from the treatment according to the criteria in Section 6.3. After 
discontinuation of [COMPANY_004]3052230, subjects will return after approximately  30 day s (see 
Time and Events Table Section 7.1) for a follow -up visit to collect safety  assessments, 
after which they  will be considered to have completed the study .
Blood samples for pharmacokinetic, pharmacogenetic, and translational research will be 
obtained at specified times during the study .  Efficacy  will be assessed every  [ADDRESS_471736], will be referred to as ‘study  
treatment’ for ease of presen tation throughout the protocol.  For EU regulatory  purposes, 
the term ‘investigational product’ will only  be used in Section 5 when describing the 
[COMPANY_004]3052230.
Protocol waivers or exemptions are not allowed.  The refore, adherence to the study  
design requirements, including those specified in the Time and 
Events Table 
(Section 7.1), are essential.
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Manual (SPM).  The SPM will provide 
the site personnel with administrative and detailed technical information that does not 
impact subject safet y.
4.2. [COMPANY_004]3052230 plus Chemotherapy
Dose escalation will follow a 3 + 3 dose -escalation procedure, described in Table 2. Dose 
limiting toxicities (DLTs) are based on an y observed toxicity  in the first 21 day s of 
treatment (please see Section 4.2.4 ).  An additional (4th) subject is allowed in each cohort 
of [ADDRESS_471737] completed a minimum of 21 day s (1 cy cle) 
isrequired prior to expanding a cohort or escalating to the next higher dose cohort.
Dose escalation will be explored in cohorts of 3 to 6 subjects to determine the MTD (or 
MFD), defined in Section 4.2.4 .  The cohort may  be expanded up to 9 subjects to further 
evaluate safet y, pharmacokinetics and tolerability before dose escalation or reduction 
decision is determined. 
2013N165256_06 CONFIDENTIA L
FGF117360
34Table 2 Dose Escalation 3+3 Design Process for A rms A , B
Number of subj ects at given dose 
level with DLTAction
0 out of 3 subjects Proceed to next relevant dose -level or expand cohort to a total of 
6 evaluable subjects as appropriate
1 out of 3 subjects Accrue 3 additional evaluable subjects at current dose level for a 
total of 6 evaluable subjects
1 out of 6 subjects Proceed to next relevant dose -level or expand cohort to 9 as 
appropriate.
2 or more out of 3 or 6 subjects in a 
dosing cohort aThe MTD has been exceeded. Dose reduction in this Arm should 
be considered. 
Either evaluate an intermediate dose lower than current dose or 
expand a prior cohort. 
a. If 9 subjects in a cohort, then 3 or more out of 9
4.2.1. Arm A
The starting dose (Dose Level 0) and escalation/de -escalation schema for [COMPANY_004]3052230 
in combination with paclitaxel + carboplatin is presented in Table 3.  Depending on 
emerging data, additional intermediate or lower dose- levels bey ond those described may  
be explored.
Table 3 Combination Therapy : Arm A [COMPANY_004]3052230 + Paclitaxel + Carboplatin
Dose LevelDose of [COMPANY_004]3052230
(Weekly)Paclitaxel + Carboplatin a
(once every 21 days)
Dose Level -2 5 mg/kg 135 mg/m2 + AUC 4 
Dose Level -1 5 mg/kg 175 mg/m2 + AUC 5 
Starting Dose Level 0 5mg/kg 200 mg/m2 + AUC 6 
Dose Level 1 10 mg/kg 200 mg/m2 + AUC 6 
Dose Level 2 20 mg/kg 200 mg/m2 + AUC 6 
a. Carboplatin dose based on Calvert’s formula.
A total of at least [ADDRESS_471738] been enrolled, the number of observed confirmed 
responses will guide further enrolment according to the stoppi[INVESTIGATOR_004].  The futility  
boundaries (inclusive) for ORR for Arm A are 0/12, 1/14, 2/17, 3/20, 4/22, 5/24, 6/26, 
7/27, 8/28, 9/29, and 10/30 subjects and are shown in tabular format in Section 12.7. Up 
to 30 subjects will be enrolled in Arm A. All available data will be considered in making 
enrollment decisions.
Arm A: Screening procedur e for subjects on chemotherapy
To avoid any undue delay in initiating s ystemic chemotherap y for subjects with newly 
diagnosed Stage IV or recurrent metastatic disease, the first cy cle of chemotherapy  may  
be initiated while determination of eligibility  is being completed for the present study .  
2013N165256_06 CONFIDENTIA L
FGF117360
35The first dose of [COMPANY_004]3052230 should be given no later than C ycle [ADDRESS_471739] the 
following done:
Complete full screening procedures for FGF117360 as outlined in Section 7.1.
All treatment related toxicities (>Grade 2) should be resolved prior to starting 
[COMPANY_004]3052230.
Ensure documentation of all medical history  (adverse events pre -baseline) in eCRF 
prior to start of treatment with [COMPANY_004]3052230.
4.2.2. Arm B
The starting dose (Dose Level 0) and escalation/de -escalation schema for [COMPANY_004]3052230 
in combination with docetaxel is presented in Table 4.  Depending on emerging data, 
additional intermediate or lower dose -levels bey ond those described may  be explored.
Table 4 Combination Therapy : Arm B [COMPANY_004]3052230 + Docetaxel
Dose Level Dose of [COMPANY_004]3052230
(weekly)Docetaxel
(once every 21 days)
Dose Level -2 5 mg/kg 40mg/m2
Dose Level -1 5 mg/kg 55mg/m2
Starting Dose Level 0 5mg/kg 75mg/m2
Dose Level 1 10 mg/kg 75mg/m2
Dose Level 2 20 mg/kg 75mg/m2
A total of at least [ADDRESS_471740] been enrolled, the number of observed confirmed 
responses will guide further enrolment according to the stoppi[INVESTIGATOR_004]. The futility  
boundaries (inclusive) for ORR for Arm B are 0/14, 1/22, 2/26, 3/28, 4/29, and 5/30 
subjects and are shown in tabular format in Section 12.7 Up to 30 subjects will be 
enrolled in Arm B. All available data will be considered in making enrollment decisions.
4.2.3. Arm C
Arm C will open for enr ollment subsequent to Amendment 3. The starting dose of 
[COMPANY_004]3052230 (Dose Level 0) in Arm C will be 10 mg/kg, as long as the 5 mg/kg dose in 
combination with chemotherap y in Arm A did not exceed the MTD. Otherwise, the 
starting dose level in Arm C will be D ose L evel -1. Dose levels and escalation/de-
escalation schema for [COMPANY_004]3052230 in combination with pemetrexed and cisplatin is 
presented in Table 5.  Depending on emerging data, additional intermediate or lower 
dose-levels bey ond those described may  be explored.
2013N165256_06 CONFIDENTIA L
FGF117360
36Table 5 Combination Therapy : Arm C [COMPANY_004]3052230 + Pemetrexed + Cisplatin
Dose LevelDose of [COMPANY_004]3052230
(Weekly)Pemetrexed + Cisplatin
(once every 21 days)
Dose Level -2 5 mg/kg 400 mg/ m2 + 60 mg/m2
Dose Level -1 5 mg/kg 500 mg/m2 + 75 mg/m2
Starting Dose Level 0 10mg/kg 500 mg/m2 + 75 mg/m2
Dose Level 1 20 mg/kg 500 mg/m2 + 75 mg/m2
A total of at least [ADDRESS_471741] been enrolled, the number of observed confirmed 
responses will guide further enrolment according to the stoppi[INVESTIGATOR_004]. The futility  
boundaries (inclusive) for ORR for Arm C are 2/12, 3/14, 4/16, 5/18, 6/20, 7/21, 8/23, 
9/24, 10/25, 11/26, 12/27, 13/28, 14/29 and 15/30 subjects and are shown in tabular 
format in Section 12.7 Up to 30 subjects will be enrolled in Arm C. All available data 
will be considered in making enrollment de cisions.
4.2.4. Dose -Limiting Toxicity
DLT will be defined as toxicities due to [COMPANY_004]3052230 or due to the combination of 
[COMPANY_004]3052230 with chemotherap y within Cycle 1 (first 21 day s of period on study ) that 
are unlikel y to be due to another cause, such as the known effects of cy totoxics 
chemotherap y alone, disease progression, or accident, according to the criteria below: 
Grade 3 or 4 clinicall y significant non -hematological toxicity  (excluding: Grade 3 
nausea/vomiting or Grade 3 diarrhea that responds to optimal me dical care within 3 
days; Grade 3 infusion reactions that can be medically  managed without the use of 
systemic pressors and allow completion of infusion.)
Grade 4 neutropenia lasting more than 7 day s
Grade 4 febrile neutropenia
Grade 4 thrombocy topenia (of any duration)
Grade 4 clinically  significant laboratory  abnormalities with duration greater than 
48hrs
Treatment delay  of 14 day s or greater due to unresolved drug -related toxicity .
Any grade [ADDRESS_471742] ed at 
which < 33% of subjects experience a DLT.  Up to [ADDRESS_471743] dose evaluated if the MTD is not reac hed (this dose 
2013N165256_06 CONFIDENTIA L
FGF117360
37will be described as the MFD).  The dose recommended for Phase [ADDRESS_471744] dose escalations may  be considered on a case -by-case basis, provided that
thehigher dose level cohort from the 3+[ADDRESS_471745] who enrolled at a 
dose level below the MTD (or MFD) and may be eligible for dose increases if the 
investigator believes the subject could benefit.
[IP_ADDRESS]. Alternative Dosing and Schedule Coh orts
Additional doses and schedules may  be explored based on emerging pharmacokinetic and 
safet y data. Alterations may  be made to the schedule ofPK/PD sampling based on 
emerging PK data.   
The sample size of the “ alterative dosing and schedule cohorts” will be based on the 3 + 3 
design with potential to expand to up to 30 subjects in this regimen.  
The rationale for exploring this alterative dosing and/or schedule is to expand on the 
safet y, tolerabilit y and preliminary efficacy .
4.3. Rationale
4.3.1. Rationale for E valuation of [COMPANY_004]3052230 in Chemotherapy  
Combinations
FGFR1 amplification has been associated with significantly  shorter disease free and 
overall survival in NSCLC [ Kim, 2013; Heist , 2012].  Carboplatin and paclitaxel can be 
used in first line therap y of NSCL C and docetaxel is a standard second line agent.  
Pemetrexed and cisplatin is the standard first line therap y for mesothelioma. Additive 
antitumor effect was demonstrated in tumor xenograft models treated with the 
combinations of [COMPANY_004] 3052230 and chemotherap y including paclitaxel and carboplatin as 
well as docetaxel. Malignant pleural mesothelioma (MPM) is a tumor ty pe where FGF2 
ligand overexpression has been observed in a high perc entage of primary  specimens and 
where [COMPANY_004]3052230 preclinical efficacy  has been observed in xenograft models. Based 
on the clinical and preclinical data, the combination of [COMPANY_004]3052230 with chemotherap y 
will be investigated in patients with NSCL C or with mesothelioma.
4.3.2. Rationale for Dose of [COMPANY_004]3052230
The highest dose tested in the Phase 1 study  FP1039 -001 was 20 mg/kg. A maximum 
tolerated dose was not determined in the Phase 1 trial; the 20 mg/kg dose was determined 
to be safe and was declared the maximum fea sible dose.  This dose was not associated 
2013N165256_06 CONFIDENTIA L
FGF117360
38with toxicity  in rat and dog toxicity  studies of 13 weeks duration.  A 10 to 20 mg/kg dose 
is estimated to be the dose range needed to achieve clinical activit y based on 
exposure/efficacy  relationships in preclinic al xenograft models.  In these efficacy  models, 
trough plasma levels of [COMPANY_004]3052230 associated with tumor growth inhibition of 54% to 
69% ranged from approximately  0.2 to 23.3 µg/mL for preclinical doses of 1.3 mg/kg to 
12.8 mg/kg.  Levels within the upper part or above that range were achieved at clinical 
doses of [COMPANY_004]3052230 of 10 and 20 mg/kg.  Weekly  dosing is required to maintain levels 
within the expected range for activity , based on PK anal ysis from the completed Phase 1 
study  (GlaxoSmithKline Document Number 2013N160379_00).
4.3.3. Rationale for Endpoints
Safety , tolerability  and efficacy  (ORR) are being assessed to address the primary  
objectives of the stud y. The safet y assessments along with the PK will be important for 
determining the MTD (or MFD). The efficacy  and pharmacod ynamic assessments will 
further support the recommended phase II dose and expand the understanding regarding 
mechanism of action. Response rate stoppi[INVESTIGATOR_377024] 
A, B and C. In each case, the null hy pothesis rate was determined using available 
literature and the alternative hy pothesis rate constituted an improvement in therapy . 
Details of null and alternative hy pothes is rates are provided in Section 12.3. Symptom 
assessments as measured by  [CONTACT_377085] L CSS-meso were added to increase the 
understanding of the patient experience and perceptions.
4.4. Stud y Treatment A ssignment
Subjects will be identified by  a unique subject number that will remain consistent for the 
duration of the study.  Upon completion of all the required screening assessments, 
eligible subjects will be registered into RAMOS (Registration and Medication Ordering 
System).
4.5. Dosage and A dministration of Study  Treatments
4.5.1. [COMPANY_004]3052230
Subjects in all arms will receive [COMPANY_004]3052230 administered as a 30 -minute infusion once 
a week (Day  1, Day  8, and Day  15) of each [ADDRESS_471746] be recorded.
[IP_ADDRESS]. Study  treatments: A lternative Dosing and Schedule cohorts
Subjects in these expansion cohorts will be dosed based on the pharmacokinetic and 
safet y data from the ongoing study .  This will be determined at FGF117360 Study  
Investigator mee tings (example: dose escalation meeting) and the minutes and 
2013N165256_06 CONFIDENTIA L
FGF117360
39agreements would be provided to I RB/Ethics prior to dosing in this “Alternative Dosing 
and Schedule” Cohorts.
4.5.2. Paclitaxel + Carboplatin
Subjects in Arm A will receive pre -treatment for paclitaxel and carboplatin according to 
institutional standards. Paclitaxel according to the dose level being investigated as 
described in Table 3will be administered intravenously  over 3 hours (or according to 
local clinica l standards) in a constant rate infusion on Day  1 of each 21 day treatment 
cycle immediatel y followed by i.v. carboplatin at a dose calculated for a target maximum 
AUC of AUC=6 as a 30 to 60 minute constant rate infusion (or according to local clinical 
standards).  A total of 4 to 6 cy cles of paclitaxel/carboplatin will be administered per 
local clinical practice.
Carboplatin will be dosed using the Calvert Formula [ Calvert , 1989]. This approach uses 
a mathematical fo rmula, which is based on a subject’s pre- existing renal function or renal 
function and desired platelet nadir. Renal excretion is the major route of elimination for 
carboplatin. The formula calculates the dose based on a subject’s glomerular filtration 
rate (GFR in mL /min) as measured b y Cr-EDTA clearance and carboplatin target area 
under the concentration versus time curve (AUC in mg/ml •min ). With the Calvert 
formula, the total dose of carboplatin is expressed in mg, NOT mg/m2:
Total Carboplatin Dose (mg) = (target AUC) x (GFR1+ 25)
1NOTE: The GFR used in the above Calvert formula to calculate AUC -based 
carboplatin dosing should not exceed 125 mL/min. Therefore, the maximum 
carboplatin dose (mg) equals the target AUC ( mg/ml•min ) multiplied by  150 mL/min.
Maximum Carboplatin Dose (mg) = target AUC (mg/ml•min) x (150 mL /min)
The maximum dose is based on a GFR estimate that is capped at 125 mL/min for patients 
with normal renal function. No higher estimated GFR values should be used.
For a target AUC = 6, the maximum dose is 6 x 150 = 900 mg
For a target AUC = 5, the maximum dose is 5 x 150 = 750 mg
For a target AUC = 4, the maximum dose is 4 x 150 = 600 mg
The maximum target AUC explored in any  cohort in this study  is AUC=6. Therefore, 
using the Calvert formula above, the maximum carboplatin dose in mg should not 
exceed 900 mg.
The Cockroft -Gault formula (see Appendix 3 ) can be used to calculate the creatinine 
clearance (CL CR), which can be substituted for the GFR in the Ca lvert formula.
Additional information, packaging, preparation and administration information can be 
found in the prescribing information for carboplatin [ Paraplatin USPI , 2010]. 
Dose modifications should follow the guid elines in Section 4.7. Start and stop times of all 
infusions must be recorded.
2013N165256_06 CONFIDENTIA L
FGF117360
404.5.3. Docetaxel
Subjects in Arm B will receive pre- treatment for docetaxel according to institutional 
standards. Docetaxel will be adminis tered according to the dose level being explored as 
described in Table 4as an i.v. infusion over 1 hour (or according to local clinical 
standards) on Day  [ADDRESS_471747] labeling (e.g. US package insert or product monograph) for 
country  specific docetaxel dosing guidelines.
Dose modifications should follow the guidelines in Section 4.7. Start and stop times of all 
infusions must be recorded.
4.5.4. Pemetrexed and Cisplatin
Subjects in Arm C will receive pre -treatment for pemetrexed and cisplatin according to 
institutional standards. Pemetrexed according to the dose level being investigated ( Table 
5) will be administered intravenousl y over 10 minutes (or according to local clinical 
standards) on Day  1 of each 21 day  treatment cy cle followed 30 minutes later by  i.v. 
cisplatin infused over 2 hours.
Subjects will be hy drated and pre -medicated with folic acid and vitamin B12 supplements 
in order to reduce the incidence and severit y of hematologic and gastrointestinal toxicities 
as well as cutaneous h ypersensitivity  reactions as per institutional guidelines.  
Recommendations for pre -medication are as follows:
1-2 liters of fluid infused for 8- 12 hours prior to cisplatin dose (or h ydration per local 
standard)
350-1000 g folic acid, once dail y, by [CONTACT_377086], during treatment, and for [ADDRESS_471748] dose of 
pemetrexed
1000 g vitamin B12 b y intramuscular injection in the week preceding the first dose 
of pemetrexed and every  three cy cles thereafter (subsequent vitamin B12 injections 
may be given on the same day  as pemetrexed)
4mg dexamethasone (or equivalent), twice daily , by [CONTACT_377087], th e day  
of, and the day after pemetrexed administration   
Additional information can be found in the prescribing information for pemetrexed 
[Alimta Package Insert, 2004] and cisplatin [ Platinol , 2010]..  
2013N165256_06 CONFIDENTIA L
FGF117360
414.6. Safet y Management Guidelines
4.6.1. Liver Chemistry Stoppi[INVESTIGATOR_377025] 8 (see Section 4.7.3 ). For subjects who are notbeing treated with docetaxel, please 
follow the guidelines below.
Liver chemistry  threshold stoppi[INVESTIGATOR_339215] y 
and to evaluate liver event etiology  during administration of study  treatment(s) and the 
follow -up period. Study  treatment(s) will be stopped if any  of the following liver 
chemistry  stoppi[INVESTIGATOR_377026]/are met:
1.Alanine aminotransferase (ALT) 3 times upper limit of normal (ULN) and bilirubin 
[ADDRESS_471749] (or ALT  3 times UL N and international normalization ratio 
[INR] >1.5)
NOTE: Serum bilirubin fractionation should be performed if testing is available. If 
fractionation is unavailable, urinary  bilirubin is to be measured via dipstick (a 
measurement of direct bilirubin, which would suggest liver injury ).
2.ALT [ADDRESS_471750].
3.ALT [ADDRESS_471751] if associated with the appearance or worsening of rash or 
hepatitis sy mptoms (fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, or jaundice) or hy persensitivity  (such as fever, rash, or eosinophilia).
4.ALT [ADDRESS_471752] persists for  4 weeks.
5.ALT [ADDRESS_471753] and cannot be monitored weekly  for 4 weeks.
Subjects with AL T [ADDRESS_471754] and <[ADDRESS_471755] and bilirubin <[ADDRESS_471756], who 
do not exhibit hepatiti s symptoms or rash, can continue study  treatment(s) as long as they  
can be monitored weekl y for 4 weeks. See following section for details on weekl y 
follow -up procedures for these subjects.
[IP_ADDRESS]. Liver Chemistry  Follow -up Procedures
Refer to the diagram in Appendix [ADDRESS_471757] meets the liver chemistry 
stoppi[INVESTIGATOR_103034] 4.6.1:
Immediately  and permanently  withdraw the subject from study  treatment. 
Notify  the [COMPANY_004] Medical Monitor within [ADDRESS_471758]’s study  treatment(s) cessation and follow -up.
Complete the “Sa fety Follow -Up Procedures” listed below.
2013N165256_06 CONFIDENTIA L
FGF117360
42Complete the liver event electronic case report forms (eCRFs). If the event also 
meets the criteria of a serious adverse event (SAE) (see Section 8.2), the SAE data 
colle ction tool will be completed separatel y with the relevant details.
Upon completion of the safet y follow- up permanently  withdraw the subject from the 
study  and do not rechallenge with study  treatment(s).
Safety Follow -Up Procedures for subjects with ALT [ADDRESS_471759]:
Monitor subjects weekly until liver chemistries (ALT, aspartate aminotransferase 
[AST], alkaline phosphatase [ALP], and bilirubin) resolve, stabilize or return to 
within baseline values.
Safety Follow -Up Procedures for subjects with ALT [ADDRESS_471760] and bilirubin [ADDRESS_471761] (or ALT [ADDRESS_471762] and INR >1.5):
This event is considered an SAE (see Section 8.2). Serum bilirubin fractionation 
should be performed if testing is available. If fractionation is unavailable, urinary  
bilirubin is to be measured via dipstick (a measurement of direct bilirubin, which 
would suggest liver injury).
Make every  reasonable attempt to have subjects return to the clinic within 24 hours 
for repeat liver chemistries, additi onal testing, and close monitoring (with specialist 
or hepatology  consultation recommended).
Monitor subjects twice weekly until liver chemistries (ALT, AST, alkaline 
phosphatase, bilirubin) resolve, stabilize or return to within baseline values.
In additi on, for all subjects with ALT [ADDRESS_471763] be made to 
also obtain the following:
Viral hepatitis serology  including:
Hepatitis A I mmunoglobulin M (IgM) antibody .
Hepatitis B surface antigen and Hepatitis B Core Antibody  (IgM).
Hepatitis C ribonucleic acid (RNA).
Cytomegalovirus IgM antibody .
Epstein -Barr viral capsid antigen IgM antibod y (or if unavailable, obtain 
heterophile antibod y or monospot testing).
Hepatitis E IgM antibody
Blood sample for PK analy sis, obtained within [ADDRESS_471764] the 
date/time of the PK blood sample draw and the date/time of the last dose of study  
treatment(s) prior to blood sample draw on the eCRF. If a PK sample cannot be 
collected in the time period indicated above, do not obtain a PK sample .
Instructions for sample handling and shippi[INVESTIGATOR_377027]. A subject 
may be requested to provide 2 samples for PK analy sis (4mL sample per compound) 
2013N165256_06 CONFIDENTIA L
FGF117360
43if the samples are taken less than [ADDRESS_471765] dose of paclitaxel (Arm A) or 
docetaxel (Arm B).
Serum creatine phosphokinase and lactate deh ydrogenase.
Fractionate bilirubin, if total bilirubin [ADDRESS_471766].
Obtain complete blood count with differential to assess eosinophilia
Record the appearance or worsening of clinical s ymptoms of hepati tis or 
hypersensitivity , such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash or eosinophilia, on the AE eCRF.
Record use of concomitant medication(s), acetaminophen, herbal remedies, other 
over-the-counter medication(s), or putative hepatotoxins on the Concomitant 
Medications eCRF.
Record alcohol use on the L iver Events eCRF.
The following are required for subjects with ALT 3 times UL N andbilirubin [ADDRESS_471767] but are optional for other abnormal liver chemistries:
Anti- nuclear antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver kidney  
microsomal antibodies.
Liver imaging (ultrasound, magnetic resonance imaging [MRI ] or computed 
tomograph y [CT] scan) to evaluate liver disease.
Liver Imaging and/or Liver Biops y eCRFs are also to be completed if these tests are 
performed.
4.6.2. QTc Stoppi[INVESTIGATOR_347082] a subject meets the corrected QT (QTc)1 interval duration criteria below following 
manual over -read of the ECG, study  treatment(s) will be withheld. 
QT interval corrected for heart rate b y Fridericia’s formula (QTcF) >530 msec
1Based on average QTc value of triplicate electrocardiograms (ECGs) with manual over -
read. For example, if an ECG demonstrates a prolonged QT interval, obtain 2 additional 
ECGs over a brief period (e .g., within approximately  10 minutes of the abnormal ECG, if 
possible, and approximately  10 minutes apart from each other), and then use the averaged 
QTc values of the [ADDRESS_471768] study  
treatment(s) withheld.
If the QTc prolongation resolves to Grade [ADDRESS_471769] may  be re -started on 
the study  treatment(s) if the investigator and [COMPANY_004] Medical Monitor agree that the subject 
will benefit from further treatment. Dose reduction should be considered if the signs or 
symptoms are indicative of a proarrhy thmic potential.
For subjects recruited in [LOCATION_009] or the [LOCATION_006], please refer to Appendix 7 for the country  
specific QTc stoppi[INVESTIGATOR_3418].
2013N165256_06 CONFIDENTIA L
FGF117360
444.6.3. Left Ventricular Ejection Fraction (LVEF) and Valvular Toxicity  
Stoppi[INVESTIGATOR_2121]
[IP_ADDRESS]. LVEF Stoppi[INVESTIGATOR_301078] y must be performed at Screening and at Cy cle 4 visit as outlined in the 
Time and Events Table (Section 7.1). Subjects who have an asy mptomatic, absolute 
decrease of >10% in left ventricular ejection fraction (LVEF) compared with baseline and
the ejection fraction is below the institution’s lower limit of normal (LLN) should 
temporaril y discontinue [COMPANY_004]3052230 and have a repeat evaluation of LVEF wi thin 1 
week. Echocardiogram (ECHO) should be repeated every  [ADDRESS_471770] and within 10% of baseline.
If the LVEF recovers (defined as LLN and absolute decrease 10% compared 
with baseline) at a ny time during the next [ADDRESS_471771] may  be restarted on 
[COMPANY_004]3052230 at a reduced dose. For such subjects, monitoring of LVEF will be 
performed 3 weeks after rechallenge, and every  3 weeks thereafter for 6 weeks 
and then per protocol.
If repeat LVEF does not recover within 4 weeks, treatment with [COMPANY_004]3052230
should be permanentl y discontinued. Ejection fraction should be monitored 
every  4weeks for a total of 16 weeks or until resolution.
Subjects with Grade 3 or 4 (sy mptomatic) left ventricular s ystolic dy sfunction must 
discontinue treatment with [COMPANY_004]3052230.  Ejection fraction should be monitored every  
4weeks for a total of 16 weeks or until resolution. 
Copi[INVESTIGATOR_377028] 
a >10% decrease in LVEF from baseline and whose cardiac ejection fraction is 
<institutional LLN may  be required by  [CONTACT_301172].  Additionally , the decrease in 
LVEF is to be reported as an SAE. Instruction s for submitting qualify ing ECHOs may  be 
found in the SPM.
[IP_ADDRESS]. Cardiac Valve Toxicity  Stoppi[INVESTIGATOR_301080] a new asy mptomatic, moderate regurgitation or stenosis by  
[CONTACT_6751] (ECHO) (Grade 2 mitral/tricuspid/aortic valvular toxicity  per National 
Cancer Institute -Common Toxicity  Criteria for Adverse Events [ NCI-CTCAE], version 
4.03) should temporaril y discontinue [COMPANY_004]3052230 and have a repeat evaluation by  
[CONTACT_301174] 1 week.  Echocardiogram should be repeated every  1 to 2 weeks for 4 
weeks o r until valve recovery  to baseline.
If the valve recovers to baseline an y time during the treatment cycle, after 
consultation and approval of the [COMPANY_004] Medical Monitor , the subject may  be 
restarted on [COMPANY_004]3052230 at a reduced dose(s).  For such subjects, moni toring of 
the valve via ECHO will then be performed 3 weeks after rechallenge, as 
clinically  appropriate.
2013N165256_06 CONFIDENTIA L
FGF117360
45If repeat ECHO does not reveal valve recovery  to baseline within a treatment 
cycle, then the subject should permanentl y discontinue [COMPANY_004]3052230 .  The v alve 
should continue to be monitored via ECHO every 3 weeks after rechallenge, as 
clinically  appropriate, until resolution.
Subjects with a Grade 3 or 4 (s ymptomatic, severe regurgitation/stenosis by  [CONTACT_301175] ) valvular toxicity  must discontinue 
[COMPANY_004]3052230 .  Valvular toxicity  should continue to be monitored every  [ADDRESS_471772] be performed at baseline and at Cy cle 4.  Copi[INVESTIGATOR_301081](s) and 
cardiology  consul tations performed on subjects who experience valvular toxicity  may  be 
required b y [COMPANY_004] for review.  Additionally, the valvular toxicity  is to be reported as an 
SAE. I nstructions for submitting qualify ing ECHOs are provided in the SPM.
4.6.4. Management of Diarrhea
Diarrhea was reported in 44% of subjects participating in Study  FP1039- 001. The 
majority  of these events were CTC grade 1 (88%) and no events of severe diarrhea were 
reported.  A baseline assessment of stool pattern is recommended in order to establish 
potential treatment emerging changes. Subjects should be instructed to immediately  
notify  their ph ysician/healthcare provider at onset of diarrhea and prompt investigation of 
potential causes should be initiated.  When infectious causes have been excluded, a nti-
diarrheals (e.g. loperamide) should be considered.  For recommended dose modifications, 
see Section 4.7. 
4.6.5. Management of Fluid Retention
Fluid retention should be graded as outlined in Table 6. No dose reduction is planned for 
fluid retention.  Patients developi[INVESTIGATOR_377029]. Regimens found to be 
effective in the mana gement of fluid retention due to docetaxel are listed below. Diuretic 
therap y ma y be initiated in the order listed at the discretion of the investigator: 
Spi[INVESTIGATOR_8407] 50 mg by [CONTACT_1966] (PO), once to three times daily. 
Furosemide 40 mg PO daily  if not responsive to spi[INVESTIGATOR_8407]. 
Potassium supplementation may  be given as needed. 
If, after a trial of > 2 weeks, this is ineffective, treat with furosemide 20 mg PO dail y 
plus metolazone 2.5 mg PO daily  with potassium supplementation as needed. 
Further thera py following fluid retention should be customized depending upon the 
clinical situation.
2013N165256_06 CONFIDENTIA L
FGF117360
46Table 6 Grading and Management of Fluid Retention
Severity Grading Edema a Effusion a
Mild (1) Asymptomatic Asymptomatic
Moderate (2) Symptom atic Symptomatic –intervention may be 
required
Severe (3) Symptomatic –discontinue study 
drugsSymptomatic –intervention required
a. Report the highest grade.
4.7. Dose Modifications
The severit y of adverse events (AEs) will be graded utilizing the National Cancer 
Institute -Common Terminology  Criteria for Adverse Events (NCI -CTCAE), 
version 4.03. Guidelines for dose modifications and interruptions for management of 
common toxicities associated with the study  treatment(s) are provided in this section.  
These include general guidelines based on the severity  (CTCAE grade) of adverse events 
for [COMPANY_004]3052230 and key recommendations provided in the package insert for paclitaxel, 
carboplatin, and docetaxel [ Taxol PI, 2011 ], [Paraplatin PI, 2010 ], [Taxot erePI, 2010 ].
4.7.1. Dose Delay s
Chemotherap y administration in all arms may  be reduced or delay ed for toxicity , or in the 
interest of subject safet y per invest igator discretion.  Requirement for more than 2 dose 
reductions will result in permanent discontinuation of chemotherap y.  If chemotherap y is 
discontinued due to toxicity , subjects may  continue to receive [COMPANY_004]3052230 (Section 
6.3).
4.7.2. Hematologic Toxicity Related to Chemotherapy
Guidelines for management of hematologic toxicity  attributed to chemotherapy  are given 
in Table 7. For severe cy topenias (grade 4), frequent follow -u p of hematology  should be 
performed (at least every [ADDRESS_471773] Grade 3) and supportive 
therap y including G -CSF (per ASCO guidelines) is encouraged.  These are recommended 
reductions. Local guidelines for dose reductions may  vary .  Dose reductions that differ 
from the following table should be discussed with the [COMPANY_004] Study  Physician
2013N165256_06 CONFIDENTIA L
FGF117360
47Table 7 Chemotherapy  Dose Delay  and Modifications for Hematologic 
Toxicity
Hematologic Toxicity
Modification Instructions Absolute Neutrophil 
Count (ANC) NadirPlatelets Nadir
≥500 to <1500 mm3 
(or <500/mm3for <7 days 
and no neutropenic fever)AND/OR
≥75,000 to <100,000/mm3Withhold chemotherapy until ANC 
≥1500/mm3and
Platelets ≥ 100,000/mm3
Restart treatment with no dose reductions
If treatment must be held for more th an 2 
weeks, discuss potential retreatment or 
discontinuation with [COMPANY_004] Study Physician
<500/mm3
for ≥7 days and no 
neutropenic fever
OR
Neutropenic feverAND/OR
<75,000/mm3Withhold chemotherapy until ANC 
≥1500/mm3and
Platelets ≥ 100,000/mm3
Arm A: Res tart combination chemotherapy at 
dose levels reduced by 1 level for both agents 
according to Table 3. 
Arm B: Restart docetaxel reduced by 1 level 
according to Table 4
Arm C: Restart combi nation chemotherapy 
reduced by 1 level for the chemotherapy dose 
according to Table 5
Note, 2 dose reductions are allowed in case 
of recurring toxicity. 
If neutropenic fever occurs prophylactic G -
CSFs should be us ed with further 
chemotherapy treatment.
4.7.3. Non- hematologic Toxicity Related to Chemotherapy
Guidelines for management of non- hematologic toxicity  attributed to chemotherapy  are 
given in Table 8.
2013N165256_06 CONFIDENTIA L
FGF117360
48Table 8 Chemotherapy  Dose Delay  and Modifications for Non -hematologic 
Toxicity
Adverse Event Action
Non-hematological, Grade 1 or 2 Continue chemotherapy.
Non-hematological, drug -related 
Grade 3 or 4 (except alopecia)Hold chemotherapy until recovery to Grade ≤1.
Arm A: Restart at dose levels reduced by 1 level for both agents 
according to Table 3.
Arm B: Restart docetaxel reduced by 1 level according to Table 4
Arm C: Restart combina tion chemotherapy reduced by 1 level for 
the chemotherapy dose according to Table 5
Exceptions
Grade 3 or 4 hypersensitivity 
reactionsFor Grade 3 hypersensitivity/infusion reactions that can be 
medically managed without the use of systemic pressors and allow 
completion of infusion, subjects are allowed to continue treatment 
at current dose with appropriate hypersensitivity prophylaxis.
Grade 4: discontinue study treatment
Grade 2 neurotoxicity Arm C : Withhold st udy treatment until recovery to Grade 1; then 
resume treatment with cisplatin reduced by 50% of previous dose
Grade 3 or 4 Neurotoxicity Withhold study treatment until recovery to Grade 1; then resume 
treatment at dose reduced by 2 levels according to Table 3(Arm A) 
or Table 4(Arm B). Permanently discontinue chemotherapy in Arm 
C. If treatment delay is more than 2 weeks, re -initiation of treatment 
should be agreed with the [COMPANY_004] study physician.
Severe or cumulative cutaneous 
reaction (any Grades)Hold until ≤Grade 1 or to baseline and restart with reduction in 
dose by 1 level according to Table 3(Arm A) or Table 4(Arm B).
AST/ALT >1.[ADDRESS_471774] and
ALP >2.5 X ULNaArm B: Hold docetaxel. Monitor liver chemistries weekly. When 
recovered, docetaxel may be restarted reduced by 1 level 
according to Table 4.Also consult Section 4.6.1 for actions with 
[COMPANY_004]3052230
Bilirubin >ULN Arm B: Hold docetaxel. Monitor liver chemistries weekly. When 
recovered, docetaxel may be restarted reduced by [ADDRESS_471775]< AST/ALT< 5xULN and 
[ADDRESS_471776]< bilirubin  < 1.25 X ULNaArm A: At time of event, if the subject is d osing >175 mg/m2 of 
paclitaxel then dose reduce to 175 mg/m2; if the subject is currently 
at 175 mg/m2  then maintain the current dose level (remain at 175 
mg/m2.). Also consult Section 4.6.[ADDRESS_471777]< AST/ALT< 5xULN and
bilirubin 1.26 -2.0 X ULNaArm A: Reduce paclitaxel to 135 mg/m2 (or dose level below if 
already treated at this level). Also consult Section 4.6.[ADDRESS_471778]< AST/ALT< 3xULN and
bilirubin 2.01 -5.0 X ULNaArm A; Reduce paclitaxel to 90 mg/m2, If this is the second dose 
reduction required for liver toxicity, discontinue treatment. Also 
consult Section 4.6.[ADDRESS_471779]/ALT> [ADDRESS_471780] and
bilirubin 2.01 -5.0 X ULNaArm A: This requires discontinuation of [COMPANY_004]3052230 and, hence, 
discontinuation from study after appropriate safety follow up.
Mucositis, Grade 3 or 4 Arm C: Reduce pemetrex ed only by 50% of previous dose
Serum creatinine >1.5 mg/100mL or 
BUN >25mg/100mLArm C: Hold chemotherapy until serum creatinine <1.5 mg/100mL 
or BUN <25mg/100mL
Creatinine clearance <45 mL/min Arm C: Hold chemotherapy until creatinine clearance ≥45 mL/min
a. Day 1 value to be used in determining elevation. Note that dose reductions for liver toxicity are permanent. Liver 
chemistry following -up procedures see Section [IP_ADDRESS] .
2013N165256_06 CONFIDENTIA L
FGF117360
494.7.4. [COMPANY_004]3052230 Dose Modifications
For toxicities at least possibly  related to [COMPANY_004]3052230, dosing may  be interrupted or 
delay ed up to 14 day s.  Approval from the [COMPANY_004] Study  Physician is required to restart a 
dose after 14 day s of dose interru ption. 
If necessary , 5 mg will be the minimum dose level.  Following a dose reduction and 
resolution of toxicity  to baseline levels, individual subjects may  be re -escalated to a 
higher dose level with the approval of the [COMPANY_004] Study  Physician.
Guidelines fo r dose modifications are outlined in Table 9
.
Table 9 [COMPANY_004]3052230 Dose Modification Guidelines
Grade Action
Grade 1 drug related event No delay or modification
Grade 2 drug related event May hold until reduced to Grade 1 or baseline at the discretion of the 
investigator, no dose reduction.
Grade 3 or higher drug related 
event (except Grade 3 nausea 
that resolves with clinical 
intervention)Hold until Grade 1 or baseline, dose reduce 50%
If the toxicity  is potentially  related to both [COMPANY_004]3052230 and chemotherap y as given in
all arms , please refer to dose modification for chemotherapy  in Section 4.7.2 and Section 
4.7.3 for potential dose reduction of both study  treatments.
Subjects who experience a toxicity  related to [COMPANY_004]3052230 that precludes further 
treatment with [COMPANY_004]3052230 will be withdrawn from the study  treatment.
[IP_ADDRESS]. [COMPANY_004]3052230 Dose Modifications regar ding infusion related reactions
Subjects should be closely monitored for [COMPANY_004]3052230 infusion
-related reactions. All 
subjects who have experienced an infusion reaction due to [COMPANY_004]3052230 (and not 
chemotherap y) should have [COMPANY_004]3052230 infused over 60 minutes instead of 30 minutes 
and pre -treated with appropriate local instituation al pre-treatment guidelines (example: 
medications such as steroids, antihistamines, acetaminophen, H- 2 antagonists, and 
antiemetics, according to local pre -treatment guidelines). If the subject continues to have 
a reaction on re -challenge ,the infusion of [COMPANY_004]3052230 may  be prolonged to [ADDRESS_471781]
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of investigational product(s) (IP) received b y the subject as per the protocol design. Stud y 
treatment may  therefore refer to the individual study  treatment or the combination of 
those study  treatments.
Refer to the SPM (the FGF117360 Pharmacy  Manual) for additional details on 
investigational product procedures.
5.1. Description of Investigational Products
5.1.1. [COMPANY_004]3052230
Product name : [CONTACT_23983]3052230, 12.8 mg/mL
Formulation description:The product is formulated in 0.94 mg/mL sodium phosphate monobasic, 
1.9 mg/mL sodium phosphate dibasic, 8.8 mg/mL sodium chlorid e, 0.2 
mg/mL polysorbate 80, pH 7.0 at a [COMPANY_004]3052230 (HGS1036) 
concentration of 12.8 mg/mL. [COMPANY_004]3052230 contains no preservative.
Dosage form: Solution for infusion
Unit dose strength(s)/Dose 
Level(s):20 mg/kg
15 mg/kg
10 mg/kg
5 mg/kg
Physical Descripti on: The drug product is a clear to opalescent, colorless to pale yellow 
solution that may contain small amounts of translucent to white 
proteinaceous particles.
Route/
Administration/ Duration:Intravenous infusion once weekly (Day 1, Day 8, Day 15) in e ach 21 -
day cycle administered using a 0.2 μm in -line filter
Dosing instructions: Administer as a 30 minute infusion
Manufacturer: [COMPANY_004]
[COMPANY_004]3052230 will be provided to sites by  [CONTACT_23983]. [COMPANY_004]3052230 is supplied in a sterile 
25mL glass vial. Each vial is intend ed for single use. The deliverable volume per vial is 
20mL. The contents of the label will be in accordance with all applicable regulatory  
requirements.
5.1.2. Chemotherapeutic A gents
Paclitaxel, carboplatin, docetaxel, pemetrexed, and cisplatin will be sourced locally  from 
commercial stock, except in countries where Regulatory  Authorities mandate that the 
Sponsor must supply  all non -investigational product (I Ps) required for study  
participation. Investigators are responsible for ensuring that subjects receive su pplies of 
paclitaxel, carboplatin, docetaxel, pemetrexed, and cisplatin for the entire duration of the 
study , as appropriate.  The contents of the label will be in accordance with all applicable 
regulatory  requirements.
2013N165256_06 CONFIDENTIA L
FGF117360
515.2. Preparation/Handling/Storage of [COMPANY_004]3052230
Preparation
Using aseptic techniques, [COMPANY_004]3052230 will be diluted in a 250 mL  (nominal volume) 
i.v. bag containing either 5% dextrose solution or normal saline. [COMPANY_004]3052230 is stable 
after dilution in 5% dextrose solution or normal saline for up to 8 hours at ambient 
temperature (~25ºC). [COMPANY_004]3052230 infusion must be completed within 8 hours of the 
dilution. Please refer to SPM for recommended IV supplies.
Handling
Under normal conditions of handling and administration, I P is not expected to pose 
signifi cant safet y risks to site staff.  A Material Safety  Data Sheet (MSDS) describing the 
occupational hazards and recommended handling precautions will be provided to site 
staff if required b y local laws or will otherwise be available from [COMPANY_004] upon request.
Take adequate precautions to avoid direct eye or skin contact [CONTACT_377088].
In the case of unintentional occupational exposure notify  the study  monitor, the [COMPANY_004] 
Medical Monitor and/or the study  manager.
Refer to the SPM (the FGF117 360 Pharmacy  Manual) for detailed procedures for the 
disposal and/or return of unused study  treatment(s).
Storage
Access to and administration of the [COMPANY_004]3052230 will be limited to the investigator and 
authorized site staff. [COMPANY_004]3052230 must be dispensed or administered only  to subjects 
enrolled in the study  and in accordance with the protocol. Refer to the SPM (the 
FGF117360 Pharmacy Manual) for storage conditions.
5.3. Product A ccountability
In accordance with local regulatory  requirements, the investigator, designated site staff, 
or head of the medical institution (where applicable) must document the amount of I P 
dispensed and/or administered to study  subjects, and the amount received from and 
returned to [COMPANY_004], when applicable.  Product accountability  records must be maintained 
throughout the course of the study .  Refer to the SPM (the FGF117360 Pharmacy  
Manual) for further detailed instructions on product accountability .
5.4. Treatment Compliance
[COMPANY_004]3052230 and chemotherap y will be intravenously administered to subjec ts at the 
study  site. Administration will be documented in the source documents and reported in 
the eCRF.
2013N165256_06 CONFIDENTIA L
FGF117360
525.5. Treatment of Study  Treatment Overdose
In the event of an overdose (defined as administration of more than the protocol -specified 
dose) of [COMPANY_004]3052230, the investigator should:
contact [CONTACT_377089]
closely  monitor the subject for adverse events (AEs)/serious adverse events 
(SAEs) and laboratory  abnormalities until [COMPANY_004]3052230 can no longer be 
detected s ystemically  (at least 14 day s)
obtain a plasma sample for PK anal ysis if requested by  [CONTACT_377090] (determined on a case -by-case basis)
document the quantity  of the excess dose as well as the duration of the 
overdosing in the eCRF.
Decisions regarding dose interruptions or mo difications will be made by  [CONTACT_377091].
In the event of an overdose of chemotherap y agents, please consult product label as well 
as following the above proce dures.
6. COM PLETION OR WITHDR AWAL  OF SUBJECTS
6.1. Screen Failures
Data for screen failures will be collected in source documentation at the site. Subjects 
who did not meet all eligibility  requirements but whose tumor tissue was tested for 
FGFR1 amplification b y the central laboratory  will be entered to the Assay  Validation 
Population.
6.2. Subject Completion Criteria
A completed subject is one who has discontinued study  treatment for reasons listed in 
Section 6.3and comple ted the follow -up visit [ADDRESS_471782] dose, or has died while on 
study .
6.3. Permanent Discontinuation from Study  Treatment
Subjects will receive study  treatment until disease progression, death or unacceptable 
toxicity , including meeting stoppi[INVESTIGATOR_377030] 4.6.1 . 
In addition, study  treatment may  be permanentl y discontinued for an y of the following 
reasons:
deviation(s) from the protocol
request of the subject or prox y (withdrawal of consent by  [CONTACT_377092] )
investigator’s discretion (which may  include safety , behavioral or administrative 
reasons )
2013N165256_06 CONFIDENTIA L
FGF117360
53a dose delay  of >[ADDRESS_471783]
intercurrent illness that prevents further administration of study  treatment(s)
termination of the study  by [CONTACT_2728]
Subject is lost to follow -up.
The primary  reason study  treatment was permanently  discontinued must be documented 
in the subject’s medical reco rds and eCRF. 
Subjects who permanently discontinue chemotherapy  may  continue [COMPANY_004]3052230 until 
meeting one of the reasons for discontinuation stated above.  The primary  reason each 
study  treatment was discontinued must be documented in the medical record a nd on the 
eCRF. The reason for discontinuing [COMPANY_004]3052230 may  differ from the reason 
chemotherap y was discontinued. 
If the subject voluntaril y discontinues from treatment due to toxicity , ‘adverse event 
(AE)’ will be recorded as the primary  reason for perma nentl y discontinuation on the 
eCRF. 
Once a subject has permanently  discontinued from study  treatment, the subject will not 
be allowed to be retreated. 
All subjects who discontinue from stud y treatment will have safet y assessments at the 
time of discontin uation and during post -study  treatment follow -up as specified in Time 
and Events Table (see Section 7.1).
6.4. Stud y Completion
The study  will be considered completed when at least 80% of subjects have completed 
the study .  Upon completion of the study , if subjects are still continuing to receive benefit 
from [COMPANY_004]3052230, plans will be developed to provide continued access to [COMPANY_004]3052230 
for those subjects.
Per the EU Clinical Trial Directive, the end of the study  is de fined as the last subject’s 
last visit.
6.5. Treatment after the End of the Study
The investigator is responsible for ensuring that consideration has been given for the 
post-study  care of the subject’s medical condition whether or not [COMPANY_004] is providing 
specific post-study  treatment.
7. STUDY A SSESSMENTS A ND PROCEDURES
A signed, written informed consent form must be obtained from the subject prior to an y 
study -specific procedures or assessments being performed.
2013N165256_06 CONFIDENTIA L
FGF117360
54The timing of each assessment is listed in the Time and Events Table (Section 7.1).  The 
timing and number of the planned samples may  be altered to a minor extent (no more 
than 1 to 3 additional samples) during the course of the study based on newly available 
data (e .g. to obtain samples closer to the time of peak plasma concentrations).  The 
change in timing or addition of time points for any of the planned samples must be 
approved and documented by  [CONTACT_23983], but this will not constitute a protocol amendment. 
The institut ional review board (IRB) or ethics committee will be informed of an y safety 
issues that require alteration of the safety monitoring scheme. Specific blood volumes for 
analysis will be specified in the SPM. 
Whenever vital signs, 12 -lead electrocardiograms (ECGs) and blood draws are scheduled 
for the same nominal time, the assessments should occur in the following order: [ADDRESS_471784] nominal time. Detai led procedures for obtaining each 
assessment are provided in the SPM.
7.1. Time and Events Table
This section consists of the Time and Events Table to describe assessment windows and 
sequencing of stud y-specific assessments and procedures. 
2013N165256_06 CONFIDENTIA L
FGF117360
55Table 10 Time and Events Schedule
Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 day 
F/U
D1 D8 D15 D1 D8 D15 D1 D8 D15
Visit WindowOnce the subject provides consent, a tumor sam ple may be submitted for Arms A and B for FGFR1 amplification at any time (there is no time limit or window).  
All other screening assessments should be conducted within 30 days of C1D1. Visit windows of ±2 days during study through EOT , +7 days for F/U . For Arm A 
subjects who wish to start chemotherapy prior to [COMPANY_004]3052230 screening period is 30 days +3 to allow baseline imaging scans to be performed prior to 
chemotherapy but within 30 +3days of [COMPANY_004]3052230 first dose.
Informed consentMain study and PGx o ptional consent; register 
subject X
Medical History, Medical history, review of inclusion & exclusion 
criteria X
Physical examand height 
(baseline only)Not needed C1D1 if screening assessments 
within prior 72 hrs. Complete phys ical exam at 
screening. Abbreviated disease -oriented 
physical exam subsequently. X X X X X X
WeightNote, during dosing period weight should be 
captured on Day 1 of each cycle.  It can be 
obtained more frequently per institutional 
standards (exampl e: if required at each infusion) X X X X X X
Ophthalmologic ExamTo be performed by [CONTACT_377093]. (Visit windows of ±[ADDRESS_471785] 
baseline). X Perform assessment if subject discontinues prior to C4. C4 only
ECHOPerfor m at EOT if subject discontinues prior to 
C4. Visit windows of ±[ADDRESS_471786] chemotherapy 
infusion and within 20 min before start of 
[COMPANY_004]3052230 infusion. X X X X
Forced Vital CapacityAssess D1 of every odd cycle, Arm C only, Visit 
windows of ±[ADDRESS_471787] baseline. X XOdd
X
Hematology and ChemistryNot needed C1D1 if screening assessments 
within pr ior 72 hrs. See Table 12for analytes. In X X X X X X XA 
only X
2013N165256_06 CONFIDENTIA L
FGF117360
56Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 day 
F/U
D1 D8 D15 D1 D8 D15 D1 D8 D15
addition Arm A: D8 of additional cycles while 
receiving paclitaxel + carboplatin only
Coagulation and 
pancreatic markers See Table 12for analytes X X X
Thyroid TSH at Screening. XTSH every [ADDRESS_471788] +7 days of firs t dose; urine or serum 
test onward X X
UrinalysisObtain prior to infusion of [COMPANY_004]3052230 on 
C1D1 X X X X
ECG (single read)Prior to [COMPANY_004]3052230 infusion and 1 hr (±10 
min) after end of [COMPANY_004]3052230 i.v. on C1D1. 
Prior to [COMPANY_004]3052230 i.v. onward X X X XAs clinically 
indicated X X
Pharmacokinetics See Table 11 X X X X X X
Immunogenicity Obtain prior to infusion of [COMPANY_004]3052230 X X D1 of every 2 cycle, C4 to C15 X
Archival Tumor Tissue Archived tumor tissue (or fresh biopsy if no 
archival tissue). Once the subject provides 
consent, a tumor sample may be submitted for 
Arms A and B for FGFR1 amplification at any 
time (there is no time limit or window). X
Circulating cell -free DNA 
Sample Predose. First sample +7 days prior to C1D1 X X
Circulating Biomarkers Plasma sample collected predose (+7 days prior 
to C1D1) X XArm C: D1 every cycle 
(1week) for 1 year, then D1 
every 2 cycles ( 2weeks) X
Blood sam ple for PGxCollect any time on study but only if PGx 
informed consent has been signed; preferred on 
C1D1 after dosing. X
Brain Scan Obtain only if symptomatic X every 12 weeks 1 week if positive at Screening, or as clinically indicated
Bone Scan X As clinically indicated
2013N165256_06 CONFIDENTIA L
FGF117360
57Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 day 
F/U
D1 D8 D15 D1 D8 D15 D1 D8 D15
Radiologic and Disease 
AssessmentCT scan, PET -CT scan or MRI. Imaging 
modality consistent during study and not change XEvery 2 cycles ( 1 week) for 1 
year; thereafter every 4 cycles 
(2 week) X
LCSS (Arms A and B); 
LCSS -meso (Arm C) Must be administered first before any other tests 
or procedures. Study staff should check for 
completeness. X X X X X X
[COMPANY_004]3052230 30 minute infusion. X X X X X X X X X
ARM A: Paclitaxel + 
Carboplatin [COMPANY_004]3052230 i nfused & observed 1 hr prior to 
chemotherapy doses. May start chemotherapy 
during screening period, see inclusion #2 X X X
ARM B: Docetaxel [COMPANY_004]3052230 infused & observed 1 hr prior to 
chemotherapy infusions. X X X
ARM C: Pemetrexed +
Cisplatin [COMPANY_004]3052230 infused & observed 1 hr prior to 
chemotherapy infusions. X X X
Adverse Event 
Assessment X Continuous monitoring during study
Concomitant Medications X Continuous monitoring during study
2013N165256_06 CONFIDENTIA L
FGF117360
58Table 11 Pharmacokinetic Sampling Schedule
FGF117360 Pharmacokinetic Sampling Schedule
Limited PKExtensive PK Extensive PK Extensive PK
Time When Window Arm A Arm B Arm C
n=20pts in each arm n>=10pts n>=10pts n>=10pts
Cycle 1 Day 1Prior to infusio n of 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
End of infusion of 
[COMPANY_004]3052230Up to 5 min prior to end of 
infusion of [COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
1hr after end of infusion of 
[COMPANY_004]3052230 10 min but after ECG[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
2hr after end of infusion of 
[COMPANY_004]3052230 or end of 
docetaxel infusion10 min or up to 5 min prior to 
end of docetaxel infusion[COMPANY_004]3052230 
PK[COMPANY_004]3 052230 
PK [COMPANY_004]3052230 PK
Cycle 1 Day 8Prior to infusion of 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052230[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
Cycle 2 Day 1Prior to infusion of 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052230 [COMPANY_004] 3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
End of infusion of 
[COMPANY_004]3052230Up to 5 min prior to end of 
infusion of [COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
1 hr after start of paclitaxel 
infusion or end of 
docetaxel or pemetrexed 
infusion10 min for paclitaxel or up to 
5min prior to end of docetaxel 
infusion or up to 1 min prior to 
end of pemetrexed infusion[COMPANY_004]3052230 
PK
Paclitaxel PK[COMPANY_004]3052230 
PK
Docetaxel PK[COMPANY_004]3052230 PK
Pemetrexed PK
Cisplatin PK
1 hr after e nd of 
pemetrexed infusion 20 minPemetrexed PK
Cisplatin PK
End of paclitaxel infusion 
or 2 hr after end of 
docetaxel or pemetrexed 
infusionup to 5 min prior to end of 
paclitaxel infusion or 20 min 
for docetaxel and pemetrexed Paclitaxel PK Docetaxel PKPemetrexed PK
Cisplatin PK
2 hr after end of paclitaxel 
infusion or 5 hr after end 
of docetaxel or 
pemetrexed infusion 30 min(selected sites)
[COMPANY_004]3052230 
PK
Paclitaxel PK(selected sites)
[COMPANY_004]3052230 
PK
Docetaxel PK(selected sites)
[COMPANY_004]3052230 PK
Pemetrexed PK
Cisplatin PK
2013N165256_06 CONFIDENTIA L
FGF117360
59FGF117360 Pharmacokinetic Sampling Schedule
Limited PKExtensive PK Extensive PK Extensive PK
Time When Window Arm A Arm B Arm C
Cycle [ADDRESS_471789] PK sampling performed (either Limited PK or Extensive PK). Serial PK samples will be performed on at l east the first [ADDRESS_471790] 6 
subjects having serial PK at the MTD/MFD. For Arm C, at least [ADDRESS_471791] in the 
study.
2013N165256_06 CONFIDENTIA L
FGF117360
607.2. Demographic/Medical History  and Baseline A ssessments
The following demographic parameters will be captured during Screening: date of birth, 
gender, race and ethnicity.
Medical/medication history  assessed as related to the eligibility  criteria listed in 
Section 3.2.
Baseline (Screening) assessments obtained will include:
Complete phy sical examination, including height (in cm) and weight (in kg).
Vital signs (i.e., blood pressure, temperature, respi[INVESTIGATOR_2842], pulse rate)
Eastern Cooperative Oncology  Group (ECOG) performance status
Clinical laboratory tests: hematology , clin ical chemistry  [and urinal ysis]
Serum beta -human chorionic gonadotropin ( -HCG) pregnancy  test for female 
subjects of childbearing potential only
12-lead electrocardiogram (ECG)
Echocardiogram (ECHO) 
LCSS for Arms A & B
For Arm C onl y: LCSS (meso) and forced vital capacity
Review of concomitant medications
Procedures conducted as part of the subject’s routine clinical management (e.g., blood 
count, imaging stud y) and obtained prior to signing of informed consent may be utilized 
for Screening or baseline purposes provided the procedure meets the protocol- defined 
criteria and has been performed in the timeframe of the study .
7.2.1. Critical Baseline Assessments
Ophthalmologic examination, ocular, and cardiovascular medical history /risk factors will 
be assessed at baseline.
Assessment regarding deregulation of FGF signaling pathway  (e.g. FGFR gene 
amplification, FGF ligand overexpression, etc) is required during screening.  Archival 
tissue may  be used for this analy sis. If archival tissue is not available, a fresh b iopsy  will 
be required. This will be assessed b y a central laboratory for Arms A and B.
For Arm C, forced vital capacit y will be assessed at screening.
7.3. Safet y Evaluations
Planned time points for all safety  assessments are provided in the Time and Events Ta ble 
(Section 7.1).
2013N165256_06 CONFIDENTIA L
FGF117360
617.3.1. Physical Examinations
A complete ph ysical examination will include assessments of the head, ey es, ears, nose, 
throat, skin, thy roid, neurological, lungs, cardiovascular, abdomen (liver and spl een), 
lymph nodes and extremities. Height and weight will also be measured and recorded.
A brief ph ysical examination will include assessments of the lungs, cardiovascular 
system, and abdomen (liver and spleen).
7.3.2. ECOG Performance Status
The performance stat us will be assessed using the ECOG scale (see Appendix 4 ) as 
specified in the Time and Events Table ( Section 7.1).
7.3.3. Vital Signs
Vital sign measurements will include sy stolic and diastolic blood pressure, temperature, 
respi[INVESTIGATOR_352363].  All vital sign measurements will be obtained after the 
subject has rested for at least [ADDRESS_471792] methods (Refer to the SPM for details )
7.3.5. Electrocardiogram
Single 12- lead ECGs will be obtained at designated time points during the study  using an 
ECG machine that automatically  calculates the heart rate and measures PR, QRS, QT, 
and corrected QT (QTc ) intervals.  At each assessment a 12-lead ECG will be performed 
by [CONTACT_377094] a [ADDRESS_471793] and is in a 
semi -recumbent position. 
The QT interval should be corrected for heart rate by [CONTACT_6550]’s form ula (QTcF). 
Additional QTc readings may  be necessary .
Refer to the SPM for details regarding ECG procedures.
7.3.6. Echocardiogram
ECHOs will be performed at baseline to assess cardiac ejection fraction and cardiac valve 
morphology  for the purpose of study  eligib ility and Cy cle 4, as specified in the Time and 
Events Table ( Section 7.1).  Additional ECHO assessments may  be performed if 
clinically  warranted. The evaluation of the echocardiographer should include an 
2013N165256_06 CONFIDENTIA L
FGF117360
62evalua tion for left ventricular ejection fraction (LVEF) and both right and left -sided 
valvular lesions.
Copi[INVESTIGATOR_377031] >10% 
in LVEF compared to baseline concurrent with LVEF <lower limit of normal ( LLN), or 
who experience valvular toxicity , may  be required by  [CONTACT_301172].
7.3.7. Ophthalmologic Examinations
An ophthalmologic exam will be performed at baseline and at C ycle 4 (or as clinically 
appropriate), as specified in the Time and Events Table (Section 7.1).  These exams will 
be performed b y an ophthalmologist or qualified optometrist and includes a slit -lamp 
examination and intraocular pressure .  During the study , ophthalmologic assessments 
performed b y the investigator will include inspection of the external ey e to assess for
redness and query  of subjects for s ymptoms of photophobia, vision problems, or ey e pain.  
If at an y time the subject complains of photophobia, changes in vision, or eye pain; the 
ophtha lmic examination finding are abnormal; or visual acuity  has worsened by  [ADDRESS_471794].
7.3.8. Laboratory  Assessments
All protocol required laboratory  assessments, as defined in ( Table 12) should be 
performed according to the Time and Events Table (Section 7.1).  Details for the 
preparation and shipment of samples to the central laboratory  will be provided in the 
SPM.
Prior to administration of the first dose of stud y treatment, results of laboratory 
assessments should be reviewed.  An y laboratory  test with a value outside the normal 
range may  be repeated (prior to the first dose) at the discretion of the investigator.
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinical significant by  [CONTACT_093] (for example SAE or AE or dose 
modification) the results must be recorded in the subject’s CRF. Refer to the SPM for 
appropriate processing and handling of samples to avoid duplicat e and/or additional 
blood draws. 
All laboratory  tests with values that are significantly  abnormal during participation in the 
study  or within [ADDRESS_471795] dose of stud y treatment should be repeated until the 
values return to normal or baseline. If such values do not return to normal within a 
period judged reasonable by  [CONTACT_093], the etiology  should be identified and the 
sponsor notified.
Hematology , clinical chemistry , urinal ysis and additional parameters to be tested are 
listed below:
2013N165256_06 CONFIDENTIA L
FGF117360
63Table [ADDRESS_471796] of Clinical Laboratory  Tests
Hematology
Platelet Count Automated WBC Differential :
Red blood cell (RBC) Count Neutrophils (absolute)
White blood cell (WBC) Count 
(absolute) Lymphocytes (absolute)
Hemoglobin Monocy tes (absolute)
Eosinophils (absolute)
Basophils (absolute)
Clinical Chemistry
Potassium, Sodium, Chloride, Total carbon dioxide, total Calcium, ionized calcium* , magnesium, phosphate, 
albumin, glucose (fasting),
Blood urea nitrogen (BUN), Creatinine , Uric Acid, creatinine clearance
Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyl transferase (GGT), 
Alkaline phosphatase, Total bilirubin (if elevated also test direct bilirubin) 
Thyroid hormone: TSH at Screening; every [ADDRESS_471797] total T3, total T4, and free T4.
Pancreatic tests (amylase and lipase)
Coagulation tests (prothrombin time, partial thromboplastin time, international normalized ratio, a nd 
fibrinogen)
Routine Urinalysis
pH, glucose, protein, blood and ketones by [CONTACT_19508] (if blood or protein is abnormal)
Other screening tests
Pregnancy test for females (serum at screening, urine or serum post dose)
*Ionized c alcium collected may not be collected in some selected sites and only total calcium is collected for 
subjects regarding safety monitoring.
7.3.9. Pregnancy  Testing and Reporting
The need for a screening pregnancy  test depends on whether a female subject is of 
childbearing potential or non- childbearing potential.
If a female subject is of childbearing potential, she must have a serum -HCG pregnancy 
test performed within [ADDRESS_471798].
Any pregnancy  that occurs during study participation (note, study  participation is defined 
as the time of the first dose of study  drug [COMPANY_004]3052230 is administered) m ust be reported 
using a clinical trial pregnancy  form. To ensure subject safet y, each pregnancy must be 
reported to [COMPANY_004] within [ADDRESS_471799] be 
followed up to determine outcome (including premature termination) and status of 
mother and child. Pregnancy complications and elective terminations for medical reasons 
must be reported as an AE or SAE. Spontaneous abortions must be reported as an SAE.
2013N165256_06 CONFIDENTIA L
FGF117360
64Any SAE occurring in association with a pregnancy  brought to the inves tigator’s 
attention after the subject has completed the stud y and considered b y the investigator as 
possibly  related to the study  treatment(s), must be promptly  reported to [COMPANY_004].
7.4. Evaluation of A nti-Cancer Activity
Disease assessment will include imaging (e. g., computed tomograph y [CT] scan, 
magnetic resonance imaging [MRI ]) as appropriate for the specific tumor ty pe.  Disease 
assessment will be completed within [ADDRESS_471800] year. Subsequent assessments will follow the 
Time and Events Table (Section 7.1), which also should be consulted for the schedule of 
assessments of anti -cancer activit y.  Assessments must be performed on a calendar 
schedule and should not be affected b y dose interruptions/delay s.  For post -baseline 
assessments, a window of  [ADDRESS_471801]’s withdrawal from study  and progressive disease has not been documented, a 
disease assessment should be obtained at the time of withdrawal from study.
Disease progression and response evaluations will be determined according to the 
definitions established in RECI ST1.1 [Eisenhauer , 2009].  Subjects whose disease 
responds (either complete response [CR] or partial response [PR]) should have a 
confirmatory  disease assessment performed no earlier than 4 we eks after the date of 
assessment during which the response was demonstrated. More frequent disease 
assessments may  be performed at the discretion of the investigator. Please see Section 
[IP_ADDRESS] for the evaluatio n of best overall response. To ensure comparabilit y between the 
baseline and subsequent assessments, the same method of assessment and the same 
technique will be used when assessing response. 
Disease response will also be quantified b y change in volume to support the exploratory  
objectives.   Comparison between RECIST evaluations, linear tumor dimensions, and 
variations in tumor volume will be performed [ O’Connor , 2008].
Inclusion of up to three pre- study  tumor imagi ng scans performed prior to baseline scans 
at study  entry  will also be encouraged in subjects whose scans are available for review.  
Prior tumor imaging scans will be analy zed (see SPM for additional details) and 
quantitative tumor data (e.g., tumor measur ements, tumor volumes) will be generated.  
Depending on data availability , the slope of tumor growth prior to study  entry  and 
following treatment may be calculated and compared in an exploratory  analy sis.  Such 
comparisons may  be important in evaluation of the clinical significance of subjects 
achieving a clinical response, particularl y in those subjects achieving SD.
Research sites will be trained in volumetric anal ysis using a standardized review 
platform.  Depending on the outcome of site based assessmen ts, images may  be collected 
centrall y for further analysis.
Please see the SPM for specific guidelines for CT and MRI  acquisitions and anal ysis.
CT: For contrast enhanced CT, contiguous slices (no gap) may be no greater than 5mm. 
However, 3mm slice thickne ss or less is strongl y preferred for volume analy sis. MRI  is 
2013N165256_06 CONFIDENTIA L
FGF117360
65acceptable, but when used, scanning should be optimized for the evaluation of the ty pe 
and site of disease and must be measured in a consistent anatomic plane for each 
timepoint. Whenever possibl e, the same scanner should be used [ Eisenhauer , 2009].
For Arms A and B, RECIST 1.[ADDRESS_471802] 
1.1. All measur ements were added to obtain the total tumor measurement. The Image 
Acquisition Guidelines portion of the SPM should be consulted for additional details on 
imaging protocols.
Brain Scan : In subjects with known brain metastases (criteria outlined in Section 3.2), a 
contrast -enhanced MRI (preferred) or CT of the brain must be obtained within [ADDRESS_471803] of the brain 
will be required in case of new clinical signs and symptoms indicative of brain 
metastases.
Bone Scan : Including evaluation of skull, total spi[INVESTIGATOR_050], clavi cle, ribs, pelvis and long 
bones. Other imaging modalities are allowed such as PET or MRI .
If a subject’s bone -scan lesions are consistent with tumor metastases, or are consistent 
with non- malignant lesions, confirmatory  imaging assessments are not necessa ry.  The 
anatomic sites and nature of the lesions must be documented in the eCRF.
If bone scan lesions are equivocal for tumor metastases, a confirmatory  imaging 
assessment must be performed using X -ray, CT, or MRI  to determine the nature of the 
lesions. T he lesion sites and nature of lesions must be documented in the eCRF.  For 
lesions that are confirmed as tumor metastases, the same imaging modality must be used 
for all subsequent follow -up bone lesion assessments.
Volumetric Analysis : Retrospective evalu ation of tumor volumes will also be performed 
in subjects with sufficient CT or MRI  imaging data. Comparison between RECI ST 
evaluations, linear tumor dimensions, and variations in tumor volume will be performed 
[O’Connor , 2008].
2013N165256_06 CONFIDENTIA L
FGF117360
667.4.1. Evaluation of Response in Arm A and A rm B (RECIST 1.1)
[IP_ADDRESS]. Evaluation of target lesions
Definitions for assessment of response for target lesion(s) are as follows:
Complete Response (CR): Disappearance of all target lesions. Any  pathological 
lymph nodes must be <10 mm in the short axis.
Partial Response (PR): At least a 30% decrease in the sum of the diameters of 
target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent 
change from baseline).
Stable Disease (SD): Neithe r sufficient shrinkage to qualify  for PR nor sufficient 
increase to qualify  for progressive disease.
Progressive Disease (PD) : At least a 20% increase in the sum of the diameters of 
target lesions, taking as a reference, the smallest sum of diameters recor ded since the 
treatment started (e.g. percent change from nadir, where nadir is defined as the 
smallest sum of diameters recorded since treatment start).  In addition, the sum must 
have an absolute increase from nadir of 5mm.
Not Applicable (NA): No target lesions at baseline.
Not Evaluable (NE): Cannot be classified b y one of the five preceding definitions.
NOTE :
If lymph nodes are documented as target lesions the short axis is added into the sum 
of the diameters (e.g. sum of diameters is the sum of the lo ngest diameters for non -
nodal lesions and the short axis for nodal lesions).  When ly mph nodes decrease to 
non-pathological size (short axis <10mm) they  should still have a measurement 
reported in order not to overstate progression.
If at a given assessment time point all target lesions identified at baseline are not 
assessed, sum of the diameters cannot be calculated for purposes of assessing CR, 
PR, or SD, or for use as the nadir for future assessments.  However, the sum of the 
diameters of the assessed l esions and the percent change from nadir should be 
calculated to ensure that progression has not been documented.  If an assessment of 
PD cannot be made, the response assessment should be NE.
All lesions (nodal and non -nodal) should have their measurements recorded even 
when very  small (e.g., 2 mm).  I f lesions are present but too small to measure, 5 mm 
should be recorded and should contribute to the sum of the diameters, unless it is 
likely  that the lesion has disappeared in which case 0 mm should be repor ted.
If a lesion disappears and reappears at a subsequent time point it should continue to 
be measured.  The response at the time when the lesion reappears will depend upon 
the status of the other lesions.  For example, if the disease had reached a CR stat us 
then PD would be documented at the time of reappearance.  However, if the response 
status was PR or SD, the diameter of the reappearing lesion should be added to the 
remaining diameters and response determined based on percent change from baseline 
and p ercent change from nadir.
2013N165256_06 CONFIDENTIA L
FGF117360
[IP_ADDRESS]. Evaluation of non -target lesions
Definitions for assessment of response for non-target lesions are as follows:
Complete Response (CR): The disappearance of all non -target lesions. All ly mph 
nodes identified as a site of disease at baseline must be non -pathological (e.g. <10 
mm short axis).
Non-CR/Non -PD: The persistence of 1 or more non- target lesion(s) or ly mph nodes 
identified as a site of disease at baseline ≥10 mm short axis.
Progressive Disease (PD): Unequivocal progression of existing non -target lesions. 
Not Applicable (NA): No non -target lesions a t baseline.
Not Evaluable (NE): Cannot be classified b y one of the four preceding definitions.
NOTE :
In the presence of measurable disease, progression on the basis of solely  non-target 
disease requires substantial worsening such that even in the presence of SD or PR in 
target disease, the overall tumor burden has increased sufficientl y to merit 
discontinuation of therapy .
Sites of non-target lesions, which are not assessed at a particular time point based on 
the assessment schedule, should be excluded fro m the response determination (e.g. 
non-target response does not have to be "Not Evaluable"). 
[IP_ADDRESS]. New lesions
New malignancies denoting disease progression must be unequivocal. Lesions identified 
in follow -up in an anatomical location not scanned at baseline are considered new 
lesions.
Any equivocal new lesions should continue to be followed.  Treatment can continue at 
the discretion of the investigator until the next scheduled assessment. If at the next 
assessment the new lesion is considered to be unequivoca l, progression should be 
documented.
[IP_ADDRESS]. Evaluation of overall response
Table 13 presents the overall response at an individual time point for all possible 
combinations of tumor responses in target and non -target lesio ns with or without the 
appearance of new lesions for subjects with measurable disease at baseline.
2013N165256_06 CONFIDENTIA L
FGF117360
68Table 13 Evaluation of Overall Response for Subjects with Measurable 
Disease at Baseline
Target Lesions Non-Target Lesions New Lesion s Overall Response
CR CR or NA No CR
CR Non-CR/Non -PD or NE No PR
PR Non-PD or NA or NE No PR
SD Non-PD or NA or NE No SD
NE Non-PD or NA or NE No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR=complete response, PR = partial respons e, SD=stable disease, PD=progressive disease, NA= Not applicable, and 
NE=Not Evaluable
NOTE :
Subjects with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time shoul d be 
classified as having "s ymptomatic deterioration."  Objective response status is 
determined b y evaluations of disease burden.  Every effort should be made to 
document the objective progression even after discontinuation of treatment. 
In some circumsta nces, it may  be difficult to distinguish residual disease from 
normal tissue.  When the evaluation of CR depends on this determination, it is 
recommended that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy ) to 
confirm the CR.
Confirmation Criteria:
To be assigned a status of PR or CR, a confirmatory  disease assessment should be 
performed no less than four weeks (28 day s) after the criteria for response are first met.
[IP_ADDRESS]. Evaluation of best overall response
The best overall response is the best response recorded from the start of the treatment 
until disease progression/recurrence and will be determined programmatically  by [CONTACT_377095]. 
To be assigned a status of SD, the post-baseline disease assessment must have met 
the SD criteria no less than 10 weeks (per Time and Events schedule Section 7.1). 
If the minimum time for SD is not met, best response will depend on the subsequent 
assessments.  For example if an assessment of PD follows the assessment of SD and 
SD does not meet the minimum time requirement the best response will be PD. 
Alternative subjects lost to follow-up after an SD assessment not meeting the 
minimum time criteria will be considered not evalu able.
2013N165256_06 CONFIDENTIA L
FGF117360
69Tips on Lymph Node Measurements:
Lym ph nodes are considered as a separate organ to measure, and up to two ly mph nodes 
can be measured per patient by  [CONTACT_393] v1.1. For unidimensional ly mph node 
measurements, use the short axis of the ly mph node at base line and then at every  
followup scan. To be considered as pathologically  enlarged and measurable at baseline, 
the ly mph node short axis diameter should be ≥15 mm.
7.4.2. Evaluation of Response in A rm C: Mesothelioma
[IP_ADDRESS]. Mesothelioma Tumor Imaging
Clinical trials of therapeutic agents in MPM may  becompromised b y inaccuracy of 
tumor measurements due to the unique pattern of growth of mesothelioma [ By[CONTACT_7943], 2004; 
Tsao , 2011]. Malignant mesothelioma commonly grows as a rind and t hus may  not 
produce spherical lesions with bidimensional, measurable diameters [ By[CONTACT_7943], 2004]. 
Modification of RECI ST criteria have been recommended to address the difficulties in 
measurement of lesions [ By[CONTACT_7943], 2004; Tsa o, 2011]. I n subjects with mesothelioma, it is 
requested that disease assessments using both RECI ST v1.[ADDRESS_471804] v1.1 criteria. Unidimensional measurements are 
added to produce the total tumor measurements (e.g., the sum of 6 pleural thickness 
measurements = one univariate diameter).
Overall tips for measurement of mesothelioma by [CONTACT_377096] [Tsao , 2011]:
1. Larger lesions are easier and more accurate to measure. Choose the larger or thickest 
of the pleural disease to measure. Magnify ing the image may  make an easier 
measurement.
2.The short -axis diameter is defined as the shortest pathway  from the tip of the tumor 
to the chest wall.
3. Ensure that that differentiation of normal chest wall from tumor is easy  at the point 
of measurement
4.To ensure accuracy , all measurements must be performed electronicall y in the same 
window setting on consecutive studies. I t is recommended that the “soft tissue” 
setting (not lung windows) be used, as it enables accurate pleural mass 
measurements with the electronic calipers and avoids the incorporation of chest wall 
or mediastinal fat within the calculations.
2013N165256_06 CONFIDENTIA L
FGF117360
705.CT scan slices up to [ADDRESS_471805] wall/mediastinum.
9.Avoid measuring regions where the tumor infiltration obscures the interface of tumor 
to normal tissue. A good interface for measurement usually  is one where the tumor 
abuts fat or an intact rib/vertebral bod y, as the density of the pleural tumor differs 
significantl y from bone or fat and the difference can be easily  observed. Avoid 
choosing an interface of tumor with muscle, as muscle and tumor have similar CT 
densities and are often difficult to distinguish when they  abut one another.
10.Following the instructions in #5, choose three different axial slices, preferably  above 
the level of the main bronchi and record two measurements per slice, thus resulting 
in six separate measurements.
11.If any nodal, subcutaneous or other bidimensionally measurable lesions are 
available, they should undergo unidimensional measurements by  [CONTACT_23603] v1.1 and 
be added to the total obtained in #7 above.
[IP_ADDRESS]. Prior Scan collection
Collection of up to three prior tumor imaging scans performed p rior to baseline scans at 
study  entry  will also be encouraged in subjects whose scans are available for review. 
These scans may  be collected and sent to an independent radiologist for review. The 
slope of tumor growth prior to study  entry  and following tre atment may  be compared in 
subsequent anal yses. Such comparisons may  be important in evaluation of the clinical 
significance of subjects achieving a clinical response, particularl y in those subjects 
achieving SD.
7.4.3. Patient Reported Outcomes
The Lung Cancer Sy mptom Scale (L CSS) or the Lung Cancer S ymptom Scale -
mesothelioma (L CSS-meso) will be self -administered by  [CONTACT_1766] (patient scales) and 
completed b y the investigator (observer scales) as indicated in the Time and Events 
schedule ( Table 10). The L CSS consists of 9 patient -reported items and 6 observer 
reported items, the LCSS -meso consists of 8 patient- reported items, and are validated in 
lung cancer and in mesothelioma patients [ Hollen, 2006]. Using visual analogue scales 
(range from 0 to100), the patient scale measures the intensity  of patient responses for 
appetite, fatigue, cough, dy spnea, hemopt ysis, pain, and summary  items symptoms of 
lung cancer, activit y level and quality of life. An example questionnaire can be found in 
the SPM. The L CSS and LCSS -meso was chosen because of its focus on disease -related 
2013N165256_06 CONFIDENTIA L
FGF117360
71symptoms, the possibility to combine the patient’s perception with the investigator’s 
contextual knowledge, its demonstrated concept and content validity , ease of application 
and minimal burden to patients. 
It is important that the LCSS and L CSS-meso patient scale is administered at the start of 
the clinic visit before an y other study assessments are performed.
7.5. Pharmacokinetics
7.5.1. Blood Sample Collection for Pharmacokinetics
Blood samples of approximately  4 mL for PK analy sis of [COMPANY_004]3052230 will be collected 
at the time points indicated in the Time and Events Schedule (Section 7.1). For subjects 
in Arm A, a 4mL blood sample for PK analy sis of paclitaxel may  be collected and 
subjects in Arm B, a 4mL blood sample for PK analy sis of docetaxel may  be collected 
(see Section 7.1). Each PK sample should be collected as close as possible to the planned 
time relative to the dose (i.e., time zero) administered to the subject on PK day s. The 
actual date and time of each blood sample collection will be recorded.
The timing and frequency  of the PK sampling may be adjusted based on emerging data. 
Details on PK blood sample collection, processing, storage and shippi[INVESTIGATOR_377032].
7.5.2. Pharmacokinetic Sample A nalysis
Plasma analy sis will be performed under the management of Worldwide Bioanal ysis, 
Drug Metabolism and Pharmacokinetics, [COMPANY_004]. Concentrations of [COMPANY_004]3052230 and 
selected chemotherap y will be determined in plasma samples using the currently  
approved anal ytical methodologies.  Raw data will be stored in the Good Laboratory  
Practice Arc hives, [COMPANY_004].
7.6. Immunogenicity
Plasma samples for determination of anti -[COMPANY_004]3052230 antibodies will be taken from all 
subjects in this study  as a safet y measurement for [COMPANY_004]3052230 at the time -points 
specified in the Time and Events Table in Section 7.1.  Timing of the assessments may  be 
adjusted based on emerging data.
Samples will be analy zed for the presence of anti- [COMPANY_004]3052230 antibodies by  [CONTACT_133374] -
electrochemiluminescent (ECL ) screening assay s.  If samples contain anti- [COMPANY_004]3052230 
antibodies as determined by  [CONTACT_377097] , they  will be further characterized 
for specificity  and antibody  titers.  The immunogenicity  assessment report will include 
the incidence and levels of anti -[COMPANY_004]3052230 binding antibodie s.
Samples obtained for immunogenicit y will be retained in long term storage and may be 
characterized for neutralizing activity  if a positive response is observed.
2013N165256_06 CONFIDENTIA L
FGF117360
727.7. Translational Research
7.7.1. Central Confirmation of FGF Signalling Pathway  Status and 
Translation al Research
Collection of archival tumor tissue is required for all subjects (see Time and Events 
Table; Section 7.1); if not available a fresh sample will be required. A formalin fixed 
paraffin embedded tumor b lock is requested or if not available, approximately  15 sections 
will be needed. Details of the tumor biopsy  collection including amount, processing, 
storage, and shippi[INVESTIGATOR_377033].
In Arms A and B, a requirement for inclusion is evidence of FGFR1 gene amplification 
in tumor tissue as determined by  a central laboratory  (CLIA or appropriate certification) 
using a laboratory  developed test.
In Arm C, FGF2 and/or FGFR1  expression will be evaluated retrospectively  by [CONTACT_377098]3052230
Any remaining tissue from this study  may  be used for:
Development and validation of a potential IUO assay and companion diagnostic test, 
e.g., but not limited to FGFR1 gene a mplification by  [CONTACT_377099]2 and/or FGFR1 
expression by  [CONTACT_4658].
Alternative biomarkers of FGF pathway  signalling such as other ligands or receptors. 
Biomarker research (protein, RNA and DNA) including status of RTK/PI3K/AKT 
pathway s and cancer development and additional testing of DNA, RNA, or protein 
biomarkers related to the function of [COMPANY_004]3052230 if ongoing research identifies or 
defines additional predictive and prognostic biomarkers
It is essential that the required amount of tumor tissue is obtained in order to perform the 
FISH assay  for entry  into the study  in Arms A and B, explore other potential measures of 
FGF signaling pathway  deregulation in all arms including Arm C, and complete the 
necessary  equivalency  and precision testing requirements for the development of an IUO 
and potential companion diagnostic test.
Tissue samples/sections will be retained for the further confirmation using the IUO 
validated assay  or potential companion diagnostic test, when available.  All samples will 
be retained for a m aximum of [ADDRESS_471806] completes the trial .
7.7.2. Peripheral Blood
[IP_ADDRESS]. Plasma for Soluble Markers
Clusters of markers (e.g. cy tokines and angiogenic factors [CAF]) circulating in the 
plasma have been found to correlate with tumor pathway  activatio n. Soluble mesotheline -
related peptides (SMRP) have been shown to be clinical markers of MPM. Blood -based 
markers have the important advantage that specimens are readil y available, simple to 
prepare and store, and can be taken prior to and during treatment . This allows for the 
2013N165256_06 CONFIDENTIA L
FGF117360
73assessment of predictive markers based on the baseline evaluation as well as markers of 
activity  and resistance based on changes that occur during treatment. Therefore, a broad 
panel of CAF, including FGF ligand s, and SMRP will be eva luated in plasma and 
correlated with clinical outcome to treatment with [COMPANY_004]3052230.
Plasma will be collected at multiple times to evaluate circulating cy tokines, angiogenesis 
and other soluble factors. Details of the blood collection (including volume to b e 
collected), processing, storage and shippi[INVESTIGATOR_377034].
[IP_ADDRESS]. Circulating cell free DNA  (cfDNA ) Analysis
Tumor -specific circulating nucleic acid (cfDNA) levels detected in plasma or serum have 
been found to correlate with increasin g tumor burden and decline following therap y. 
Furthermore, cfDNA in cancer subjects can harbor many genetic alterations (mutations, 
microsatellite alterations, aberrant meth ylation), which are generally  consistent with the 
tumor.  Thus, tumor -specific circ ulating cfDNA has the potential to be a useful biomarker 
of therapeutic response as well as offering a less invasive blood based technique for 
identify ing and selecting subjects for certain treatments.  Given the promise of cfDNA 
blood based test for subje ct selection, this test will be explored to determine whether 
mutations in cfDNA correlate with that in the tumor tissue from which it is derived. This 
test will also be explored to correlate increasing cfDNA levels with increasing tumor 
burden.
Plasma sam ples collected at timepoints described in Time and Events Schedule (Section 
7.1)will be anal yzed for mutations in genes relevant to RTK/MAPK/PI 3K pathway  and 
cancer biology  in cfDNA.  Details of the blood colle ction (including volume to be 
collected), processing, storage and shippi[INVESTIGATOR_377034].
7.8. Pharmacogenetics
An important objective of the clinical study  is pharmacogenetic (PGx) research. 
Participation in PGx is optional but all sub jects who are eligible for the clinical study  will 
be given the opportunity  to participate.  Subjects may  decline participation without effect 
on their medical care or care during the clinical study.  A separate consent signature [CONTACT_377139].
Subjects who provide consent will have a blood sample taken for anal ysis.  The 
presence/absence of genetic variations in selected candidate genes in DNA from blood 
will be anal yzed to determine their relationship with response (safety, tolerability , 
pharmacokinetics (PK) and efficacy ) to treatment with [COMPANY_004]2052230.
Information regarding PGx research is included in Appendix [ADDRESS_471807] (IRB)/ethics committee (EC) and, where required, the applicable regulatory  agenc y 
must approve the PGx assessments before these can be conducted at the site.  The 
approval(s) must be in writing and will clearl y specify approval of the PGx assessments 
(i.e., approval of Appendix 1 ).  In some cases, approval of the PGx assessments can occur 
after approval is obtained for the rest of the study .  If so, then the written approval will 
clearl y indicate approval of the PGx assessments is being deferred and the study, except 
for PGx assessments, can be initiated.  Whe n PGx assessments will not be approved, then 
2013N165256_06 CONFIDENTIA L
FGF117360
74the approval for the rest of the study  will clearl y indicate this and therefore, PGx 
assessments will not be conducted.
8. ADVERSE EVENTS A ND S ERIOUS ADVERSE EVENT S
The investigator or site staff will be responsibl e for detecting, documenting and reporting 
events that meet the definition of an AE or SAE as outlined in Section 8.1and 
Section 8.2, respectivel y.
8.1. Definition of an AE
Any untoward medical occurrence in a subject or clinical investigation subject, 
temporally  associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.  For marketed medicinal products, this 
also includes failure to produce expected benefits, abuse, or misuse. Examples of events 
meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or grade of the condition
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study
Signs, sy mptoms, or the clinical sequelae of a suspected interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE). 
Events that do not meet the definition of an AE include:
Medical or surgical procedure (e.g., endoscop y, appendectom y); the condition that 
leads to the procedure is an AE.
Situa tions where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
The disease/disorder being studied, or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
2013N165256_06 CONFIDENTIA L
FGF117360
758.2. Definition of a SA E
A SAE is any untoward medical occurrence that, at any  dose:
a.Results in death
b.Is life -threatening
NOTE: The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to an 
event, which h ypothetically  might ha ve caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]: In general, hospi[INVESTIGATOR_5184] 
(usually  involving at least an overnight stay ) at the hospi[INVESTIGATOR_6879] e mergency  ward for 
observation and/or treatment that would not have been appropriate in the phy sician’s 
office or out -subject setting.  Complications that occur during hospi[INVESTIGATOR_23918]. If a complication prolongs hospi[INVESTIGATOR_23919], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability /incapacity , or
NOTE: The term disability means a substantial disruption of a person’s ability  to 
conduct normal life functions.  This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may  
interfere or prevent everyday  life functions but do not constitute a substantial 
disruption.
e.Is a congenital anomal y/birth defect. 
f.Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951].  These should also be considered 
serious. Examples of such events are invasive or malignant cancers, intensive 
treatm ent in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
g.Protocol -Specific SAEs:
All events of possible study  treatment -induced li ver injury  with 
hyperbilirubinemia as defined as alanine aminotransferase (ALT) 3 times upper 
limit of normal (UL N) and bilirubin ≥[ADDRESS_471808] (>35% direct) (or 
ALT≥3times ULN and international normalization ratio (INR) >1.5, if INR is 
measured) or termed ‘Hy’s Law’ events (INR measurement is not required and 
the threshold value stated will not apply  to subjects receiving anticoagulants).
2013N165256_06 CONFIDENTIA L
FGF117360
76NOTE: Bilirubin fractionation is performed if testing is available.  If testing is 
not available, record presence of detectable urinary  bilirubin on dipstick 
indicating direct bilirubin elevations and suggesting liver injury .  If testing is 
unavailable and a su bject meets the criterion of total bilirubin ≥[ADDRESS_471809], 
then the event is still reported as a serious adverse event (SAE). If INR is 
obtained, include values on the SAE form. INR elevations >1.[ADDRESS_471810] severe 
liver injury . 
Any new primary  cancers.
Cardiac toxicity  including LVEF changes or treatment emergent cardiac valve 
toxicity .
Treatment emergent acute anterior uveitis.
8.3. Disease -Related Events and/or Disease -Related Outcomes 
Not Qualify ing as SAEs
An event that is part of the natural course of the d isease under study (i.e., disease 
progression or hospi[INVESTIGATOR_44814]) does not need to be reported as 
a SAE. Death due to disease under stud y is to be recorded on the Death eCRF. However, 
if the underl ying disease (i.e., progression ) is greater than that which would normally  be 
expected for the subject, or if the investigator considers that there was a causal 
relationship between treatment with study  treatment(s) or protocol design or procedures 
and the disease progression, then this must be reported as a SAE.
8.4. Laboratory  and Other Safety  Assessment A bnormalities 
Reported as A Es and SA Es
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis), or 
other safet y assessments (e.g., ECGs, radiological scans, vital signs measurements) 
including those that worsen from baseline, and events felt to be clinicall y significant in 
the medical and scientific judgment of the investigator are to be recorded as an AE or 
SAE, in accordance with the definitions provided.
In ad dition, an associated AE or SAE is to be recorded for any  laboratory  test result or 
other safet y assessment that led to an intervention, including permanent discontinuation 
of study  treatment, dose reduction, and/or dose interruption/delay .
Any new primary cancer must be reported as an SAE. 
However, an y clinicall y significant safet y assessments that are associated with the 
underly ing disease, unless judged by  [CONTACT_23996]'s condition, are not to be report ed as AEs or SAEs .
8.5. Time Period and Frequency  of Detecting AEs and SA Es
The investigator or site staff is responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE. 
2013N165256_06 CONFIDENTIA L
FGF117360
77AEs will be collected from the time the first do se of study  treatment is administered until 
30 day s following discontinuation of study  treatment regardless of initiation of a new 
cancer therap y or transfer to hospi[INVESTIGATOR_6125]. 
SAEs will be collected over the same time period as stated above for AEs. In addition , 
any SAE assessed as related to study  participation (e.g., protocol -mandated procedures, 
invasive tests, or change in existing therap y), study  treatment or [COMPANY_004] concomitant 
medication must be recorded from the time a subject consents to participate in the study  
up to and including an y follow -up contact.  All SAEs will be reported to [COMPANY_004] within 
24 hours, as indicated in Section 8.5.2 .
After discontinuation of study  treatment, the investigator will monitor all AEs/ SAEs that 
are ongoing until resolution or stabilization of the event or until the subject is lost to 
follow -up.  At an y time after [ADDRESS_471811] be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence. Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since your 
last visit/contact?”
8.5.2. Prompt Reporting of SA Es and Other Events to [COMPANY_004]
SAEs, pregnancies, and liver function abnormalities meeting pre- defined criteria will be 
reported promptl y by [CONTACT_377100].
2013N165256_06 CONFIDENTIA L
FGF117360
78Initial ReportsFollow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hours SAE data collection tool 24 hours Updated SAE data 
collection tool 
Pregnancy 2 Weeks Pregnancy Notification 
Form2 Weeks Pregnancy Follow -up 
Form
Liver chemistry abnormalities:
ALT  [ADDRESS_471812] and 
bilirubin [ADDRESS_471813] 
(>35%  direct) (or ALT  [ADDRESS_471814] and INR >1.5, 
if INR is measured)c24 hoursa SAE data collection tool;
Liver Event eCRF and 
liver imaging and/or 
biopsy eCRFs if 
applicableb24 hours Updated SAE data 
collection tool. 
Updated Liver Event 
eCRFb
ALT  [ADDRESS_471815]; ALT 
[ADDRESS_471816] 4weeks24 hoursa Liver Event eCRFb 24 hours Updated Liver Event 
eCRFb
ALT  [ADDRESS_471817] and <[ADDRESS_471818] and bi lirubin <[ADDRESS_471819] safety.
b. Liver event documents should be completed as soon as possible
c. INR measurement is not required; if measured, the threshold value stated will not apply to subjects receiving 
anticoagulants.
Please refer to Section 4.6.1 for liver chemistry  stoppi[INVESTIGATOR_377035] -up 
procedures.
Methods for detecting, recording, evaluating, and following up on AEs and SAEs are 
provided in the SPM .
8.5.3. Regulatory  reporting requirements for SA Es
Prompt notification of serious adverse events (SAEs) by  [CONTACT_377101].
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authority, institutional review board (IRB)/ethics committee (EC) and 
investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
2013N165256_06 CONFIDENTIA L
FGF117360
79An investigator who receives an investigator safety repor t describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/EC, if appropriate according to local requirements.
9. CONCOM ITANT MEDICA TIONS A ND NON -DRUG 
THERA PI[INVESTIGATOR_377036] y new 
medications from the time of first dose of stud y treatment until the end of the study  (Final 
Study  Visit).  Any  concomitant medication(s), including non -prescription medication(s) 
and herbal product(s), taken during the study  will be recorded in the eCRF. Additionally , 
a complete list of all prior anti-cancer therapi[INVESTIGATOR_42214].
If future changes are made to the list of permitted/prohibited medications, formal 
documentation will be provided by  [CONTACT_90621].  An y such changes 
will be communicated to the investigative sites in the form of a letter.
9.1. Permitted Medication(s)
Subjects should receive full supportive care during the stud y, including tr ansfusion of 
blood and blood products, and treatment with antibiotics, antiemetics, antidiarrheals, and 
analgesics, as appropriate. Pre -medication for chemotherapy  is allowed per institutional 
guidelines.
The proph ylactic use of hematopoietic colony  stimul ating factors is not recommended in 
Cycle [ADDRESS_471820] 
prophy lactic use for subjects during the dose escalat ion period or alternative dose finding 
period.  During expansion phase, growth factor support therap y (e.g., G -CSF, GM -CSF) 
may be administered as a prophy laxis for chemotherapy -related neutropenia according to 
the NCCN Clinical Pr actice Guidelines in Onco logy: Myeloid Growth Factors v.1.2010 
[NCCN , 2010] or the European Organisation for Research and Treatment of Cancer 
guidelines for the use of G -CSFs [ Aapro , 2011].  All growth factor use must be recorded 
as concomitant medication. 
Aromatase inhibitors, octreotide, and GnRH analogues are permitted if the subject has 
been receiving these therapi[INVESTIGATOR_377037]. 
Other non- investigational conco mitant medications are discouraged unless medically  
indicated.
9.2. Prohibited Medications
Investigational medications other than [COMPANY_004]3052230 are prohibited throughout the study . 
Anti-cancer agents other than those described within this protocol are prohibited.
Use of oral contraceptives (either combined or progesterone onl y)/estrogenic vaginal 
ring/percutaneous contraceptive patches/implants of levonorgestrel/injectable 
progesterone is prohibited in this study  as it is not known if there is the potential of 
inhibition/induction of enzy mes that affect the metabolism of estrogens and/or progestins.
2013N165256_06 CONFIDENTIA L
FGF117360
80Agents known to alter the metabolism of the baseline chemotherapi[INVESTIGATOR_014], including 
non-traditional medications such as herbal remedies, should be avoided.  If such use is 
identified, then use should be properl y recorded.
Pre-medication (such as anti -histamines or corticosteroids) prior to infusion of 
[COMPANY_004]3052230 should not be used unless the subject has experienced an infusion reaction 
to previous administration or it is a req uired component of concomitant chemotherapy .
9.3. Permitted Non -Drug Therapi[INVESTIGATOR_377038], including advanced or 
metastatic NSCL C, including resection of non- dominant metastases, is prohibited.
In exceptional cases, palliative radiation of bone metastasis may  be allowed during the 
screening or treatment period if all of the following conditions are met:
There is no evidence of disease progression for subjects on study  treatment
Intention of palliation is only  for s ymptom control of bone pain and does not include 
any “target” lesion.
Single -dose palliation is planned (≤8 GY allowed; no prolonged or fractionated RT 
is allowed)
The investigator has reviewed the case with the [COMPANY_004] medical monitor.
[COMPANY_004]3052230 should be stopped [ADDRESS_471821] -
radiation.
10. LIFESTYLE A ND/OR DIETA RY RESTRICTIONS
10.1. Contraception
10.1.1. Female Subjects
A female of non -childbearing potential (i.e., physiologicall y incapable of becoming 
pregnant) is defined as any  female who has had a hy sterectom y, bilateral oophorectom y 
(ovariectomy ) or bil ateral tubal ligation, or is post- menopausal .
A practical definition accepts menopause after 1 year without menses with an appropriate 
clinical profile, e.g., age appropriate, >[ADDRESS_471822] a follicular stimulating hormone 
(FSH) value >40 mIU/mL and an estradiol value < 40pg/mL (<140 pmol/L).
A female of childbearing potential is defined as any  female who does not meet the 
criteria of non -childbearing potential as descr ibed in the previous paragraph.
Female subjects of childbearing potential must not become pregnant during the study  and 
so must be sexually  inactive by  [CONTACT_377102] a failure 
rate of <1%.
2013N165256_06 CONFIDENTIA L
FGF117360
81Abstinence
Sexual inactivity  by [CONTACT_377103]. Periodic abstinence (e.g. calendar, ovulation, sy mptothermal, post -
ovulation methods) and withdrawal are notacceptable methods of contraception. 
Contraceptive Methods with a Failure Rate of <1%
Intrauterine device or intrauterine s ystem that meets the <1% failure rate as stated in 
the product label
Male partner sterilization (vasectomy with documentation of azoospermia) prior to 
the female subject's entry intothe study , and this male is the sole partner for that 
subject.  For this definition, “documented” refers to the outcome of the 
investigator's /designee’s medical examination of the subject or review of the 
subject's medical history  for study  eligibility , as obtained via a verbal interview with 
the subject or from the subject’s medical records.
Double- barrier method: condom and occlusive cap (diaphragm or cervical/vault 
caps) plus vaginal spermicidal agent (foam/gel/film/cream/suppository) 
These allowed methods of contrace ption are only effective when used consistently, 
correctly and in accordance with the product label. The investigator is responsible 
for ensuring subjects understand how to properly use these methods of 
contraception.
Complete abstinence from sexual interc ourse or contraception must be practiced for 
14days prior to first dose of study  treatment, through the dosing period, and for at least 
[ADDRESS_471823]’s semen, male subjects must use one of 
the following contraceptive methods until [ADDRESS_471824] dos e of chemotherapy:
Abstinence, defined as sexual inactivity  consistent with the preferred and usual 
lifesty le of the subject.  Periodic abstinence (e.g. calendar, ovulation, s ymptothermal, 
post-ovulation methods) and withdrawal are not acceptable methods o f 
contraception.
Complete abstinence from sexual intercourse prior to first dose of chemotherapy  
treatment, through the dosing period, and for at least [ADDRESS_471825] dose of 
chemotherap y treatment.
Condom (during non- vaginal intercourse with any  partner -male or female) OR 
Double- barrier method: condom and occlusive cap (diaphragm or cervical/vault 
caps) plus spermicidal agent (foam/gel/film/cream/suppository )
2013N165256_06 CONFIDENTIA L
FGF117360
8211. DATA MANAG EMENT
For this study , data will be collected using defined eCRFs, transmitted electronically  to 
[COMPANY_004] and combined with data provided from other sources in a validated data sy stem.
Patient reported data will be collected via paper questionnaires and will be entered into 
the eCRF centrally . Data will be checked for completeness by  [CONTACT_377104] -compliance will be noted.
Management of clinical data will be performed in accordance with applicable [COMPANY_004] 
standards and data cleaning procedures to ensure the integrity of the data, e.g. removing 
errors and inconsistencies in the data. AEs and concomitant medications terms will be 
coded using Medical Dictionary  for Regulatory  Activities (MedDRA) and an internal 
validated medication dictionary , [COMPANY_004] Drug. Electronic CRFs (eCRFs), includi ng queries 
and audit trails, will be retained by [CONTACT_23983], and copi[INVESTIGATOR_377039] y.
12. DATA ANALYSIS AND ST ATISTICAL CONSIDERA TIONS
12.1. Considerations of statistical design
The sections below show the planned do se cohorts as well as the decision rules, by  [CONTACT_377105], specify ing the number of subjects with a confirmed objective response (according to 
RECI ST 1.[ADDRESS_471826] for Arm C ) needed for continuing enrolment or 
stoppi[INVESTIGATOR_16589] .  The methodology  is based on the predictive probability  of success if 
enrolment continues to 30 subjects [ Lee, 2008].  The predictive probability design is 
similar to a Green -Dahlberg design in that it allows for early  stoppi[INVESTIGATOR_377040] a minimum enrolment has 
been reached whereas the Green -Dahlberg design does this at one fixed interim and at the 
end of enrolment. While the two designs have similar ty pe I and t ype II error rates, the 
probability  of earl y termination is greater with the predictive probability design.  A 
randomized Phase II or Phase III study  may  be conducted based on the results from this 
study . 
12.2. Hypotheses
No formal statistical h ypotheses are being tested during the dose escalation portions of 
Arms A, B, and C.  Analy sis of the data obtained from the dose escalation parts of the 
study  will be focused on comparison between dose cohorts and onl y descriptive methods 
will be used in anal ysis of the data.
For the dose expansion portions of the study , hypothesized response rates are provided in 
Section 12.3.  In each case, a test that the response rate is less than or equal to the null 
hypothesis rate versus the response rate is greater than or equal to the alternative rate is 
being performed using the stoppi[INVESTIGATOR_377041].  Descriptive statistics will be used to 
describe the observed response rates at the dose used in the expanded cohorts for each of 
the arms.
2013N165256_06 CONFIDENTIA L
FGF117360
8312.3. Sample Size Determination
12.3.1. Arm A: [COMPANY_004]3052230 + Paclitaxel + Carboplatin
An initial dose escalation will be used to establish the MTD (or MFD) for [COMPANY_004]3052230. 
Once the final dose is confirmed, at least [ADDRESS_471827] recent phase 3 
evaluation of this regimen in NSCL C subjects including the squamous subset 
[Socinski ,2012].
The null hy pothesis is:
H0: p≤25%
The alternative hy pothesis is:
HA:p≥45%
Starting with a cohort of [ADDRESS_471828] a t ype I error rate ( ) of 0 .11 and 86% power.  The trial is stopped earl y 
for futility  if the predict ive probability  of success is less than 0.1%.  The Bay esian prior 
used in determining the design was Beta (0.3, 0.7), a relativel y non -informative prior 
with a mean response rate of 30%.  Under the null hy pothesis, the expected sample size is 
24.2 subjects and probability  of earl y termination is 83.5%. Under the alternative 
hypothesis, the expected sample size is 29.7 subjects and the probabilit y of earl y 
termination is 9%.
12.3.2. Arm B: [COMPANY_004]3052230 + Docetaxel
An initial dose escalation will be used to establish the MTD. Once the final dose is 
confirmed, at least 14 and up to 30 subjects in total will be enrolled at that dose, using 
decision rules defined in Section 4.2.2 .  The assumptions underly ing the design are 
detai led below and are based on previousl y published randomized phase 3 data in the 2nd
line setting of metastatic NSCL C [Hanna , 2004]. 
The null hy pothesis is:
H0: p≤10%
The alternative hy pothesis is:
HA:p≥25%
Starting with a cohort of [ADDRESS_471829] a t ype I error rate ( ) of 0.07 and 79% power.  The trial is stopped earl y 
for futility  if the predict ive probability  of success is less than 0.1%.  The Bay esian prior 
used in determining the design was Beta (0.15, 0.85), a relatively  non-
informative prior 
with a mean response rate of 15%.  Under the null hy pothesis, the expected sample size is 
2013N165256_06 CONFIDENTIA L
FGF117360
8424.0 subjec ts and probability  of earl y termination is 84.5%. Under the alternative 
hypothesis, the expected sample size is 29.5 subjects and the probabilit y of earl y 
termination is 12.2%.
12.3.3. Arm C: [COMPANY_004]3052230 + Pemetrexed + Cisplatin
An initial dose escalation will be u sed to establish the MTD. Once the final dose is 
confirmed, at least [ADDRESS_471830] 
line setting of malignant pleural mesothelioma [ Vogelzang , 2003].
The null hy pothesis is:
H0: p ≤40%
The alternative hy pothesis is:
HA:p ≥60%
Starting with a cohort of [ADDRESS_471831] a type I error rate (α) of 0.10 and 82% power.  The trial is stopped earl y 
for futility  if the predi ctive probability  of success is less than 0.1%.  The Bay esian prior 
used in determining the design was Beta (0. 5, 0.5), a relativel y non -informative prior 
with a mean response rate of 50%.  Under the null hy pothesis, the expected sample size is 
23.1 subje cts and probability  of earl y termination is 86.4%. Under the alternative 
hypothesis, the expected sample size is 29.5 subjects and the probabilit y of earl y 
termination is 13.7%.
12.4. Sample Size Sensitivity
No anal ysis of sample size sensitivity  was performed.
12.4.1. Sample Size Re -estimation
Sample size re -estimation is not planned for this study .
12.5. Data Analysis Considerations
12.5.1. Analysis Populations
The All Treated Population is defined as all subjects who receive at least one dose of 
[COMPANY_004]3052230. Safet y and anti -cancer a ctivity  will be evaluated based on this analy sis 
population. 
The PK Population will consist of all subjects from the All Treated Population for whom 
a PK sample is obtained and anal yzed.
The Assay Validation Population is defined as all subjects who were consented, 
screened for the study  (regardless if the subject met eligibility  requirements for study  
2013N165256_06 CONFIDENTIA L
FGF117360
85enrollment) and whose tissue was assay ed by  [CONTACT_377106]1
amplification.  Data from this population may  be used for future validation of the assay .
12.6. Treatment Comparisons
No statistical comparisons will be made between doses for a given study  arm. Safety , PK, 
PD, biomarker, and anti- tumor activity  summaries will be provided by  [CONTACT_377107]3052230 for each study  arm.
12.7. Interim Analysis
Preliminary  safet y data, including adverse events, changes in laboratory values and other 
safet y parameters will be evaluated for each dose escalation cohort  prior to making dose 
escalation decisions.
For each stud y arm, after the initial 12 (Arms A and C) or 14 (Arm B) subjects have 
enrolled at the final dose, response data will be reviewed on an ongoing basis and the 
number of responses observed will be compared with the stoppi[INVESTIGATOR_377042] 4.2.1 (Arm A) , Section 4.2.2 (Arm B), and Section 4.2.3 (Arm C) . 
For Arm C onl y, the totality  of the data will be reviewed prior to stoppi[INVESTIGATOR_377043] -binding. The final anal ysis for Arm C will require 
16/[ADDRESS_471832] at the final 
analysis with alpha level 0.10 and power of 82%.
The rules for Parts A , B and C are also show n in a tabular format below:
2013N165256_06 CONFIDENTIA L
FGF117360
86Table 14 Stoppi[INVESTIGATOR_47490] A rm A : [COMPANY_004]3052230 + Paclitaxel + Carboplatin
Number of Patients Enrolled This Number of Objective 
Responses to Stop Early for 
Futility
12 0
13 0
14 1
15 1
16 1
17 2
18 2
19 2
20 3
21 3
22 4
23 4
24 5
25 5
26 6
27 7
28 8
29 9
30 10
2013N165256_06 CONFIDENTIA L
FGF117360
87Table 15 Stoppi[INVESTIGATOR_47490] A rm B: [COMPANY_004]3052230 + Docetaxel
Number of Patients 
EnrolledThis Number of Objective 
Responses to Stop Early for 
Futility
14 0
15 0
16 0
17 0
18 0
19 0
20 0
21 0
22 1
23 1
24 1
25 1
26 2
27 2
28 3
29 4
30 5
2013N165256_06 CONFIDENTIA L
FGF117360
88Table 16 Stoppi[INVESTIGATOR_47490] A rm C: [COMPANY_004]3052230 + Pemetrexed + Cisplatin
Number of Patients 
EnrolledThis Number of Objective 
Respo nses to Stop Early for 
Futility
12 2
13 2
14 3
15 3
16 4
17 4
18 5
19 5
20 6
21 7
22 7
23 8
24 9
25 10
26 11
27 12
28 13
29 14
30 15
12.8. Key Elements of A nalysis Plan
Data will be listed and summarized according to the [COMPANY_004] reporting standa rds, where 
applicable. Complete details will be documented in the Reporting and Analysis Plan 
(RAP).  Any  deviations from, or additions to, the original anal ysis plan described in this 
protocol will be documented in the RAP and final study  report.
As it is anticipated that accrual will be spread thinly  across centers and summaries of data 
by [CONTACT_377108], data from all participating centers will be 
pooled prior to anal ysis.
All data up to the time of study  completion/withdrawal from stud y will be included in the 
analysis, regardless of duration of treatment.
As the duration of treatment for a given subject will depend on efficacy  and tolerability , 
the duration of follow -up will vary  between subjects. Consequently  there will be n o 
imputation for missing data. 
Demographic and baseline characteristics will be summarized.
2013N165256_06 CONFIDENTIA L
FGF117360
8912.8.1. Anti-Cancer A ctivity Analyses
The All Treated Population will be used for anti -cancer activity  anal yses. Anti -cancer 
activity  will be evaluated using RECI ST, versi on 1.[ADDRESS_471833] adequate assessment (e.g. 
assessment where visit level response is CR, PR, or SD) prior to the initiation of therap y. 
Otherwise, if the subject does not have a documented date of events, PFS will be 
censored at the date of the last adequate assessment.  Further details on rules for 
censoring will be provided in the RAP. PFS will be summarized using the Kaplan -Meier 
method.
12.8.2. Safety  Analyses
The All Treated Population will be used for the analy sis of safet y data. All serially 
collected safet y endpoints (e.g. laboratory tests, vital signs, ECGs) will be summarized 
according to the scheduled, nominal visit at which they were collected and across all on -
treatment time points using a “worst -case” analy sis.  Complete details of the safet y 
analyses will be provided in the RAP.
[IP_ADDRESS]. Extent of Exposure
The number of subjects administered study  treatment will be summarized according to 
the duration of therap y. 
[IP_ADDRESS]. Adverse Events
AEs will be coded using the standard Me dDRA and grouped by  [CONTACT_9313]. AEs 
will be graded b y the investigator according to the National Cancer Institute- Common 
Toxicity  Criteria for Adverse Events (NCI -CTCAE), (version 4.03) .
Events will be summarized by  [CONTACT_377109], by s ystem 
organ class and preferred term. Separate summaries will be given for all AEs, treatment -
related AEs, SAEs and AEs leading to discontinuation of study  treatment. AEs, if listed 
in the NCI -CTCAE (version 4.03) will be summarized by  [CONTACT_377110].  
Otherwise, the AEs will be summarized by  [CONTACT_11196] .
The incidence of deaths and the primary  cause of death will be summarized.
For the dose -escalation portions of the study , dose -limiting toxicities (DL Ts) will be 
listed for each subject and summarized by  [CONTACT_377111] L ibrary  standards. 
[IP_ADDRESS]. Clinical Laboratory  Evaluations
Hematology  and clinical chemistry  data will be summarized using frequencies and 
proportions according to National Cancer Inst itute-Common Toxicity  Criteria for 
2013N165256_06 CONFIDENTIA L
FGF117360
90Adverse Events (NCI -CTCAE) (version 4.03) .  Laboratory  test results outside the 
reference range that do not have an associated NCI- CTCAE criteria will be summarized 
using proportions. Further details will be provided in t he Reporting and Analy sis Plan 
(RAP).
[IP_ADDRESS]. Other Safety  Measures
Data for vital signs, ECGs, and ECHOs will be summarized based on predetermined 
criteria identified to be of potential clinical concern.  I mmunogenicit y data will be 
summarized and listed. Further details will be provided in the RAP.
12.8.3. Patient Reported Outcomes
Change from baseline scores in L CSS and LCSS -meso will be calculated for all scales 
and timepoints. Change from baseline of 10mm was previousl y identified as clinically 
meaningful (P. Hollen, personal communication). The number of subjects achieving a 
10mm improvement at any timepoint will be tabulated for each component of the L CSS. 
For each component of the L CSS, plots of individual and/or mean/median values and 
change from baseline values ov er time will be produced.  If warranted, mixed- effects 
models may  be used to model subject data over time for components of particular 
interest. Associations with efficacy  assessments and between patient reported and 
clinician reported s ymptomatic will be explored when warranted. Further details will be 
provided in the RAP.
12.8.4. Pharmacokinetic A nalyses
PK analy ses will be the responsibility  of Clinical Pharmacokinetics/Modelling & 
Simulation, [COMPANY_004]. Plasma [COMPANY_004]3052230 concentration- time data may  be combined with 
data from other studies and will be anal yzed using a population pharmacokinetic 
approach.  A nonlinear mixed effects model will be used to determine population 
pharmacokinetic parameters (clearances, CL and volumes of distribution, V) and identify  
important covariates (e.g., age, weight, or disease related covariates).  Summary  exposure 
measures (Cmax, AUC and average concentration Cav defined as time corrected AUC 
[AUC/ ]) will also be computed. Results of this analy sis may  be provided in a separate 
report.
Plasma concentration- time data will be listed and summarized using descriptive statistics 
(n, mean, SD, median, minimum and maximum).
12.8.5. Pharmacokinetic/Pharmacody namic A nalyses
Observed or predicted concentrations or summary  exposure measure (eg; Cmax, Ctrough, 
and Cav) may  be combined with safet y and efficacy pharmacod ynamic measures of 
interest to examine potential exposure response relationships.  Graphical evaluation will 
first be performed. 
Where evidence of activity  is seen, linear and/or non -linear m ixed effect models may  be 
fitted to the data to estimate PK/PD parameters of interest (e.g. slope, baseline (E0), 
concentration for 50% of maximum effect (EC50) and maximum effect (Emax)).
2013N165256_06 CONFIDENTIA L
FGF117360
91Overall efficacy  data, as assessed by  [CONTACT_377112] 1.1 crite ria (best confirmed 
response) and overall tumor burden, may  be described using ordered categorical model 
and continuous models with summary  exposure parameters (eg; Cmax, Ctrough, and 
Cav) as covariates derived from the population PK anal ysis.  Further model details will 
be provided in the Reporting and Anal ysis Plan.
12.8.6. Tumor Kinetics A nalysis
Data from some arms of the study  may  be combined to describe the kinetics of tumor 
growth based on the sum of longest diameters and/or volume of target lesions. 
The ki netics of tumor growth may be described as a function of time using the NSCL C 
model described b y the FDA [ Wang , 2009]. The tumor size (TS) is expressed as:
TS(t) = BSL•e-SRt+ PR•t
where TS(t) denotes the tumor size mea sured as the sum of longest distance (mm) of 
lesions or volume (mm3) at time t, BSL  is the baseline tumor size, SR is the exponential 
tumor shrinkage rate constant and PR is the linear tumor progression rate.
The kinetics of tumor growth may  also be descri bed as a function of time using the model 
described b y Claret [ Claret , 2009]. The model is expressed as:
dTS(t)/dt = (KL -KD•e-t)•TS(t)
where TS(t) denotes the sum of longest distance (mm) of lesions or volume (mm3) a t 
time t, with TS(0) being the baseline tumor size, KL represents the exponential tumor 
growth rate, KD represents the exponential rate of tumor shrinkage (i.e. drug effect on 
total tumor size), λ is the rate constant for drug resistance/disease progressio n.  A 
measure of exposure of one or more of the administered medications may  be included in 
the models.
The equation proposed by [CONTACT_377113]/or Claret will be fit to the observed data using a 
mixed -effects model with NONMEM VII.  Other models of the kinetics of tumor growth, 
such as a 2- parameter model, may  be used to analyze the data [ Stein , 2011; Stein , 2012].
The time to tumor growth (TTG) may be estimated with parameters from the appro priate 
model. Subject characteristics such as baseline tumor size, performance status, L DH, age, 
sex, race, prior therapi[INVESTIGATOR_014], or radiotherap y, ma y be evaluated to determine which 
covariates have a significant effect on the kinetics of tumor growth.
12.8.7. Translat ional Research A nalyses
Exploratory  anal ysis may be performed to examine potential relationships between 
anticancer activity  and changes in markers of deregulation of FGF signaling pathway  
(example: FGFR1 gene amplification) or tumor biology  (e.g. cy tokine s, acute phase 
proteins, relevant transcripts and/or proteins) or between anticancer activit y and potential 
markers of sensitivity .
2013N165256_06 CONFIDENTIA L
FGF117360
92The results of translational research investigations may  be reported separately  from the 
main clinical study  report or as an amendment.  All endpoints of interest from all 
comparisons will be descriptively  and/or graphically  summarized as appropriate to the 
data. Further details on the translational research anal yses will be addressed in the RAP.
12.8.8. Pharmacogenetic A nalyses
Furthe r details on pharmacogenetic (PGx) anal yses will be addressed in Appendix 1 and 
the PGx Reporting and Analy sis Plan (RAP).
13. STUDY CONDUCT CONSID ERA TIONS
13.1. Posting of Information on Clinicaltrials.gov
Study  information fro m this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
13.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a study
 site, [COMPANY_004] will obtain approval from the appropriate 
regulatory  agency  to conduct the study  in accordance with International Conference on 
Harmonization Good Clinical Practice (ICH GCP) and applicable country -specific 
regulatory  requirements.
The study  will be conducted in accordance wit h all applicable regulatory  requirements.
The study  will be conducted in accordance with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles that are outlined in the Declaration of Helsinki 
2008, including, but not limited to:
Institutional review board (I RB)/ethics committee (EC) review and approval of study  
protocol and an y subsequent amendments
Subject informed consent
Investigator reporting requirements
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, or both.
Written informed consent must be obtained from each subject prior to participation in the 
study .
13.3. Urgent Safety  Measures
If an event occurs that is related to the conduct of the study  or the development of the I P, 
and this new event is likely  to affect the stud y of subjects, the Sponsor, and the 
investigator will take appropriate urgent safet y measures to protect subjects against an y 
immediate hazard.
2013N165256_06 CONFIDENTIA L
FGF117360
93The Sponsor will work with the investigator to ensure the Institutional review board 
(IRB)/ethics committee (EC) is notified.
13.4. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations, Good Clinical Practice (GCP) and [COMPANY_004] 
procedures, the site will be contact[CONTACT_377114] t he protocol, stud y requirements, and their responsibilities to satisfy regulatory, 
ethical, and [COMPANY_004] requirements.  When reviewing data collection procedures, the 
discussion will include identification, agreement and documentation of data items for 
which the eCRF will serve as the source document.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents and to allocate their time and 
the time to their staff to monitor to d iscuss findings and an y issues.
Monitoring visits will be conducted in a manner to ensure that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, ICH GCP, and all applicable regulatory  requirements.
13.5. Qualit y Assurance
To ensure compliance with I nternational Conference on Harmonization Good Clinical 
Practice (I CH GCP) and all applicable regulatory  requirements, [COMPANY_004] may  conduct 
quality  assurance audits of the site.  Regulatory  agencies may  conduct a regulatory  
inspection at an y time during or after completion of the study.  In the event of an audit or 
inspection, the investigator (and institution) must agree to g rant the auditor(s) and 
inspector(s) direct access to all relevant documents and to allocate their time and the time 
of their staff to discuss any findings/relevant issues.
13.6. Stud y and Site Closure
The end of the stud y will be defined as the date of the last visit of the last subject
enrolled.
Upon completion or termination of the study , the monitor will conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regulations, International Conference on Harmonization Good Clinical Practice (ICH 
GCP), and [COMPANY_004] Standard Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or terminate the stud y at an y time for 
reasons including (but not limited to) safety  issues, ethical issues, or severe 
noncompliance.  If [COMPANY_004] determines that such action is required, [COMPANY_004] will discuss the 
reasons for taking such action with the investigator or head of the medical institution 
2013N165256_06 CONFIDENTIA L
FGF117360
94(where applicable). When feasible, [COMPANY_004] will provide advance notice to the investigator
or head of the medical institution of the impending action.
If a study is suspended or terminated for safety reasons, [COMPANY_004] will promptly inform all 
investigators, heads of the medical institutions (where applicable),and/or institutions 
conducting the study .  [COMPANY_004] will also promptly  inform the relevant regulatory  authorities 
of the suspension/termination along with the reasons for such action.  Where required b y 
applicable regulations, the investigator or head of the medical institution must inform the 
IRB/EC promptly  and provide the reason(s) for the suspension/termination.
[COMPANY_004] may  also close study  sites which fail to recruit subjects within a predefined 
timeframe, as defined within the SPM.
13.7. Records Retention
Following closure of the study , the investigator o r head of the medical institution (where 
applicable) must maintain all site study records (except for those required by  [CONTACT_24000]) in a safe and secure location.  The records must 
be easil y accessible when needed (e.g., f or a [COMPANY_004] audit or regulatory  inspection) and 
must be available for review in conjunction with assessment of the facility , supporting 
systems, and relevant site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintained in a format other than hard copy  (e.g., microfiche, scanned, 
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy of the original. In addition, they  must meet accessibility  and retrieval standards, 
including regeneration of a hard cop y, if required.  The investigator must also ensure that 
an acceptable back -up of the reproductions exists and that there is an acceptable quality  
control procedure in place for creating the reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining the site records in order 
to comply  with all applicable regulatory  requirements.  The minimum retention time will 
meet the strictest standard applicable to a particular site, as dictated b y local 
laws/regulations, [COMPANY_004] standard operating procedures, and/or institutional requirements.
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, including, 
but not limited to archival of records at an off- site facility  or transfer of ownership of the 
records in the event that the investigator is no longer associated with the site.
13.8. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to st atistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
2013N165256_06 CONFIDENTIA L
FGF117360
95[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
The results summary  will be posted to the [COMPANY_004] Clinical Study  Register no later than [ADDRESS_471834]’s last visit (L SLV).
When manuscript publication in a peer -reviewed journal is not feasible, a statement will 
be added to the register to explain the reason for not publishing.
2013N165256_06 CONFIDENTIA L
FGF117360
9614. REFERENCES
Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines fo r the use 
of granulocy te-colony stimulating factor to reduce the incidence of chemotherap y-
induced febrile neutropenia in adult patients with ly mphoproliferative disorders and solid 
tumours. Eur J Cancer. 2011;47:8–32.
Alimta (pemetrexed) Product I nformati on. 2004.
Beenken A, Mohammadi M. The FGF family : biology , pathoph ysiology  and therap y. Nat 
Rev Drug Discov. 2009 Mar;8(3):235 -53
Berger W, Setinek U, Mohr T, et al. Evidence for a role of FGF -2 and FGF receptors in 
the proliferation of non -small cell lung cancer cells. Int J Cancer. 1999; 83: 415
–423.
By[CONTACT_195163], Nowak AK. Modified RECI ST criteria for assessment of response in 
malignant pleural mesothelioma. Ann Oncol . 2004; 2: [ADDRESS_471835] -line treatment for epi[INVESTIGATOR_76296]: a phase I dose-
intensity  escalation study. Semin Oncol . 1994; ([ADDRESS_471836] 12): [ADDRESS_471837], Gumbrell LA, et al., Carboplatin dosage: prospective evaluation 
of a sim ple formula based on renal function. J Clin Oncol . 1989; 11:1748-56.
Chandler LA, Sosnowski BA, Greenlees L, et al., Prevalent expression of fibroblast 
growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer. 1999; 
81: 451–58.
Claret L., Girard P., Hoff PM, et al. Model -based prediction of Phase III overall survival 
in colorectal cancer on the basis of Phase II tumor dy namics. J Clin Oncol 2009;7:[ADDRESS_471838] growth factor 
are co -
expressed in malignant mesothelioma. Clin Exp Metastasis. 2004;21:469 -476.
Devine, BJ. Case Number 25 Gentamicin Therap y: Clinical Pharmacology Case Studies. 
Drug Intelligence and Clinical Pharmacy . 1974; 8:650 -655
DeYoung MP, Shenk C, Bleam M, Barnette M, Ganji G, Hoang B, Tunstead J, Bellovin 
D, Los G, Minthorn E, Kumar R. Preclinical efficacy  of targeting FGF autocrince 
signaling in mesothelioma with the FGF ligand trap, FP -1039/[COMPANY_004]3052230.  AACR 
2014.
Dutt A,Ramos AH, Hammerman PS, et al. Inhibitor -sensitive FGFR1 amplification in 
human non -small cell lung cancer. PLoS ONE , 2011 :6(6):e20351 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.[ADDRESS_471839], Compton CC, et al. (eds) AJCC Cancer Staging Manual, 7th E dition. 
[LOCATION_001], NY. Springer, 2010, pp 253-70.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: Revised RECI ST guidelines (version 1.1). European Journal of Cancer. 2009; 45: 
228-247.
Ettinger DS, Akerley  W,Borghaei H, et al., Malignant pleural mesothelioma. J Natl 
Compr Canc Netw . 2012; 10(1): [ADDRESS_471840] growth factor receptor- mediated 
signals contribute to the malignant phenot ype of non- small cell lung can cer cells: 
therapeutic implications and synergism with epi[INVESTIGATOR_377044]. 
Mol Cancer Therapeutics 2008;7:3408–3419. [PubMed: 18852144]
GlaxoSmithKline Document Number 2013N160379_00 Version 01. [COMPANY_004]3052230 
Investiga tor's Brochure. Report Date: APR -2013.
Goudar RK. Review of pemetrexed in combination with cisplatin for the treatment of 
malignant pleural mesothelioma. Ther Clin Risk Manag. 2008; 4(1): 205 -11.
Gralla RJ, Hollen P, L iepa A, et al. Improving quality  of life in patients w ith malignant 
pleural mesothelioma:  Results of the randomized pemetrexed + cisplatin vs cisplatin trial 
using the LCSS -meso instrument. Proc Am Soc Clin Oncol 2003; 22:622a (abstr 2496) .
Hanna N, Shepherd FA, Fossella FV, et al. Randomized Phase III trial of pemetrexed 
versus docetaxel in patients with non- small cell lung cancer previously  treated with 
chemotherap y. J Clin Oncol 2004;22(9):1589- 1597.
Harding T, Palencia S, Long L et al. Preclinical efficacy of FP -1039 (FGFR1:Fc) in 
endometrial carcinoma mo dels with activating mutations in FGFR2. Proceedings of the 
101stmeeting of the American Association for Cancer Research, 2010, April 17 -21; 
Washington DC, Philadelphia (PA):AACR, 2010:Abstract nr 2597. 
Harding TC, Long L, Palencia S, et al. Blockade of non- hormonal fibroblast growth 
factors b y FP-1039 inhibits growth of multiple ty pes of cancer. Science Translational 
Medicine, 2013;5(178):1 -9.
Haskell H, Natarajan M, Hecker TP, et al., Focal adhesion kinase is expressed in the 
angiogenic blood vessels of malignant astrocy tic tumors in vivo and promotes capi[INVESTIGATOR_377045]. Clin Cancer Res. 2003; (6): 
[ADDRESS_471841] RS, L ecia LV, Engelman JA. Genetic Changes in Squamous Cell Lung Cancer: A 
Review. Journal of Th oracic Oncology . 2012, 7(5): 924 -933.
Hollen PJ, Gralla RJ, Kris MG, et al., Measurement of quality  of life in patients with lung 
cancer in multicenter trials of new therapi[INVESTIGATOR_014]. Psy chometric assessment of the L ung 
Cancer S ymptom Scale. Cancer . 1994; 73(8): 2087 -98.
2013N165256_06 CONFIDENTIA L
FGF117360
98Hollen PJ, Gralla RJ, L iepa AM, et al., Adapting the L ung Cancer Sy mptom Scale 
(LCSS) to mesothelioma: using the LCSS -Meso conceptual model for validation. Cancer
2004; 101(3): 587 -95.
Hollen PJ, Gralla RJ, L iepa AM, et al., Measuring quality  of life in patients with pleural 
mesothelioma using a modified version of the Lung Cancer S ymptom Scale (L CSS): 
psychometric properties of the L CSS-Meso. Support Care Cancer . 2006; 14(1): 11 -21.
Itoh N. The Fgf families in humans, mice, and zebrafish: their ev olutional processes and 
roles in development, metabolism, and disease. Biol Pharm Bull. 2007;30:1819–25.
Jassem J, Ramlau R, Santoro A, et al., Phase III trial of pemetrexed plus best supportive 
care compared with best supportive care in previously  treated patients with advanced 
malignant pleural mesothelioma. J Clin Oncol . 2008; 26(10): 1698-704.
Kao SC, van Zandwijk N, Corte P, et al., Use of cancer therap y at the end of life in 
patients with malignant pleural mesothelioma. Support Care Cancer . 2013; 21: 697-705.
Kim HR, Kim JD, Kang DR, et al. Fibroblast Growth Factor Receptor 1 gene 
amplification is associated with poor survival and cigarette smoking dosage in patients 
with resected squamous cell lung cancer. J Clin Oncol. 2013;31(6):[ADDRESS_471842] Update . 2009; 12(4- 5): 95–102. 
doi:10.1016/j.drup.2009.05.001.
Krug L, Kindler H, Calvert H, et al.  VANTAGE 014: Vorinostat in patients with 
advanced malignant pleural mesothelioma who have failed prior pemetrexed and either 
cisplatinor carboplatin therap y: a phase III, randomized, double -blind, placebo -
controlled 
trial. Eur J Cancer . 2011; 47(suppl 2): 2-3.
Kumar -Singh S, Wey ler J, Martin MJ et al. Angiogenic cytokines in mesothelioma: a 
study  of VEGF, FGF -1 and -2, and TGF β expression. J Pathol. 1999;189:72 -78.
Lamont FR, Tomlinson DC, Cooper PA, et al. , Small molecule FGF receptor inhibitors 
block FGFR -dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer . 
2011: 104(1): 75 -82.
LeeJJ, L iu DD. A predictive probability  design for phase II cancer clinical trials. Clinical 
Trials. 2008; 5( 2):93-106 .
Li Q, Wang W, Yamada T, et al. Pleural Mesothelioma I nstigates Tumor -Associated 
Fibroblasts To Promote Progression via a Malignant Cy tokine Network. Am J Pathol.
2011;179:1483-1493.
Luo M, Guan J L. Focal adhesion kinase: a prominent determinant in breast cancer 
initiation, progression and metastasis. Cancer Lett . 2010; 289(2): 127-39.
2013N165256_06 CONFIDENTIA L
FGF117360
99Lutz ST, Huang DT, Ferguson CL, et al., A retrospective qualit y of life analysis using the 
Lung Cancer S ymptom Scale in patients treated with palliative radiotherap y for advanced 
nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys . 1997; 37(1): 117-22.
Manegold C, Sy manowski J, Gatzemeier U, et al., Second- line (post -study ) 
chemotherap y received by  [CONTACT_377115]. Ann Oncol . 2005; 
16(6): 923-7.
Marek L, Ware KE, Fritzsche A et al. Fibroblast growth factor (FGF) and FGF receptor -
mediated autocrine signaling in non- small -cell lung cancer cells. Mol Pharmacol.
2009;75:196 -207.
Miller VA, Rigas JR, Francis PA, et al., Phase II trial of a 75 -mg/m2 dose of docetaxel 
with prednisone premedication for patients with advanced non -small cell lung cancer. 
Cancer . 1995; 75(4): 968 -72.
National Comprehensive Cancer Network NCCN Guidelines for Treatment of Cancer b y 
Site, 2012; Clinical Practice Guidelines in Oncology: M yeloid Growth Factors, 2010.
http://www.nccn.org/professionals/phy sician_gls/f_guidelines.asp.
NCI Common Terminology  Criteria for Adverse Events, Version 4.03, DCTD, NCI, 
NIH, DHHS, [ADDRESS_471843] . 1994; 86: 356–61.
NKF: NKF KDOQI Guidelines [I nternet]. National Kidney  Foundation. KDOQI Clinical 
Practice Guidelines for Chronic Kidney  Disease: Evaluation, Classification, and 
Stratification. Published 2002. Available from 
http://www.kidney .org/professionals/KDOQI/guidelines _ckd/p5_lab_g5.htm
O’Connor JP, Jackson A, Asselin MC, et al. Quantitative imaging biomarkers in the 
clinical development of targeted therapeutics: current and future perspectives. Lancet 
Oncology . 2008; 9(8): 766-776.
Oken MM, Creech RH, Tormey  DC, et al.,: Toxicity  and response criteria of the Eastern 
Cooperative Oncology  Group. Am J Clin Oncol . 1982; 5: 649 -655.
Paraplatin (carboplatin) Product I nformation. July  2010.
Platinol (cisplatin) Product I nformation. September 2010.
Sharpe R, Pearson A, Herrera-Abreu MT et al. FGFR signaling promotes the growth of 
triple -negative and basal -like breast cancer cell lines both in vitro and in vivo . Clin 
Cancer Res . 2011;17:5275-5286.
2013N165256_06 CONFIDENTIA L
FGF117360
100Socinski MA, Bondarenko I , Karaseva NA, et al. Weekly  nab-paclitaxel in combination
with carboplatin versus solvent based paclitaxel plus carboplatin as first -line therapy  in 
patients with advanced non -small cell lung cancer: Final results of a Phase III trial. J Clin 
Oncol 2012;30:[ADDRESS_471844] growth factors: An epi[INVESTIGATOR_377046]. Proc Natl Acad Sci . 2000;97:8658–63.
Stebbing J, Powles T, McPherson K, et al., The efficacy and safety of weekly  vinorelbine 
in relapsed malignant pleural mesothelioma. Lung Cancer . 2009; 63(1): 94-7.
Stein WD, Gulley  JL, Schlorn J, et al. Tumor regression and growth rates determined in 
five intramural NCI prostate cancer trials: the growth rate constant as an indicator of 
therapeutic efficacy . Clin Cancer Res 2011;17:907-917.
Stein WD, Wilkerson J, Kim ST, et al. Analy zing the pi[INVESTIGATOR_377047] -α in renal cell carcinoma, using a method that assesses tumor regression and 
growth. Clin Cancer Res. 2012;18:2374-2381.
Taxol (paclitaxel) Product I nformation. April 2011.
Taxot ere (docetaxel) Product I nformation. May  2010.
The Criteria Committee of the [LOCATION_001] Heart Association (NYHA). Nomenclature and 
Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. [LOCATION_011], Mass: 
Little, Brown & Co.; 1994:253-256.
Tsao AS, Garland L, Redman M, et al., A practical guide of the Southwest Oncology  
Group to measure malignant pleural mesothelioma tumors by  [CONTACT_377116]. J Thorac Oncol . 2011; 6(3): 598 -601.
Tsao AS, Wistuba I , Roth JA, et al., Malignan t pleural mesothelioma. J Clin Oncol . 
2009; 27(12): 2081-90.
Tsujioka H, Yotsumoto F, Shirota et al., Emerging strategies for ErbB ligand -based 
targeted therap y for cancer. Anticancer Res . 2010; 30(8): 3107-12.
Turner N, Grose R.  Fibroblast growth factor signaling: from development to cancer.  
Nat. Rev.Cancer . 2010;10:[ADDRESS_471845] 2005, 
http://www.fda.gov/bbs/topi [INVESTIGATOR_1102]/NEWS/2005/NEW01220.html
2013N165256_06 CONFIDENTIA L
FGF117360
101Vogelzang NJ, Rusthoven JJ, Sy manowski J, et al., Phase III study  of pemetrexed in 
combination with cisplatin versus cisplatin alone in patients with malignant pleural 
mesothelioma. J Clin Oncol . 2003; 21(14): 2636-44.
Wang Y, Su ng C, Dartois C, et al. Elucidation of relationship between tumor size and 
survival in non -small -cell lung cancer patients can aid earl y decision making in clinical 
development. Clin Pharmacol Therap 2009; 86: 167-174.
Weiss J, Sos ML , Seidel D, et al., Fr equent and focal FGFR1 amplification associates 
with therapeuticall y tractable FGFR1 dependency in squamous cell lung cancer. Sci 
Transl Med. 2010; 2(62) 62ra93. http://stm.sciencemag.org/content/2/62/62ra93.full.pdf
Xin G, Wang M, Jian L, et al., Protein- to-creatinine ratio in spot urine samples as a 
predictor of quantitation of proteinuria. Clinica Chimica Acta. 2004; 350: 35-39.
2013N165256_06 CONFIDENTIA L
FGF117360
[ZIP_CODE]. APPENDICES
15.1. Appendix 1: Pharmacogenetics (PGx)
PGx Research
PGx –Background
Pharmacogenetics (PGx) is the study  of variability in drug response due to hereditary  
factors in different populations. There is increasing evidence that an individual's genetic 
composition (i.e., genot ype) may  impact the pharmacokinetics (PK) (absorption, 
distribution, metabolism, and elimination), pharm acod ynamics (PD) (relationship 
between concentrations and pharmacologic effects or the time course of pharmacologic 
effects) and/or clinical outcome (in terms of efficacy  and/or safet y and tolerability). Some 
reported examples of PGx associations with safe ty/adverse events include:
Drug Disease Gene Outcome
Abacavir HIV
[Hetherington , 2002; 
Mallal , 2002]Human 
Leukocyte 
Antigen B (HLA -
B*5701)Individuals with HLA -B*5701 var iant may be at 
increased risk for experiencing hypersensitivity to 
abacavir. Clinical assays are available for HLA -B*5701 
but none has been validated. HLA -B*[ADDRESS_471846] abacavir clinical 
risk management strategies aime d at minimizing rare 
but serious outcomes associated with abacavir 
hypersensitivity
Carbamazepi[INVESTIGATOR_377048], Bipolar 
disorders & 
Analgesia 
Chung, 2010; 
Ferrell , 2008.HLA-B*[ADDRESS_471847] 
Asian ancestry who carry HLA-B*[ADDRESS_471848] updated the carbamazepi[INVESTIGATOR_377049] -B*1502 prior to initiating treatment 
with carbamazepi[INVESTIGATOR_050].
Warfarin Cardiovascular
[Neergard, 2006;
Wilke , 2005]CYP2C9 SAEs experienced by [CONTACT_377117]2C9 gene that 
influences the degree of anticoagulation achieved.
Irinotecan Cancer
FDA News Release, 
2005UGT1A1 Variations in the UGT1A1 gene can influence a 
patient’s ability to break down irinotecan, which can 
lead to increased blood levels of the drug and a higher 
risk of side effects. A dose of irinotecan that is safe for 
one patient with a particular UGT1A1 gene variation 
might be too high for another subject without this 
variation, raising the risk of certain side effectsA genetic 
blood test (Invader UGT1A1molecular assay) is 
available that can detect variation s in the gene.
A key  component to successful PGx research is the collection of samples during the 
conduct of clinical studies.
2013N165256_06 CONFIDENTIA L
FGF117360
103Collection of whole blood, may enable PGx anal ysis to be conducted if at any time it 
appears that there is a potential unexpected or unexplained variation in handling or 
response to [COMPANY_004]3052230.
PGx Research Objectives
The objective of the PGx research (if there is a potential unexpected or unexplained 
variation) is to investigate a possible genetic relationship to handling or resp onse to 
[COMPANY_004]3052230. If at an y time it appears there is potential variability  in response in this 
clinical study  or in a series of clinical studies with [COMPANY_004]3052230 that may  be attributable 
to genetic variations of subjects, the following objectives may  be investigated:
 Relationship between genetic variants and the PK and/or PD of study  treatment
Relationship between genetic variants and safet y and/or tolerability  of study  
treatment
Relationship between genetic variants and efficacy of stud y treatment.
Study Population
Any subject who has given informed consent to participate in the clinical study , has met 
all the entry  criteria for the clinical study , and receives study  treatment may  take part in 
the PGx research. An y subject who has received an allogeneic b one marrow transplant 
must be excluded from the PGx research.
Subject participation in the PGx research is voluntary  and refusal to participate will not 
indicate withdrawal from the clinical study . Refusal to participate will involve no penalt y 
or loss of benefits to which the subject would otherwise be entitled.
Study Assessments and Procedures
In addition to any  blood samples taken for the clinical study , a whole blood sample 
(~6mL) will be collected for the PGx research using a tube containing EDTA. I t is 
recommended that the blood sample be taken at the first opportunity  after a subject has 
been randomized and provided informed consent for PGx research, but may be taken at 
any time while the subject is participating in the clinical study .
The PGx sample is labeled (or “coded”) with a study specific number that can be traced 
or linked back to the subject only  by [CONTACT_132018]. Coded samples do not 
carry personal identifiers (such as name [CONTACT_24004] y number). The blood sample is 
taken on a single occasion unless a duplicate sample is required due to inability  to utilize 
the original sample. 
The DNA extracted from the blood sample may  be subjected to sample quality  control 
analysis. This anal ysis will involve the genot ypi[INVESTIGATOR_377050] l genetic markers to confirm 
the integrit y of individual samples. If inconsistencies are noted in the anal ysis, then those 
samples may  be destroy ed. 
2013N165256_06 CONFIDENTIA L
FGF117360
104The need to conduct PGx anal ysis may  be identified after a study  (or set of studies) of 
[COMPANY_004]3052230 has bee n completed and the study  data reviewed. In some cases, the 
samples may  not be studied. e.g., no questions are raised about how people respond to 
[COMPANY_004]3052230. 
Samples will be stored securel y and may be kept for up to [ADDRESS_471849] 
complet es the study  or [COMPANY_004] may  destro y the samples sooner. [COMPANY_004] or those working with 
[COMPANY_004] (for example, other researchers) will use samples collected from the study  for the 
purpose stated in this protocol and in the informed consent form. 
Subjects can request the ir sample to be destro yed at any  time.
Subject Withdrawal from Study
If a subject who has consented to participate in PGx research and has a sample taken for 
PGx research withdraws from the clinical study  for any  reason other than lost to follow -
up, the subject will be given the following options:
The sample is retained for PGx research.
Any PGx sample is destroy ed.
If a subject withdraws consent from the PGx research or requests sample destruction for 
any reason, the investigator must complete the appropri ate documentation to request 
sample destruction within the timeframe specified by  [CONTACT_42394]. In either case, [COMPANY_004] will only  keep study  
information collected/generated up to that point.
Screen and Baseline F ailures
If a blood sample for PGx research has been collected and it is determined that the 
subject does not meet the entry  criteria for participation in the clinical study, then the 
investigator must complete the appropriate documentation to request sampl e destruction 
within the timeframe specified b y [COMPANY_004] and maintain the documentation in the site study 
records.
PGx A nalyses
The aim of pharmacogenetic anal yses will be to investigate the relationship between 
genetic variations in germline DNA and response t o study  treatment. The specific t ype of 
genetic investigation to be applied will be dependent on the most scientifically  feasible 
approach available to address understanding of the response to the stud y treatment.
Generally , two approaches may  be utilized to explore the association of genetic variation.
1.Candidate gene anal ysis where variations in specific genes may  be studied that 
encode the drug target, or drug mechanism of action pathway s, drug metabolizing 
enzy mes, drug transporters or which may  underpin adverse events, disease risk or 
drug response.
2013N165256_06 CONFIDENTIA L
FGF117360
105These candidate genes that may  be investigated in this study  include the following: the 
[COMPANY_004] Absorption, Distribution, Metabolism and Excretion genes. These play a central 
role in drug PK and PD.  In addition, continuing research may  identify  other enzy mes, 
transporters, proteins, or receptors that may  be involved in response to [COMPANY_004]3052230. The 
genes that may  code for these proteins may  also be studied.
2.Genome -wide scans involving a large number of poly morphic markers (e.g., single 
nucleotide poly morphisms) located throughout the genome. This approach is often 
employ ed when potential genetic effects are not well understood.
The results of PGx investigations will be reported either as part of the main clinical st udy 
report or as a separate report. All endpoints of interest from all comparisons will be 
descriptivel y and/or graphically summarized as appropriate to the data. In all cases, 
appropriate statistical methods will be used to analyze the genetic markers in the context 
of other clinical data. Statistical methods may  include, but are not limited to Hardy -
Weinberg Equilibrium testing, Comparison of Demographic and Baseline Characteristics 
by [CONTACT_377118], Evaluation of Genot ypic Effects, Evaluation of Treatment by [CONTACT_377119] -Gene Interaction, Linkage Disequilibrium, Multiple Comparison and Multiplicity  
and/or Power and Sample Size Considerations A detailed description of the anal yses to 
be performed will be documented in the pharmacogenetics RAP.
Informed Co nsent
Subjects who do not wish to participate in the PGx research may  still participate in the 
clinical study . PGx informed consent must be obtained prior to an y blood being taken for 
PGx research.
Provision of Study Results and Confidentiality  of Subject’ s PGx Data
[COMPANY_004] may  summarize the cumulative PGx research results in the clinical study  report,.
In general, [COMPANY_004] does not inform the investigator, subject or any one else (e.g., family  
members, study  investigators, primary  care ph ysicians, insurers, or emplo yers) of the 
PGx research results unless required b y law. The information generated from PGx 
research is preliminary  in nature, and the significance and scientific validity  of the results 
are undetermined at such an earl y stage of research. 
2013N165256_06 CONFIDENTIA L
FGF117360
106References
Chung WH, Hung SL, Chen YT. Genetic predisposition of life -threatening antiepi[INVESTIGATOR_23935] -
induced skin reactions. Expert Opin. Drug Saf. 2010; 9: 15-21.
Ferrell PB, McLeod HL. Carbamazepi[INVESTIGATOR_050], HLA -B*1502 and risk of Stevens -Johnson 
syndrome and toxic epi[INVESTIGATOR_78950]: US FDA recommendations. 
Pharmacogenomics. 2008; 9: 1543 -46.
Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, 
Davies K, Handley  A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond L M, Roses 
AD. Genetic variations in HLA- B region and h ypersensitivity  reactions to abacavir. 
Lancet. 2002; 359:1121-2.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Say er D, Castley  A, Mamotte 
C, Maxwell D, James I . Association between presence of HLA- B*5701, HLA -DR7, and 
HLA -DQ3 and hy persensitivity  to HIV -1 reverse -transcriptase inhibitor abacavir. Lancet . 
2002; 359:727-32.
Neergard. Reducing the risk of blood thinners. Associated press, September 2006. 
U.S. Food and Drug Administration, FDA Clears Genetic Test That Advances 
Personaliz ed Medicine Test Helps Determine Safety  of Drug Therapy  [ADDRESS_471850] 2005, 
http://www.fda.gov/bbs/topi[INVESTIGATOR_1102]/NEWS/2005/NEW01220.html
Wilke RA, Musana AK, Weber WW. Cy tochrome P450 gene -based drug prescribing, 
and factors impacting translation into routine clinica l practice. Personalized Med 2005; 2: 
213–224.
2013N165256_06 CONFIDENTIA L
FGF117360
[ZIP_CODE].2. Appendix 2: NYH A Functional Classification Sy stem
The [LOCATION_001] Heart Association (NYHA) Functional Classification: Class I, II, III 
or IV Heart Failure [NYHA , 1994] provides a simple way  of classify ing the extent of 
heart failure. It places subjects in one of 4 categories based on the level of limitation 
experienced during ph ysical activity :
Class Symptoms
Class I
(Mild)No limitation of phy sical activity. Ordinary  physical act ivity does 
not cause undue fatigue, palpi[INVESTIGATOR_42243] (shortness of 
breath).
Class II
(Mild)Slight limitation of phy sical activity . Comfortable at rest, but 
ordinary  physical activity results in fatigue, palpi[INVESTIGATOR_377051].
Class III
(Moderate)Marked limitation of physical activity . Comfortable at rest, but less 
than ordinary  physical activity  results in fatigue, palpi[INVESTIGATOR_377052].
Class I V
(Severe)Unable to carry  out any physical activity without discomfort. 
Symptoms of cardiac insuffic iency  at rest. If any  physical activity  is 
undertaken, discomfort is increased.
2013N165256_06 CONFIDENTIA L
FGF117360
[ZIP_CODE].3. Appendix 3: COCKCROFT -GAULT FORMULA
ClCr (mL/min) = Q x (140 -age[yr]) x ideal body weight [kg]*
72 x serum creatinine [mg/dL]
Q = 0.85 for females
Q = 1.0 for males
OR
ClCr (mL/min) = K x (140 -age[yr]) x ideal body weight [kg]*
Serum creatinine [umol/L]
K = 1.0 for females 
K = 1.23 for males
*Calculation of Ideal Body Weight Using the Devine Formula [ Devine , 197 4]
Ideal body weight:
Males = 50.0 kg + (2.3 kg x each inch over 5 feet) or 50.0 kg + (0.906 kg x each cm over 
152.4 cm)
Females = 45.5 kg + (2.3 kg x each inch over 5 feet) or 45.5 kg + (0.906 kg x each cm over 
152.4 cm)
Example: Male, actual body w eight = 90.0 kg, height = 68 inches
Ideal body weight = 50.0 + (2.3) (68 -60) = 68.4 kg.
2013N165256_06 CONFIDENTIA L
FGF117360
[ZIP_CODE].4. Appendix 4: ECOG Performance Status1
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are 
protected by [CONTACT_14561].
2013N165256_06 CONFIDENTIA L
FGF117360
[ZIP_CODE].5. Appendix 5: Liver Chemistry  Monitoring, Interruption 
Stoppi[INVESTIGATOR_53051] -up Criteria

2013N165256_06 CONFIDENTIA L
FGF117360
[ZIP_CODE].6. Appendix 6: Urine Protein Creatinine (UPC) Ratio
Clinical meaning of UPC
There is a good correlation between the ratio of protein concentration to creatinine 
concentration in a random urine sample and the amount of protein excreted over 
24hours. Creatinine excretion is fairly  constant throughout the day  regardless of changes 
in urine flow rate.
Normal protein excretion is <150 mg/24 hours and is similar for men and women.
Men excrete 20 mg to 25 mg of creatinine/kg of body  weight/day .
Women excrete 15 mg to 20 mg of creatinine/kg of body  weight/da y.
Calculating UPC
UPC ratio = Urine protein (mg/dL) / Urine creatinine (mg/dL). 
UPC ratio ≈ equivalent to grams of protein excreted in urine over 24 hrs. 
Example: Patient has a urine protein = 90 mg/dL and urine creatinine = 30 mg/dL. 
UPC ratio= (90 mg/dL) / (30 mg/dL) = 3 
The calculated UPC ratio is 3, which correlates to roughl y 3 g protei n excretion in a 
24-hour period.
Units for UPC ratio
Note: To calculate UPC, protein and creatinine concentrations must be expressed in the 
same units (mg/dL, g/L, or μmol/L). If, for example, protein concentration is expressed in 
mg/dL and creatinine concentration is expressed in µmol/L , conversion of one of the 
concentration values is required. Conversion factors are: 
From To Conversion Factor 
Conventional Units: mg/dL SI Units: µmol/L Multiply by 88.4
SI Units: µmol/L Conventional Units: mg/dL Divide 88.4 
[Xin, 2004] [ NKF Guidelines, 2002]
2013N165256_06 CONFIDENTIA L
FGF117360
[ZIP_CODE].7. Appendix 7: Country  Specific Requirements
[LOCATION_009] or [LOCATION_006]:
French or [LOCATION_006] Specific QTc Stoppi[INVESTIGATOR_2121]:
In line with local requirements, French subjects that meet the criteria QTc1 below will 
have [COMPANY_004]3502230 withheld:
QTcB > [ADDRESS_471851] 
study  treatment withheld:
QTc > 500 msec
1Based on average correcte d QT (QTc) interval value of triplicate electrocardiograms 
(ECGs) to include manual over -read. For example, if an ECG demonstrates a prolonged 
QT interval, obtain [ADDRESS_471852] [COMPANY_004]3502230 
withheld.
QT interval (corrected for HR) ≥500 msec; [COMPANY_004]3502230 will be permanently  
discontinued.
QTc interval increase from baseline ≥ 60 msec and maximum QTc  < 500 msec; 
[COMPANY_004]3502230 may  be restarted at a reduced dose level after discussion with the medical 
monitor once the QTc returns to baseline.  If QTc prolongation meeting stoppi[INVESTIGATOR_377053] -challenge, [COMPANY_004]3502230 must be permanently  discontinued.
If the QTc prolongation resolves to Grade [ADDRESS_471853] will 
benefit from further treatment.
No other known country  specific requirements are currentl y required.
2013N165256_06 CONFIDENTIA L
FGF117360
[ZIP_CODE].8. Appendix 8: Protocol A mendment Changes
Amendment [ADDRESS_471854] of Specific Changes
CHANGE 1: Medical monitor contact [CONTACT_377120]:
Role Name [CONTACT_377140] -hours 
Phone/Cell/
Pager 
NumberFax 
Number[COMPANY_004] Address
Medical 
Monitor
MDGlaxoSmithKline
[ADDRESS_471855]
[PO_BOX]
Collegeville, PA [ZIP_CODE]
Email:
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N165256_06 CONFIDENTIA L
FGF117360
114Medical 
MonitorMD GlaxoSmithKline
[ADDRESS_471856]
[PO_BOX]
Collegeville, PA [ZIP_CODE]
Email:
Additional medical monitor or sponsor contacts may be provided in a letter to i nvestigator during the course 
of the study conduct without involving a protocol amendment.  
NEW TEXT:
(new text bold and underlined , deleted text in strikethrough)
Role Name [CONTACT_301229] -hours 
Phone/Cell/
Pager 
NumberFax 
Number[COMPANY_004] Addre ss
Medical 
Monitor
MDGlaxoSmithKline
[ADDRESS_471857]
[PO_BOX]
Collegeville, PA [ZIP_CODE]
Email:
Medical 
Monitor MD, PhDGlaxoSmithKline
[ADDRESS_471858]
[PO_BOX]
Collegeville, PA [ZIP_CODE] -0989, 
[LOCATION_002]
Email: 
Secondary 
Medical 
MonitorMDGlaxoSmithKline
[ADDRESS_471859], 
Collegeville, PA [ZIP_CODE]- 0989, 
[LOCATION_002]
Email:   
Additional medical monitor or sponsor contacts may be provided in a letter to investigator during the course 
of the study conduct without involving a protocol a mendment.   
CHANGE 2: Clarifications to be consistent with previous amendments
PREVIOUS TEXT, Synopsis:
Rationale for change: This was modified was made in Amendment 4 changes and bod y of 
protocol but n ot in sy nopsis.  This change is to ensure consistenc y within protocol.
1.Histologicall y or c ytologically  confirmed diagnosis:
Arms A and B: Stage IV or recurrent metastatic squamous NSCL C (TNM Staging 
for NSCL C, 7thEdition) with FGFR1 gene amplification by  [CONTACT_377121].
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N165256_06 CONFIDENTIA L
FGF117360
115NEW TEXT, Synopsis:
(new text bold and underlined , deleted text in strikethrough)
1.Histologicall y or c ytologically  confirmed diagnosis:
Arms A and B: Stage IIIB or IV or recurrent metastatic squamous NSCLC (TNM 
Staging for NSCLC, 7thEdition) with FGFR1 gene amplification b y centr al 
laboratory  testing.
Rationale for change: This was modified was made in Amendment 4 changes but not 
within the text.  This change is to ensure consistency  within protocol.
NEW TEXT, Sectino [IP_ADDRESS]. Preclinical data on [COMPANY_004]3052230
Added reference [DeYoun g, 2014].
Which was updated in REFERENCES, Section 14
DeYoung MP, Shenk C, Bleam M, Barnette M, Ganji G, Hoang B, Tunstead J, 
Bellovin D, Los G, Minthorn E, Kumar R. Preclinical efficacy of targeting FGF 
autocrince signaling in mesothelioma with the FGF ligand trap, FP-
1039/[COMPANY_004]3052230.  AACR 2014.
PREVIOUS TEXT, Section 3.2.1, Inclusion criteria:
Availability  of archival tumor tissue required for assessment of deregulated FGF pathway  
signaling eg, FGFR1 amplification or FGF2 expression.
NEW TEXT, Section 3. 2.1, Inclusion criteria:
Availability  of archival tumor tissue required for assessment of deregulated FGF pathway  
signaling eg, FGFR1 amplification or FGF2 or FGFR1 expression.
Change 3: Chemotherapy treatment per local standards
NEW TEXT, Section 4.1.
Subjects on pemetrexed/cisplatin may have their cisplatin stopped after 4 cycles per 
local clinical standards.
NEW TEXT, Section 4.5.4.
1-2 liters of fluid infused for 8- 12 hours prior to cisplatin dose (or hydration per 
local standard)
CHANGE 4: Infusion Re actions and dosing timings
PREV IOUS TEXT, Exclusion criteria, S ection 1.6, Summary of Risk Management: 
If infusion reactions are noted in subjects not already  premedicated with glucocorticoids, 
antihistamines and H2 receptor antagonists, appropriate preme dication against 
2013N165256_06 CONFIDENTIA L
FGF117360
116hypersensitivity  reactions may  be initiated prior to the next infusions at the discretion of 
the investigator according to the institution’s standard practice.  
NEW TEXT, Exclusion criteria, Section 1.6, Summary of Risk Management:
(new t ext bold and underlined , deleted text in strikethrough)
If infusion reactions are noted in subjects not already  premedicated with glucocorticoids, 
antihistamines and H2 receptor antagonists, appropriate premedication against 
hypersensitivity  reactions may  be initiated prior to the next infusions at the discretion of 
the investigator according to the institution’s standard practice.  All subjects who have 
experienced an infusion reaction should have [COMPANY_004]3052230 infused over [ADDRESS_471860] a reaction on re- challenge, the infusion of 
[COMPANY_004]3052230 may be prolonged for 90 minutes”
NEW TEXT, Section 4.7.4 [COMPANY_004]3052230 Dose Modification
[IP_ADDRESS] [COMPANY_004]3052230 Dose Modifications regarding infusion related 
reactions
Subjects should be closely monitored for [COMPANY_004]3052230 infusion -related reactions. 
All subjects who have experienced an infusion reaction due to [COMPANY_004]3052230 (and 
not chemotherapy) should have [COMPANY_004]3052230 infused over 60 minutes instead of 30 
minutes and pre -treated with appropriate local instituationl pre -treatment 
guidelines (example: medications such as steroids, antihistamines, acetaminophen, 
H-2 antagonists, and antiemetics, according to local pretreat ment guidelines). If the 
subject continues to have a reaction on re- challenge the infusion of [COMPANY_004]3052230 
may be prolonged to [ADDRESS_471861] infusions.
2013N165256_06 CONFIDENTIA L
FGF117360
117CHANGE 5: Time and Events Screening Window for Arm A subjects
PREVIOUS TEXT , Section 7 Study Assessments and Procedures :
Table 10 Time and E vents Schedule
Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 
day 
F/U
D1 D8 D9 D15 D1 D8 D15 D1 D8 D15
Visit WindowOnce the subject provides consent, a tumor sample may be submitted for Arms A and B for FGFR1 amplification at any time (there is no time limit or 
window).  All other screening assessments should be conducted within 30 days of C1D1. Visit windows of ±2 days during study t hrough EOT, +7 days 
for F/U.
Ophthalmologic ExamTo be performed by [CONTACT_377093]. X Perform assessment if subject discontinues prior to C4. C4 only
ECHOPerform at EOT if subject discontinues prior to 
C4. Visit windows of ±7 days during study. X C4 onlyearly 
disc
Forced Vital CapacityAssess D1 of every odd cycle, Arm C only, Visit 
windows of ±7 days days during study . X XOdd
X
2013N165256_06 CONFIDENTIA L
FGF117360
118REVISED TEXT , Section 7 Study Assessments and Procedures :
(new text bold and underlined , deleted text in strikethrough)
Table 10 Time and Events Schedule
Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 
day 
F/U
D1 D8 D9 D15 D1 D8 D15 D1 D8 D15
Visit WindowOnce the subject provides consent, a tumor sample may be submitted for Arms A and B for FGFR1 amplification at any time (there is no time limit or 
window).  All other screening assessments should be conducted within 30 days of C1D1. Visit windows of ±2 days during study t hrough EOT, +7 days 
for F/U. For Arm A subjects who wish to start chemotherapy prior to [COMPANY_004]3052230 screening period is 30 days +3 to allow baseline imaging 
scans to be performed prior to chemotherapy but within 30+3days of [COMPANY_004]3052230 first dose .
Rationale for change: This was modified was m ade in Amendment [ADDRESS_471862]. (Visit windows of ±[ADDRESS_471863] 
baseli ne). X Perform assessment if subject discontinues prior to C4.C4 
only
ECHOPerform at EOT if subject discontinues prior to 
C4. Visit windows of ±[ADDRESS_471864] 
baseline. XC4 
onlyearly 
disc
Forced Vital CapacityAssess D1 of every odd cycle, Arm C only, Visit 
windows of ±[ADDRESS_471865] baseline. X XOdd
X
2013N165256_06 CONFIDENTIA L
FGF117360
119CHANGE 6: Time and Events PK Sampling for Cisplatin in Arm C subjects
PREVISION TEXT, Section 7: Table 11 Pharmacokinetic Sampling Schedule
FGF117360 Pharmaco kinetic Sampling Schedule
Limited PKExtensive PK Extensive PK Extensive PK
Time When Window Arm A Arm B Arm C
n=20pts in each arm n>=10pts n>=10pts n>=10pts
Cycle 2 Day 1Prior to infusion of 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052 230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
End of infusion of 
[COMPANY_004]3052230Up to 5 min prior to end of 
infusion of [COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
1 hr after start of paclitaxel 
infusion or end of 
docetaxel or pemetrexed 
infusion10 min for paclitaxel or up to 
5min prior to end of docetaxel 
infusion or up to 1 min prior to 
end of pemetrexed infusion[COMPANY_004]3052230 
PK
Paclitaxel PK[COMPANY_004]3052230 
PK
Docetaxel PK[COMPANY_004]3052230 PK
Pemetrexed PK
1 hr after end of 
pemetrexed infusion 20 minPemetrexed PK
End of paclitaxel infusion 
or 2 hr after end of 
docetaxel or pemetrexed 
infusionup to 5 min prior to end of 
paclitaxel infusion or 20 min 
for docetaxel and pemetrexed Paclitaxel PK Docetaxel PKPemetrex ed PK
2 hr after end of paclitaxel 
infusion or 5 hr after end 
of docetaxel or 
pemetrexed infusion 30 min(selected sites)
[COMPANY_004]3052230 
PK
Paclitaxel PK(selected sites)
[COMPANY_004]3052230 
PK
Docetaxel PK(selected sites)
[COMPANY_004]3052230 PK
Pemetrexed PK
REVISED T EXT , Section 7 : Table 11 Pharmacokinetic Sampling Schedule
FGF117360 Pharmacokinetic Sampling Schedule
Limited PKExtensive PK Extensive PK Extensive PK
Time When Window Arm A Arm B Arm C
n=20pts in each arm n>=10pts n>=10pts n>=10pts
Cycle 2 Day 1Prior to infusion of 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
End of infusion of 
[COMPANY_004]3052230Up to 5 min prior to end of 
infusion of [COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]30522 30 
PK [COMPANY_004]3052230 PK
2013N165256_06 CONFIDENTIA L
FGF117360
120FGF117360 Pharmacokinetic Sampling Schedule
Limited PKExtensive PK Extensive PK Extensive PK
Time When Window Arm A Arm B Arm C
1 hr after start of paclitaxel 
infusion or end of 
docetaxel or pemetrexed 
infusion10 min for paclitaxel or up to 
5min prior to end of docetaxel 
infusion or up to 1 min prior to 
end of pemetrexed infusion[COMPANY_004]3052230 
PK
Paclitaxel P K[COMPANY_004]3052230 
PK
Docetaxel PK[COMPANY_004]3052230 PK
Pemetrexed PK
Cisplatin PK
1 hr after end of 
pemetrexed infusion 20 minPemetrexed PK
Cisplatin PK
End of paclitaxel infusion 
or 2 hr after end of 
docetaxel or pemetrexed 
infusionup to 5 min prior to end of 
paclitaxel infusion or 20 min 
for docetaxel and pemetrexed Paclitaxel PK Docetaxel PKPemetrexed PK
Cisplatin PK
2 hr after end of paclitaxel 
infusion or 5 hr after end 
of docetaxel or 
pemetrexed infusion 30 min(selected sites)
[COMPANY_004]3052230 
PK
Paclitaxel PK(selected sites)
[COMPANY_004]3052230 
PK
Docetaxel PK(selected sites)
[COMPANY_004]3052230 PK
Pemetrexed PK
Cisplatin PK
2013N165256_06 CONFIDENTIA L
FGF117360
121CHANGE 7:Ionized Calcium monitoring for sites in [LOCATION_008]
PREVIOUS TEXT , Section 7.3.8 Laboratory Assessments ::
Table [ADDRESS_471866] of C linical Laboratory  Tests
Hematology
Platelet Count Automated WBC Differential :
Red blood cell (RBC) Count Neutrophils (absolute)
White blood cell (WBC) Count 
(absolute) Lymphocytes (absolute)
Hemoglobin Monocytes (absolute)
Eosinophils (absolute)
Basophils (absolute)
Clinical Chemistry
Potassium, Sodium, Chloride, Total carbon dioxide, total Calcium, ionized calcium, magnesium, phosphate, 
albumin, glucose (fasting),
REVISED TEXT , Section 7.3.8 Laboratory Assessments:
(new text bold and underli ned, deleted text in strikethrough)
Table [ADDRESS_471867] of Clinical Laboratory  Tests
Hematology
Platelet Count Automated WBC Differential :
Red blood cell (RBC) Count Neutrophils (absolute)
White blood cell (WBC) Count 
(absolute) Lymphocytes (absolute)
Hemo globin Monocytes (absolute)
Eosinophils (absolute)
Basophils (absolute)
Clinical Chemistry
Potassium, Sodium, Chloride, Total carbon dioxide, total Calcium, ionized calcium *,magnesium, 
phosphate, albumin, glucose (fasting),
*Ionized calcium collec ted may not be collected in some selected sites and only total calcium is 
collected for subjects regarding safety monitoring.
2013N165256_06 CONFIDENTIA L
FGF117360
122Amendment [ADDRESS_471868], the time & 
event tables, concomitant medications and Cockcroft- gault formula description.
We have expanded the lines of treatment to address the changing parameters in the 
NSCL C development and treatments.  We have broadened the lines of therapy  to allow 
for additional subjects t o benefit from [COMPANY_004]3052230 in combination with chemotherap y.  
In addition, the mechanism of resistance for current FGF inhibitors may  be different from 
[COMPANY_004]3052230 and therefore those who previously failed FGFR inhibitor treatment will be 
included.
The protocol was expanded to allow intra -subject dose escalation or de -escalation.  This 
allows subjects who receive benefit during the dose escalation to transition to the 
recommended expansion dose.  In addition, additional wording has been added to allow 
alterna tive dosing and schedules to be explored.  Example, if a MTD is not obtained the 
study  could explore lower doses or MFD levels based on the totality  of the data (eg, 
safet y, pharmacokinetics, pharmacod ynamics, etc).  
List of Specific Changes
CHANGE 1: Med ical monitor contact [CONTACT_377120]:
Role Name [CONTACT_301229] -hours 
Phone/Cell/
Pager 
NumberFax 
Number[COMPANY_004] Address
Primary 
Medical 
Monitor 
 
MDGlaxoSmithKline
[ADDRESS_471869]
[PO_BOX]
Collegeville, PA [ZIP_CODE]
Email: 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N165256_06 CONFIDENTIA L
FGF117360
123Role Name [CONTACT_301229] -hours 
Phone/Cell/
Pager 
NumberFax 
Number[COMPANY_004] Address
Secondary 
Medical 
Monitor 
 
MDGlaxoSmithKline
Five Moore Drive,
Mailstop 17.2225.2B
Research Triangle Park, NC 
[ZIP_CODE]
Email: 
NEW TEXT :
(new text bold and underlined , deleted text in strikethrough)
Role Name [CONTACT_301229] -hours 
Phone/Cell/
Pager 
NumberFax 
Number[COMPANY_004] Address
Primary 
Medical 
Monitor 
 
MDGlaxoSmithKline
[ADDRESS_471870]
[PO_BOX]
Collegeville, PA [ZIP_CODE]
Email: 
Secondary 
Medical 
Monitor 
 
MDGlaxoSmithKline
Five Moore D rive,
Mailstop 17.2225.2B
Research Triangle Park, NC 
[ZIP_CODE]
Email: 
Medical 
Monitor 
 
MDGlaxoSmithKline
[ADDRESS_471871]
[PO_BOX]
Collegeville, PA [ZIP_CODE]
Email:
Medical 
Monitor 
MDGlaxoSmithKline
[ADDRESS_471872]
[PO_BOX]
Collegeville, PA [ZIP_CODE]
Email:
Additional medical monitor or sponsor contacts may be provided in a l etter to investigator during 
the course of the study conduct without involving a protocol amendment.  
PP
D
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
PP
D
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N165256_06 CONFIDENTIA L
FGF117360
124CHANGE 2: Abbreviations 
(new text bold and underlined , deleted text in strikethrough)
NEW TEXT:
TGI tumor growth inhibition 
CHANGE 3: Study Design 
(new text bold and underlined , deleted text in strikethrough)
PREVIOUS TEXT:
Study Design : This will be a multi -arm, multicenter, non -randomized, parallel -
group, uncontrolled, open- label Phase IB stud y designed to evaluate the safety, 
tolerability  and pre liminary  activity  of [COMPANY_004]3052230 in combination with 
paclitaxel + carboplatin in previously  untreated metastatic squamous NSCLC 
(Arm A), in combination with docetaxel in metastatic squamous NSCL C that has 
progressed after 1 line of chemotherapy (Arm B), or in combination with 
pemetrexed + cisplatin in MPM previously  untreated with chemotherap y or 
investigational agents (Arm C). 
REVISED TEXT:
Study Design : This will be a multi -arm, multicenter, non -randomized, parallel -
group, uncontrolled, open- label Phase IB stud y designed to evaluate the safety, 
tolerability  and preliminary  activity  of [COMPANY_004]3052230 in combination with 
paclitaxel + carboplatin in previously  untreated metastatic squamous NSCLC 
(Arm A), in combination with docetaxel in metastatic squamous NSCL Cthat has 
progressed after at least 1 line of chemotherap y(Arm B), or in combination with 
pemetrexed + cisplatin in MPM previously  untreated with chemotherap y or 
investigational agents (Arm C). 
CHANGE 4:Exploratory Endpoints and Objectives 
(new text b old and underlined , deleted text in strikethrough)
Section Summary
PREVIOUS TEXT:
Objectives and Endpoints:
The primary  objectives and endpoints are noted below. The full objectives and 
endpoints (primary , secondary  and translational ) are located in the ma in protocol 
in Section 2.
2013N165256_06 CONFIDENTIA L
FGF117360
125REVISED TEXT:
Objectives and Endpoints:
The primary  objectives and endpoints are noted below. The full objectives and 
endpoints (primary , secondary  and translational exploratory ) are located in the 
main protocol in Section 2.
Section: 2.3 Exploratory
PREVIOUS TEXT:
Objectives
Exploratory To develop and validate a Fluorescence 
in situ hybridization (FISH) -based 
assay to measure FGFR1 gene 
amplification status..
Endpoint
Exploratory Identification and validation of 
alternati ve measures of FGF signaling 
pathway deregulation retrospectively 
(eg, FGF2 overexpression) as predictive 
biomarkers for subject selection and 
potential development of a companion 
diagnostic
REVISED TEXT:
Objectives
Exploratory To develop and validate an assay to 
measure of  FGFR1 gene 
amplification status such as, but not 
limited to , a Fluorescence in situ
hybridization (FISH) -based assay to 
measure FGFR1 gene amplification 
status .
Endpoint
Exploratory Identification and validation of 
alternative measures of FGF signaling 
pathway deregulation retrospectively
such as ligand or receptor 
overexpression for example but not 
limited to FGF2 or FGFR1 expression   
FGF2 overexpression as predictive 
biomarkers for subject selection and 
potential development of a companion 
diagnostic
2013N165256_06 CONFIDENTIA L
FGF117360
126CHANGE 5: Number of subjects
(new text bold and underlined , deleted text in strikethrough)
Section: Summary
NEW TEXT, Summary section:
Number of Subjects : Approximately  70 subjects (minimum of 38 and up to 120, 
alternative dosi ng cohorts could potentially add another ~6 to ~40 subjects ).
NEW TEXT, Section 3.1:
Number of Subjects : Approximately  70 subjects (minimum of 38 and up to 120, 
alternative dosing cohorts could potentially add another ~6 to ~40 subjects ).
CHANGE 6: Precli nical data on [COMPANY_004]3052230
(new text bold and underlined , deleted text in strikethrough)
PREVIOUS TEXT:
[IP_ADDRESS] Preclinical data on [COMPANY_004]3052230
Seventy -eight tumor -derived xenograft models were treated with [COMPANY_004]3052230 
(FP1039) as a single agent.  Twenty -eight models were found to show significant 
tumor growth inhibition (TGI) , including models of NSCL C, small cell lung 
cancer, mesothelioma, squamous cell carcinoma of the head and neck (SCCHN), 
endometrial, colon and breast cancer [ Harding , 2010; Harding , 2013] .  In lung 
cancer xenografts, [COMPANY_004]3052230- teated tumors harboring FGFR1 gene 
amplification display ed an average of 56% TGI compared to 22% TGI in non -
amplified FGFR1 xenografts (p=0.03)[ Harding , 2013]. FGF2 mRNA levels 
display ed the highest ratio (247.7- fold) of median gene expression between 
[COMPANY_004]3052230 responder and nonresponder xenograft models and was the only 
marker that correlated with response in the subset of non- amplified FGFR1 lung 
cancer xenografts where significant tumor growth inhibition was obs erved 
[Harding , 2013]. 
To further extend this observation, [COMPANY_004]3052230 was tested in models of 
mesothelioma, a tumor type shown to express high levels of FGF2 mRNA in cell 
lines and in primary  tumor specimens [DeYoung, 2014]. [COMPANY_004]3052230 inhibited 
MAPK sign aling as evidenced b y decreased phospho
-ERK levels in both NCI -
H226 and MSTO -211H cells. When both cell lines were grown as tumor 
xenografts in mice, [COMPANY_004]3052230 inhibited tumor growth in a dose -dependent 
manner (NCI
-H226: 16 – 78% TGI; MSTO -211H: 20 –50% TGI). Because FGFs 
also play  a key  role in angiogenesis, the effects of [COMPANY_004]3052230 on tumor vessel 
2013N165256_06 CONFIDENTIA L
FGF117360
127formation in NCI -H226 xenografts were explored [DeYoung, 2014]. Dose-
dependent and statistically- significant reductions in tumor vessel density  were 
observed in [COMPANY_004]3052230-treated tumors compared to vehicle- treated tumors 
using MECA -32 endothelial cell IHC staining. Therefore, FGFR1 amplification 
or FGF2 overexpression served as predictive markers of response to 
[COMPANY_004]3052230.
REVISED TEXT:
[IP_ADDRESS] Preclinical da ta on [COMPANY_004]3052230
Seventy -eight tumor -derived xenograft models were treated with [COMPANY_004]3052230 
(FP1039) as a single agent.  Twenty -eight models were found to show significant 
tumor growth inhibition (TGI), including models of NSCL C, small cell lung 
cancer, mes othelioma, squamous cell carcinoma of the head and neck (SCCHN), 
endometrial, colon and breast cancer [ Harding , 2010; Harding , 2013].  I n lung 
cancer xenografts, [COMPANY_004]3052230- teated tumors harboring FGFR1 gene 
amplification display ed an average of 56% tumor growth inhibition TGI 
compared to 22% tumor growth inhibition TGI in non -amplified FGFR1 
xenografts (p=0.03)[ Harding , 2013]. FGF2 mRNA levels display ed the highest 
ratio (247.7-fold) of median gene expression between [COMPANY_004]3052230 responder 
and nonresponder xenograft models and was the only  marker that correlated with 
response in the subset of non- amplified FGFR1 lung cancer xenografts where 
significant tumor growth inhibition was observed [ Harding , 2013 ]. 
To further extend this observation, [COMPANY_004]3052230 was t ested in models of 
mesothelioma, a tumor type shown to express high levels of FGF2 mRNA in 
cell lines and in primary tumor specimens [DeYoung, 2014]. [COMPANY_004]3052230 
inhibited MAPK signaling as evidenced by [CONTACT_377122] -ERK levels in 
both NCI- H226 and MSTO -211H cells. When both cell lines were grown as 
tumor xenografts in mice, [COMPANY_004]3052230 inhibited tumor growth in a dose -
dependent manner (NCI -H226: 16 – 78% TGI; MSTO -211H: 20 – 50% 
TGI). Because FGFs also play a key role in angiogenesis, the effects of 
[COMPANY_004]3 052230 on tumor vessel formation in NCI -H226 xenografts were 
explored [DeYoung, 2014]. Dose- dependent and statistically -significant 
reductions in tumor vessel density were observed in [COMPANY_004]3052230 -treated 
tumors compared to vehicle -treated tumors using MECA -32 endothelial cell 
IHC staining. Therefore, FGFR1 amplification or FGF2 overexpression served 
as predictive markers of response to [COMPANY_004]3052230.
CHANGE 7: Subject selection criteria, S ection 3.2
(new text bold and underlined , deleted text in strikethrough)
PREVIOUS TEXT:
Inclusion criteria 2:
Arm C: recurrent after local therap y or unresectable malignant pleaural 
mesothelioma (MPM) with measurable lesions.
2013N165256_06 CONFIDENTIA L
FGF117360
128Arm A: Subjects who have received no prior therapy  for Stage IV or recurrent 
metastatic disease. Note, to avoid any undue delay of initiating sy stemic 
chemotherap y for these subjects with newly  diagnosed metastatic disease, it is 
allowed to initiate the first cy cle of chemotherap y while eligibility for the study  is 
still being determined, as long as the fir st dose of [COMPANY_004]3052230 is given no later than 
Cycle 2 Day 1 of chemotherapy . In addition, subjects with Stage IV disease and 
recurrence after previous NSCL C that has been treated with surgery  and adjuvant 
chemotherap y or a radio- chemotherap y regimen with curative intent are eligible, 
provided 6 months has passed since this treatment ended[ TNM classification of 
malignant tumors, 7thedition, 2009; Edge , 2010].
Arm B: Subjects who have documented tumor progression (based on radiological 
imaging) or intolerabil ity after receiving onl y one prior line of platinum containing 
combination chemotherapy  for Stage IV or recurrent metastatic disease [ TNM 
classification of malignant tumors, 7thedition, 2009; Edge , 2010]. Continued 
‘maintenance’ chemotherapy  will be consi dered part of the first line regimen if the 
same agents are used. If new agents are used for maintenance treatment, this will be 
considered a second line of therapy. Note: first line treatment should not include 
docetaxel but may  have included paclitaxel.
Inclusion criteria 3:
Availability  of archival tumor tissue required for assessment of deregulated FGF 
pathway  signalling, eg, FGFR1 amplification or FGF2 expression. If archival tissue 
is not available, a fresh biopsy  is required. Please refer to Section 7.7.1.
In Arms A and B , subjects will be prospectivel y screened for FGFR1 gene 
amplification using a FISH assay  (note, local testing is permitted for pre- screening 
of subjects prior to central testing). For inclusion in this study , based on the central 
laboratory  testing, FGFR1 gene amplification must meet one of the following 
criteria: a ratio of FGFR1 /CEN 8 of ≥2; or average number of FGFR1 signals per 
tumor nucleus of ≥6; or the percent age of tumor nuclei containing ≥5 FGFR1 signals 
is ≥50%. 
Inclusion c riteria 3:
Measurable disease per RECI ST version 1.1.
Inclusion criteria 8:
Eastern Cooperative Oncology  Group (ECOG) Performance Status of 0 -1 for Arm A 
subjects and 0- 2 for Arms B and C. 
Inclusion criteria 10, Table 1:
Serum Creatinine
Or
Measured or Ca lculated Creatinine Clearance c1.[ADDRESS_471873]
Or
≥45 mL/min  
Cardiac
Left ventricular ejection fraction ≥LLN (according to local institutional norms) by [CONTACT_18585]
2013N165256_06 CONFIDENTIA L
FGF117360
129Exclusion criteria 1:
For Arms A, B, C: Treatment with any  FGFR inhibitor.
Exclusion criteria 10:
Symptomatic leptomeningeal or brain metasta ses or spi[INVESTIGATOR_13377].
NOTE : Subjects previously  treated for these conditions are eligible if they  meet both
of the criteria below :
(1) have had stable CNS disease for at least 4 weeks after local therapy  as assessed by  
[CONTACT_9661] (contrast enhanced magnetic resonance imaging (MRI) or computed 
tomograph y (CT)),
REVISED TEXT:
Inclusion criteria 2:
Arm C: recurrent after local therap y or unresectable malignant pleural
mesothelioma ( MPM )with measurable lesions.
Arm A: Subjects who have received no prior therapy  for Stage IIIB or Stage IV or 
recurrent metastatic disease. Note, to avoid an y undue delay  of initiating s ystemic 
chemotherap y for these subjects with newly  diagnosed metastatic disease, it is 
allowed to initiate the first cy cle of chemotherap y while eligibility  for the study  is 
still being determined, as long as the first dose of [COMPANY_004]3052230 is given no later than 
Cycle 2 Day  1 of chemotherapy . In addition, subjects with Stage IIIB or Stage IV 
disease and recurrence after previous NSCL C that has been treated with surgery  and 
adjuvant chemotherap y or a radio -chemotherap y regimen with curative intent are 
eligible, provided 6 months has passed since this treatment ended[ TNM 
classification of malignant tumors, 7thedition, 2009; Edge , 2010].
Arm B: Subjects who have documented tumor progression (based on radiological 
imaging) or intolerability after receiving only one or at least one prior line of 
platinum containing combination chemotherap y forStage IIIB or Stage IV or 
recurrent metastatic disease [ TNM classification of malignant tumors, 7thedition, 
2009; Edge , 2010]. Continued ‘maintenance’ chemotherapy  will be considered part 
of the first line regimen if the same agents are used. If new agents are used for 
maintenance treatment, this will be conside red a second line of therap y.Note: first 
line Prior treatment should not include docetaxel but may  have included paclitaxel.
Inclusion criteria 3:
Availability  of archival tumor tissue required for assessment of deregulated FGF 
pathway  signalling, egbut  not limited to, FGFR1 amplification or FGF2 or FGFR1
expression. I f archival tissue is not available, a fresh biopsy  is required. Please refer 
to Section 7.7.1.
In Arms A and B , subjects will be prospectivel y screened for FGFR1 gene 
amplification using a FISH assay  (note, local testing is permitted for pre- screening 
of subjects prior to central testing) for the dose expansion and the MTD/MFD 
cohorts only . For inclusion in this study , based on the central laboratory  testing, 
FGFR1 gene amplification must me et one of the following criteria: a ratio of 
2013N165256_06 CONFIDENTIA L
FGF117360
130FGFR1 /CEN 8 of ≥2; or average number of FGFR1 signals per tumor nucleus of ≥6; 
or the percentage of tumor nuclei containing  ≥5 FGFR1 signals is ≥50%. 
Inclusion criteria 4:
Measurable disease per RECI ST version 1.1(Arm A and B) and modified 
RECIST for Arm C.
Inclusion criteria 8:
Eastern Cooperative Oncology  Group (ECOG) Performance Status of 0 -1 for Arms 
A and C subjects and 0- 2 for Arm sBand C . 
Inclusion criteria 10, Table 1:
Serum Creatinine
Or
Measured or Calculated Creatinine Clearance c1.[ADDRESS_471874]
Or
≥45 mL/min (Arm A or B) ≥65 mL/min (Arm C )
Cardiac
Left ventricular ejection fraction ≥50% LLN (according to local institutional norms) by 
[CONTACT_377123] 1:
For Arms A , B,andC: Treatment with an y FGFR inhibitor.
Exclusion criteria 10:
Symptomatic leptomeningeal or brain metastases or spi[INVESTIGATOR_13377].
NOTE : Subjects previously  treated for these conditions are eligible if they  meet both
of the criteria below:
(1) have had stable CNS disease for at least 4 weeks after local therap y as assessed by  
[CONTACT_9661] (contrast enhanced magnetic resonance imaging (MRI) or computed 
tomograph y (CT)) prior to Day 1 ,
CHANGE 8: Intra -subject dosing and alternative dosing and schedule cohorts
(new text underlined , deleted text in strikethrough)
NEW TEXT: 
4.2.[ADDRESS_471875] dose escalations may  be considered on a case -by-case basis, provided 
thatthehigher dose level cohort from the 3+[ADDRESS_471876] who enrolled at a dose level below the MTD (or MFD) and may  
be eligible for dose increases if the investigat or believes the subject could benefit. 
2013N165256_06 CONFIDENTIA L
FGF117360
1314.2.6.1 Alternative Dosing and Schedule Cohorts
Additional doses and schedules may  be explored based on emerging 
pharmacokinetic and safety  data. Alterations may  be made to the schedule of PK/PD 
sampling sbased on e merging PK  data.  
The sample size of the “alterative dosing and schedule cohorts” will be based on the 
3 + 3 design with potential to expand to up to 30 subjects in this regimen.  
The rationale for exploring this alterative dosing and/or schedule is to expand on the 
safet y,  tolerabilit y and preliminary  efficacy .
[IP_ADDRESS] Study treatments: Alternative Dosing and Schedule cohorts
Subjects in these expansion cohorts will be dosed based on the pharmacokinetic 
and emerging safet y data from the ongoing stud y. This will be determined at 
FGF117360 Stud y Investigator meetings (example: dose escalation meeting) and 
the minutes and agreements would be provided to IRB/Ethics prior to dosing in 
this “Alternative Dosing and Schedule” Cohorts.
CHANGE 9: Subject selecti on criteria, Section 3.2
(new text bold and underlined , deleted text in strikethrough)
PREVIOUS TEXT:
4.7.[ADDRESS_471877] safet y per investigator 
discretion .
4.7.4 [COMPANY_004]3052230 Dose Modifications
If the toxicity  is potentially  related to both [COMPANY_004]3052230 and chemotherap y as 
given in Arm A or B , please refer to dose modification for chemotherap y in 
Section 4.7.2 and Section 4.7.3 for potential dose reduction of both study  
treatments.
REVISED TEXT:
4.7.[ADDRESS_471878] safety per investigator discretion.
4.7.4 [COMPANY_004]3052230 Dose Modi fications
If the toxicity  is potentially  related to both [COMPANY_004]3052230 and chemotherap y as 
given in Arm A or B, all arms, please refer to dose modification for chemotherapy  
2013N165256_06 CONFIDENTIA L
FGF117360
132in Section 4.7.2 and Section 4.7.3 for potential dose reduction of both stud y 
treatment s.
CHANGE 10: Section 7, Time and Events
(new text bold and underlined , deleted text in strikethrough)
2013N165256_06 CONFIDENTIA L
FGF117360
133PREVIOUS TEXT:
Table 10 Time and Events Schedule
Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 
day 
F/U
D1 D8 D9 D15 D1 D8 D15 D1 D8 D15
Visit WindowTissue prescreen for Arms A and B within 60 days and all other screening assessments within 30 days of C1D1. Visit windows of ±2 days during study 
through EOT, +7 days for F/U. Cycle 1 Day 9 assessments for Arm C only.
Physical exam, weight, 
and height (baseline only)Not needed C1D1 if screening 
assessments within prior [ADDRESS_471879] discontinues 
prior to C4. X C4 onlyearly 
disc
Forced Vi tal Capacity Assess D1 of every odd cycle, Arm C only X X O
Archival Tumor Tissue Archived tumor tissue (or fresh biopsy if 
no archival tissue). X
Brain Scan X every 12 weeks 1 week if positive at Screening, or as clinically i ndicated
2013N165256_06 CONFIDENTIA L
FGF117360
134REVISED TEXT:
Table 10 Time and Events Schedule
Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 
day 
F/U
D1 D8 D9 D15 D1 D8 D15 D1 D8 D15
Visit WindowTissue prescreen for A rms A and B within [ADDRESS_471880] provides consent, a tumor sample may be submitted for Arms A and B for FGFR1 amplification at any time (ther e is no time 
limit or window).  All other s creening assessments should be conducted within 30 days of C1D1. Visit windows of ±2 days during study through 
EOT, +7 days for F/U .
Physical exam, weight,
and height (baseline only)Not needed C1D1 if screening 
assessments within prior 72 hrs. Complete 
physical exam at screening. Abbreviated 
disease -oriented physical exam 
subsequently. X X X X X X
WeightNote, during dosing period weight 
should be captured on Day 1 of each 
cycle.  It can be obtained more 
frequently per institutional standards 
(example: if required at each infusion) X X X X X X
Ophthalmologic ExamTo be performed by [CONTACT_377124]. (Visit windows of 
±[ADDRESS_471881] baseline). X Perform assessment if subject discontinues prior to C4. C4 only
ECHOPerform at EOT if subject discontinues 
prior to C4. ( Visit windows of ±[ADDRESS_471882] baseline). X C4 onlyearly 
disc
Forced Vital CapacityAssess D1 of every odd cycle, Arm C 
only. (Visit windows of ±[ADDRESS_471883] 
baseline). X X Odd
Archival Tumor Tissue Archived tumor tissue (or fresh biopsy if 
no archival tissue). Once the subject 
provides consent, a tumor sample may 
be submitted for Arms A and B for 
FGFR1 amplification at any time (the re X
2013N165256_06 CONFIDENTIA L
FGF117360
135Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 
day 
F/U
D1 D8 D9 D15 D1 D8 D15 D1 D8 D15
is no time limit or window).
Brain Scan Obtain only if sym ptomatic X every 12 weeks 1 week if positive at Screening, or as clinically indicated
2013N165256_06 CONFIDENTIA L
FGF117360
136CHANGE 11: Section 7.3.9, Pregnancy Testing and Reporting
(new text bold and underlined , deleted text in strikethrough)
PREVIOUS TEXT:
Any pregnancy  that occurs during stud y participation must be reported using a 
clinical trial pregnancy  form .
REVISED TEXT:
Any pregnancy  that occurs during study participation (note, study participation 
is defined as the time of the first dose of study drug [COMPANY_004]3052230 is 
administered) must be reported using a clinical trial pregnancy  form .
CHANGE 12 : Section [IP_ADDRESS]
MOVE TEXT: Move section below from protocol Section [IP_ADDRESS] to Section [IP_ADDRESS]
Tips on Lymph Node Measurements:
Lym ph nodes are considered as a s eparate organ to measure, and up to two ly mph 
nodes can be measured per patient b y RECI ST v1.1. For unidimensional lymph 
node measurements, use the short axis of the ly mph node at baseline and then at 
every  followup scan. To be considered as pathologically enlarged and mea surable 
at baseline, the l ymph node short axis diameter should be ≥15 mm.
CHANGE 1 3: Section 7.7.1, Central Confirmation of FGF Signalling Pathway  Status 
and Translational Research
(new text bold and underlined , deleted text in strikethrough)
PREVIOUS TEXT :
In Arm C, FGF2 and/or FGFR1 expression will be evaluated retrospectively b y 
IHC to determine if expression levels of these proteins are associated with 
response to [COMPANY_004]3052230
Any remaining tissue from this study  may  be used for:
Development and validatio n of a potential IUO assay and companion 
diagnostic test, e.g., but not limited to FGFR1 gene amplification b y FISH or 
FGF2 and/or FGFR1 expression by  [CONTACT_4658].
Alternative biomarkers of FGF pathway  signalling such as other ligands or 
receptors. 
REVISED TEXT:
In Arm C, FGF2 and/or FGFR1 expression will be evaluated retrospectively  by [CONTACT_377125]2 these proteins are associated with response to 
[COMPANY_004]3052230
2013N165256_06 CONFIDENTIA L
FGF117360
137Any remaining tissue from this study  may  be used for:
Development and validation of a potential IUO assay  and companion diagnostic test, 
e.g., but not limited to FGFR1 gene amplification by  [CONTACT_377099]2 and/or 
FGFR1 expression by  [CONTACT_4658].
Alternative biomarkers of FGF pathway  signalling such as other ligands or 
receptors . 
CHANGE 14 : Section 9.1, 
(new text bold and underlined , deleted text in strikethrough)
PREVIOUS TEXT:
In Arm A and Arm B, the proph ylactic use of hematopoietic colony  stimulating 
factors is not allowed in Cy cle 1.  However, growth factor support therap y (e.g., G -
CSF, GM-CSF) may  be administered as a prophy laxis for chemotherapy -related 
neutropenia according to the NCCN Clinical Practice Guidelines in Oncology : 
Myeloid Growth Factors v.1.2010 [ NCCN , 2010] or the European Organisation for 
Research and Treatment of Cancer guidelines for the use of G -CSFs [ Aapro , 2011]
REVISED TEXT:
In Arm A and Arm B, The prophy lactic use of hematopoietic colony  stimulating 
factors is not recommended allowed in Cy cle [ADDRESS_471884] prophylactic use for subjects 
during the dose escalation period or alternative dose finding period. During 
expansion phase , However , growth factor support therap y (e.g., G-CSF, GM -CSF) 
may be administered as a prophy laxis for chemotherapy -related neutropenia 
according to the NCCN Clinical Pr actice Guidelines in Oncology : Myeloid Growth 
Factors v.1.2010 [ NCCN , 2010] or the European Organisation for Research and 
Treatment o f Cancer guidelines for the use of G- CSFs [ Aapro , 2011].  
CHANGE 14 : Section 12.7, Interim Analysis,
(new text bold and underlined , deleted text in strikethrough)
The rules are also shown in a tabular format below:
REVISED and NEW TEXT:
For Arm C only, the totality of the data will be reviewed prior to stoppi[INVESTIGATOR_377054]-binding. The final analysis for 
Arm C will require 16/[ADDRESS_471885] at the fina l analysis with alpha level 0.10 and power of 82%.
The rules for Parts A, B and C are also shown in a tabular format below:
2013N165256_06 CONFIDENTIA L
FGF117360
138CHANGE 15 : Section 15.3, App endix 3: Cockcroft- Gault Formula
(new text bold and underlined , deleted text in strikethrough)
PREVIOU S TEXT:
Example: Male, actual body weight = 90.0 kg, height = 68 inches
Ideal body weight = 50.0 + (2.3) (68 -60) = 68.[ADDRESS_471886]’s actual body weight is >30% over ideal body weight. Therefore, in this case, the 
subject’s ideal body weight of 68.4 kg should be used in calculating estimated CrCl.
REVISED TEXT:
Example: Male, actual body weight = 90.0 kg, height = 68 inches
Ideal body weight = 50.0 + (2.3) (68 -60) = 68.[ADDRESS_471887]’s actual body weight is >30% over ideal body weight. Therefor e, in this case, the 
subject’s ideal body weight of 68.4 kg should be used in calculating estimated CrCl.
2013N165256_06 CONFIDENTIA L
FGF117360
139Amendment 3
Where the Amendment Applies
This amendment applies to all sites.
Summary of Amendment Changes with Rationale
Amendment 3 changed Arm C of the protocol from [COMPANY_004]3052230 monotherap y of 
subjects with solid tumors to combination chemotherap y ([COMPANY_004]3052230 plus pemetrexed 
and cisplatin) of subjects with mesothelioma. Associated additions to the protocol include 
safet y precautions for pemetrexed an d cisplatin, use of modified RECI ST for evaluation 
of clinical response, assessment of forced vital capacity . Patient reported outcomes using 
the L ung Cancer S ymptom Scale (L CSS) was added for subjects with lung cancer and 
LCSS -meso for subjects with mesot helioma. Additional background and rationale were 
added. Stoppi[INVESTIGATOR_377012]. Translational research objectives 
were clarified.
List of Specific Changes
Section 1.[ADDRESS_471888] in Cancer
REVI SED TEXT: (new text bold and underli ned, deleted text in strikethrough)
The last [ADDRESS_471889] 3 paragraphs:
FGF ligand -dependent signaling occurs through autocrine production of FGFs
directly from cancer cells or through paracrine production of FGFs from the local 
stroma [ Turner, 2010]. FGF2 -FGFR1 autocrine feedback loops have been 
characterized in several tumor types and may have a role in drug resistance upon 
exposure to chemotherap y or targeted agents such as gefitinib [ Sharpe , 2011; 
Marek , 2009]. Overexpression of FGFs is readily detectable by 
[CONTACT_377126], as several studies have shown high levels of 
FGF2 protein in MPM tumor specimens [ Kumar-Singh , 1999; Davidso n, 2004; Li , 
2011]. Further, overexpression or high systemic levels of FGF ligands correlate with 
tumorigenesis and poor patient outcome. These discoveries support the notion that 
specific treatments targeting FGF pathway alterations may provide benefit in this 
population .
Section 1.[ADDRESS_471890] 3 paragraphs in Section 1.1.
PREVI OUS TEXT:
In animal models, activation of an inducible FGFR1 gene in a mouse mammary  tumor 
virus -Wnt-1 transgenic mouse dramatically  enhanced mammary  tumorigenesis [Pond, 
2010]. Further it has been shown that FGFR1 gene amplification is associated with 
2013N165256_06 CONFIDENTIA L
FGF117360
140sensitivity  to FGFR1 inhibition in non -small cell lung cancer (NSCLC) cell lines [Dutt, 
2011]. 
Various in vitro studies utilizing NSCL C cell lines reveal that specific FGFs (FGF2 and 
FGF9) as well as FGFR1 and FGFR2 are frequently  co-expressed [Berger, 1999; 
Chandler, 1999; Fischer, 2008; Kono, 2009].  I n addition, frequent expression of FGF2, 
FGFR1 and FGFR2 mRNA and protein in primar y NSCL C specimens have been 
demonstrated [Kono, 2009].
The relevance of the FGF pathway  in cancer has also been studied in human primary  
specimens. First, it has been demonstrated that FGFR1 gene is amplified at the genomic 
level in a subset of breast, ova rian, and lung cancer subjects [Knights, 2010]. This 
amplification contributes to the characteristics that allow tumor formation. Further, it has 
been shown that increased expression of FGFRs, FGFR1 gene amplification, or 
production of FGFs correlates with poor prognosis in a variet y of tumor t ypes including 
NSCL C [Ngu yen, 1994; Kim, 2013]. For example, reduced metastasis -free survival was 
found in a subset of breast cancer subjects carry ing the 8p11- 12 amplification containing 
the FGFR1 gene [Gelsi -Boyer, 2005; Grose, 2005].  Recently , a focal amplification of the 
FGFR1 gene has been detected in approximately  20% of subjects with squamous NSCL C 
[Weiss, 2010], a histological subty pe of NSCL C which previousl y had very limited 
evidence of molecular alterations amenable to targeted drug therapy . This discovery  
supports the notion that specific treatments targeting FGF pathway  alterations may  
provide benefit in this population.
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
In animal models, activation of an inducible FGFR1 gene in a mouse mammary  tumor 
virus -Wnt-1 transgenic mouse dramaticall y enhanced mammary tumorigenesis [Pond, 
2010]. 
Various in vitro studies utilizing NSCL C cell lines reveal that specific FGFs (FGF2 and 
FGF9) as well as FGFR1 and FGFR2 are frequently  co-expressed [Berger, 1999; 
Chandler, 1999; Fischer, 2008; Kono, 2009].  I n addition, frequent expression of FGF2, 
FGFR1 and FGFR2 mRNA and protein in primary NSCL C specimens have been 
demonstrated [Kono, 2009]. Furth er it has been shown that FGFR1 gene amplification is 
associated with sensitivity  to FGFR1 inhibition in non -small cell lung cancer (NSCL C) 
cell lines [Dutt, 2011].
The relevance of the FGF pathway  in cancer has also been studied in human primary  
specimens . First, it has been demonstrated that FGFR1 gene is amplified at the genomic 
level in a subset of breast, ovarian, and lung cancer subjects [Knights, 2010]. This 
amplification contributes to the characteristics that allow tumor formation . Further, it has 
been shown that Increased expression of FGFRs, FGFR1 gene amplification, or 
production of FGFs correlates with poor prognosis in a variet y of tumor t ypes including 
NSCL C [Ngu yen, 1994; Kim, 2013]. For example, reduced metastasis -free survival was 
found in a subset of breast cancer subjects carry ing the 8p11 -12 amplification containing 
the FGFR1 gene [Gelsi -Boyer, 2005; Grose, 2005].  Recently , A focal amplification of 
the FGFR1 gene has been detected in approximately  20% of subjects with squamous 
NSCL C [Wei ss, 2010], a histological subty pe of NSCL C which previously  had very  
2013N165256_06 CONFIDENTIA L
FGF117360
141limited evidence of molecular alterations amenable to targeted drug therapy. This 
discovery  supports the notion that specific treatments targeting FGF pathway  alterations 
may provide bene fit in this population .
Section 1.3 Mesothelioma
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough ) New 
section added:
Malignant mesothelioma remains a deadly disease with few effective therapi[INVESTIGATOR_014]. 
Although the incidence of mesothelioma is leveling off in the [LOCATION_002], the 
incidence in Western Europe, China, Russia, and India continues to rise [Ettinger, 
2012]. The median overall survival ranges from 9- 17 months regardless of disease 
stage [Tsao, 2009]. The standard of care for the front -line treatment of 
mesothelioma remains cisplatin and pemetrexed with the combination regimen 
having a 41% response rate, a median time to progression of 5.7 months, a median 
overall survival of 12.1 months, and significant improvements in quality of life 
[Vogelzang, 2003; Gralla, 2003]. There remains no widely approved regimen for 
recurrent mesothelioma although pemetrexed (if not used in the front -line), 
vinorelbine, and gemcitabine are agents that have been used with limited success 
[Jassem, 2008; Stebbing, 2009; Manegold, 2005]. A recently completed Phase III 
study of vorinostat versus placebo in 660 patients with recurrent mesothelioma 
reported a median progression- free survival (PFS) of 6.3 versus 6.1 weeks and 
median overall survival (OS) of [ADDRESS_471891] Phase III study completed to date in 
recurrent mesothelioma [Krug, 201 1]. These poor PFS and OS data underscore the 
need for more effective therapi[INVESTIGATOR_377055] .
Section [IP_ADDRESS] Preclinical data on [COMPANY_004]3052230
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough ) New 
text added:
Seventy -eight tumor -derived xenograft models were treated with [COMPANY_004]3052230 (FP1039) 
as a single agent.  Twent y-eight models were found to show significant tumor growth 
inhibition, including models of NSCL C, small cell lung cancer, mesothelioma , squamous 
cell carcinoma of the head and neck (SCCHN), endometrial, colon and breast cancer 
[Harding, 2010; Harding, 2013].  I n lung cancer xenografts, [COMPANY_004]3052230 -teated tumors 
harboring FGFR1 gene amplification display ed an average of 56% tumor growth 
inhibition compared to 22% tumor growth inhibition in non- amplified FGFR1 xenografts 
(p=0.03)[ Harding, 2013]. FGF2 mRNA lev els displayed the highest ratio (247.7 -fold) 
of median gene expression between [COMPANY_004]3052230 responder and nonresponder 
xenograft models and was the only marker that correlated with response in the 
subset of non -amplified FGFR1 lung cancer xenografts where si gnificant tumor 
growth inhibition was observed [Harding, 2013]. Therefore, FGFR1 amplification 
or FGF2 overexpression served as predictive markers of response to [COMPANY_004]3052230 .
2013N165256_06 CONFIDENTIA L
FGF117360
142Section 1.5.3 Pemetrexed/cisplatin
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough ) New 
section added:
Pemetrexed is a folate analog inhibitor that disrupts folate -dependent metabolic 
processes essential for cell replication. In vitro studies have shown that pemetrexed 
inhibits thymidylate synthase, dihydrofol ate reductase, and glycinamide 
ribonucleotide formyltransferase, which are folate -dependent enzymes involved in 
de novo biosynthesis of thymidine and purine nucleotides. Cisplatin is a heavy -metal 
complex containing a central platinum atom with 2 chloride atoms and 2 ammonia 
molecules in the cis position. Pemtrexed in combination with cisplatin is 
recommended for the treatment of mesothelioma [Alimta PI, 2004].
The most common adverse reactions (incidence ≥20%) with single -agent use of 
pemetrexed are fatigue, nausea, and anorexia. Additional common adverse reactions 
when used in combination with cisplatin include vomiting, neutropenia, leukopenia, 
anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation [Alimta PI, 
2004].
Common adverse reactions (incidence ≥20%) associated with cisplatin include 
nephrotoxicity, ototoxicity, myelosuppression, and nausea/vomiting. Other toxicities 
include vascular complications, serum electrolyte imbalance, Hyperuricemia, 
neurotoxicity, ocular toxicity, anaphylactic -type reactions, and hepatotoxicity 
[Platinol PI, 2010].
Section 1.6 Summary of Risk Management
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough) New 
text added:
Anterior uveitis:
• Optic neuritis, papi[INVESTIGATOR_044], and cerebral blindne ss have been reported in 
patients receiving standard recommended doses of cisplatin .
Peripheral neuropath y:
• Peripheral neuropath y is a potentially  overlappi[INVESTIGATOR_377020]3052230 
and, taxanes such as paclitaxel and docetaxel, and cisplatin .
Hemat ologic toxicity :
Furthermore, paclitaxel or,docetaxel, and cisplatin have known bone -marrow toxicity
2013N165256_06 CONFIDENTIA L
FGF117360
143Nephrotoxicity:
• Dose -related and cumulative renal insufficiency, including acute renal 
failure, is the major dose- limiting toxicity of cisplatin. Renal toxicity has been noted 
in 28% to 36% of patients treated with a single dose of 50 mg/m2. It is first noted 
during the second week after a dose and is manifested by [CONTACT_377127], serum uric acid and/or a decrease in creatinine clearanc e. Renal toxicity 
becomes more prolonged and severe with repeated courses of the drug. Renal 
function must return to normal before another dose of cisplatin can be given.
• One patient with severe renal impairment (creatinine clearance 19 mL/min) 
who did n ot receive folic acid and vitamin B12 died of drug- related toxicity 
following administration of pemetrexed alone.
Ototoxicity:
• Ototoxicity has been observed in up to 31% of patients treated with a single 
dose of cisplatin 50 mg/m2, and is manifested by [CONTACT_30547]/or hearing loss in the 
high frequency range (4000 to 8000 Hz). Decreased ability to hear normal 
conversational tones may occur. Deafness after the initial dose of cisplatin has been 
reported. Hearing loss can be unilateral or bilateral and tend s to become more 
frequent and severe with repeated doses. Careful monitoring per standard of care 
should be performed.
Section 2 Objectives and Endpoints and Synopsis
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Primary Objec tives:
To characterize the safety and tolerability  of [COMPANY_004]3052230 in combination with 
chemotherap y regimens (Arm A and B) or as single agent (Arm C).
To determine the regimen of [COMPANY_004]3052230 in combination with chemotherapy  (Arm A 
and B) for evaluation in fut ure studies based on the maximum tolerated dose (or 
maximum feasible dose).
Primary Endpoints:
Best response defined as complete or partial response, stable disease or progressive 
disease according to RECI ST 1.[ADDRESS_471892] (for MPM)
ORR defined as the proportion of subjects with investigator -assessed confirmed complete 
response or partial response per RECI ST 1.[ADDRESS_471893] (for MPM)
Secondary Objectives
Assess improvement in Pulmonary Function Tests in Patients with MPM.
2013N165256_06 CONFIDENTIA L
FGF117360
144Secondary Endpoints
PFS is defined as the interval between first dose of [COMPANY_004]3052230 and the earliest date of 
disease progression or death due to an y cause b y investigator assessment per RECI ST 1.[ADDRESS_471894] (for MPM)
Change from baseline in Forced Vital Capacity (FV C) in patients with MPM.
Exploratory Objectives
To identify  biomarkers that may  predict response or resistance
To evaluate the pharmacody namic response in tumors circulation following treatment 
(re-biops y is required for tumors that are accessible for biop sy) for Arm C
To investigate additional measures of FGF signaling pathway  deregulation as potential 
predicative biomarkers for [COMPANY_004]3052230 in tissue .
To evaluate changes in patient reported outcomes .
Exploratory Endpoints
Changes in proteins/RNA circulating biomarkers (eg, proteins )implicated in FGFR or 
disease biology signaling (eg. MAPK/PI 3K pathway s) and/or cancer development
signalling in pre -and post -dose tumor tissue blood samples .
Association of FGFR1 gene amplification with clinical response to su pport the 
development of a laboratory  developed test for an investigation use (LDT/ only test (IUO) 
and potential companion diagnostic for subject selection.
Identification and validation of alternative measures of FGF signaling pathway  
deregulation as retrospectively (eg, FGF2 overexpression ) as predictive biomarkers for 
subject selection and potential development of a companion diagnostic
Change from baseline and association with ORR in observer and patient assessed 
components of the Lung Cancer Symptom Sc ale (LCSS) and LCSS -mesothelioma
Section 3.1 Number of Subjects
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Approximately  70 subjects will be enrolled in the study  (minimum of ~ 3638and up to 
~104 approximately 120 ). In addi tion to minimum and maximum sample sizes for each 
arm, sample sizes that would be expected under the null and alternative h ypothesis rates 
for Arms A and B are provided in Section 12.3.
2013N165256_06 CONFIDENTIA L
FGF117360
145Section 3.2.1 Inclusion Criteria and Synopsis
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Inclusion criterion 2:
Arm C: advanced solid tumor with deregulated FGF pathway  signaling, for which all 
lines of standard therapi[INVESTIGATOR_377056].
Arm C: recurrent after local therapy or unresectable MPM with measurable lesions
Arm C: Subjects who have exhausted all lines of standard therapi[INVESTIGATOR_377057].  Note: squamous NSCL C subjects who have 
documented tumor progression (based on radiological imaging) after receiving two or 
more prior lines of s ystemic therapy  (including platinum containing chemotherapy  
regimens) for Stage IV or recurrent metastatic disease may  be enrolled [ of malignant 
tumors, 7th edition, 2009; , 2010].  Subjects with ER positive breast cancer having 
disease progression while on aromatase inhibitor therap y are allowed to continue 
aromatase inhibitor therapy , subjects with prostate cancer may  continue to be treated with 
GnRH as clinically appropriate, and subjects with carcinoid cancer may continue 
treatment with octreotide.
Arm C: Subjects who have received no prior systemic therapy for MPM.
Inclusion criterion 3:
3. Availability  of archival tumor tissue required for assessment of deregulated FGF 
pathway  signaling e.g.eg, FGFR1 amplification or FGF2 expression .
In Arm C, FGF2 expression by [CONTACT_377128] a central laboratory and is not required for study entry .
Inclusion criterion 7:
For Arm A and B: Men with a female partner of childbearing potential must have either 
had a prior vasectom y or agree to use effective contraception as described in Section 
10.1.[ADDRESS_471895] dose of chemotherap y, to allow for clearance of an y 
altered sperm. Arm C: No male contraception restrictions.
Section 3.2.2 Exclusion Criteria and Synopsis
REVI SED TEXT: (new text bold and underlined , deleted tex t in strikethrough)
Exclusion Criterion 1:
For Arms B, C: Treatment with any  anti-cancer therap y (for biological anti -cancer 
therapi[INVESTIGATOR_377021] 2.) during the preceding 4 weeks or within 4 half -lives of the 
2013N165256_06 CONFIDENTIA L
FGF117360
146therap y, whichever is longer ( except: anti -cancer hormonal treatment of prostate cancer, 
breast cancer or octreotide for treatment of carcinoid cancer).
Exclusion criterion 11:
Have a known immediate or delay ed hy persensitivity  reaction or idiosy ncrasy  to drugs 
chemicall y related to study drugs ([COMPANY_004]3 052230, docetaxel, paclitaxel, carboplatin, 
pemetrexed, cisplatin ) and or their excipi[INVESTIGATOR_377058] 4.1 Discussion of Study Design and Synopsis
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrou gh)
This will be a multi -arm, multicenter, non -randomized, parallel- group, uncontrolled, 
open -label Phase IB study designed to evaluate the safet y, tolerability  and preliminary  
activity  of [COMPANY_004]3052230 in combination with paclitaxel + carboplatin (Arm A), in
combination with docetaxel (Arm B), or [COMPANY_004]3052230 as monotherapy in combination 
with pemetrexed + cisplatin (Arm C). All subjects enrolled will have documented 
deregulation of FGF pathway  signaling (e.g. FGFR gene amplification).
Previous Figure 1, Stud y Schema:

2013N165256_06 CONFIDENTIA L
FGF117360
147Revised Figure 1, Stud y Schema:
Pemetr exed /Cisplatin +
[COMPANY_004]30522 30
3+3 design to deter mine
MTD   (MFD) in subj ects w ith MPMArm CPaclitaxel/ Carboplatin +
[COMPANY_004]30522 30
N=at least 12 and up to 3 0 sqNSCLC
Docetaxel + [COMPANY_004]3052230
3+3 design to deter mine MTD (MFD) 
in subjects with sqNSCLCDoce taxel + [COMPANY_004]3052230
N=at least 14 and up to 30  sqNSCLCArm BPaclitaxel/ Carboplatin +
[COMPANY_004]30522 30
3+3 design to deter mine
MTD  (MFD ) in subj ects with sqNSCLCArm A
Pemetr exed /Cisplatin +
[COMPANY_004]30522 30
N=at least 12 and up to 30 MPM
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Enrollment to Arms A and B will open first and simultaneously . Dose escalation in Arm 
A and Arm B will follow a 3+3 design as outline d in Section 4.2 for determination of 
MTD (or MFD).  A cohort expansion of at least 12 subjects will be treated at the MTD 
(or MFD) in each arm, with the option of expanding to a maximum of [ADDRESS_471896] 12 subjects and up to a ma ximum of 20 subjects will be treated in Arm C.
[COMPANY_004]3052230 will be administered as a 30 -minute intravenous (i.v.) infusion once a week 
(Day  1, Day  8, Day  15) of each 21 -day cycle. Paclitaxel/carboplatin and, docetaxel, and 
pemetrexed/cisplatin will be admin istered i.v. on Day  1 of each 21 -day cycle. The 
number of cy cles of paclitaxel/carboplatin will be limited to 4 to 6 cy cles. Subjects may  
continue to receive docetaxel and pemetrexed/cisplatin until disease progression or as 
long as they  are considered to derive benefit from treatment.  Subjects who discontinue 
chemotherap y (Arm A and Arm B ) for reasons other than disease progression, may  
continue to receive [COMPANY_004]3052230 as long as they  are considered to derive benefit from 
the treatment according to the crit eria in Section 6.3. After discontinuation of 
[COMPANY_004]3052230, subjects will return after approximately  30 day s (see Time and Events 
Table Section 7.1) for a follow- up visit to collect safet y assessments, after which they 
will be considered to have completed th e stud y.
Blood samples for pharmacokinetic, pharmacogenetic, and translational research will be 
obtained at specified times during the study .  Efficacy  will be assessed every  [ADDRESS_471897]-dose will be required from a minimum of 6 subjects with accessible tumors for 
2013N165256_06 CONFIDENTIA L
FGF117360
148repeated biopsy  in Arm C.  Additional subjects may  be asked to provide biopsies based 
on emerging data .
Section 4.2 [COMPANY_004]3052230 plus Chemotherapy in Arm A an d Arm B
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Arm A and Arm B Dose escalation will follow a 3 + 3 dose- escalation procedure . . .
Section 4.2.1 Arm A
REVI SED TEXT: (new text bold and underlined , deleted text in striket hrough)
A total of at least [ADDRESS_471898] been enrolled, the number of observed confirmed 
responses will guide further enrolment according to the stoppi[INVESTIGATOR_37660].  The futility 
boundaries (inclusive) for ORR for Arm A are 0/12, 1/14, 2/17, 3/20, 4/22, 5/24, 6/26, 
7/27, 8/28, 9/29, and 10/30 subjects and are shown in tabular format in Section 12.7
rules summarized in Section .. Up to 30 subjects will be enrolled in Arm A. All available 
data will be considered in making enrollment decisions
Section 4.2.2 Arm B
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
A total of at least 1214subjects will be enrolled at the target dose to further evaluate 
safet y and efficacy. After 1214subjects have been enrolled, the number of observed 
confirmed responses will guide further enrolment according to the stoppi[INVESTIGATOR_377059] . The futility boundaries (inclusive) for ORR for Arm B are 0/14, 1/22, 
2/26, 3/28, 4/29, and 5/30 subjects and are shown in tabular format in Section 12.7.. 
Up to 30 subjects will be enrolled in Arm B. All available data will be considered in 
making enrollment decisions.
Section 4.2.3 Arm C (new section)
REVI SED TEXT: (new te xt bold and underlined , deleted text in strikethrough)
Arm C will open for enrollment subsequent to Amendment 3. The starting dose of 
[COMPANY_004]3052230 (Dose Level 0) in Arm C will be 10 mg/kg as long as the 5 mg/kg dose 
in combination with chemotherapy in Arm A did not exceed the MTD. Otherwise 
the starting dose level in Arm C will be Dose Level -1. Dose levels and escalation/de -
escalation schema for [COMPANY_004]3052230 in combination with pemetrexed and cisplatin is 
presented in Table 3.  Depending on emerging data, addi tional intermediate or 
lower dose -levels beyond those described may be explored.
2013N165256_06 CONFIDENTIA L
FGF117360
149Table 5 Combination Therapy: Arm C [COMPANY_004]3052230 + Pemetrexed + 
Cisplatin
Dose LevelDose of [COMPANY_004]3052230
(Weekly)Pemetrexed + Cisplatin
(once every 21 days)
Dose Level -2 5 mg /kg 400 mg/m2 + 60 mg/m2
Dose Level -1 5 mg/kg 500 mg/m2 + 75 mg/m2
Starting Dose Level 0 10mg/kg 500 mg/m2 + 75 mg/m2
Dose Level 1 20 mg/kg 500 mg/m2 + 75 mg/m2
A total of at least [ADDRESS_471899] been enrolled, the number of observed 
confirmed responses will guide further enrolment according to the stoppi[INVESTIGATOR_004]. 
The futility boundaries (inclusive) for ORR for Arm C are 2/12, 3/14, 4/16, 5/18, 
6/20, 7/2 1, 8/23, 9/24, 10/25, 11/26, 12/27, 13/28, 14/29 and 15/30 subjects and are 
shown in tabular format in Section 12.7. Up to 30 subjects will be enrolled in Arm 
C. All available data will be considered in making enrollment decisions.
Section 4.3 [COMPANY_004]3052230 i n Arm C
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Section 4.[ADDRESS_471900] 6 and up to 18 -20 subjects will be treated in Arm C at a dose of 20 mg/kg. Other 
doses may  be explored in this arm
Section 4.3.1 Rationale for Evaluation of [COMPANY_004]3052230 in Chemotherapy 
Combinations
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
4.3.1 Rationale for Evaluation of [COMPANY_004]3052230 in Chemotherap y Combination 
(Paclitaxel + Carboplatin, or Docetaxel) in NSCLC with deregulated FGF pathway  
signaling Combinations
FGFR1 amplification has been identified in approximately  20% of squamous NSCL C 
with suggested tumor dependence on FGF pathway signaling [, 2010].   FGFR1 
amplification has been associated with sign ificantly  shorter disease free and overall 
survival in NSCL C [Kim, 2013; Heist, 2012].  Carboplatin and paclitaxel can be used in 
first line therap y of NSCLC and docetaxel is a standard second line agent.  Pemetrexed 
and cisplatin is the standard first lin e therapy for mesothelioma. Additive antitumor 
effect was demonstrated in tumor xenograft models treated with the combinations of 
[COMPANY_004] 3052230 and chemotherapy including paclitaxel and carboplatin as well as 
docetaxel. Malignant pleural mesothelioma (MPM) i s a tumor type where FGF2 
ligand overexpression has been observed in a high percentage of primary specimens 
and where [COMPANY_004]3052230 preclinical efficacy has been observed in xenograft models . 
Based on the clinical and preclinical data, the combination of [COMPANY_004]3 052230 in 
2013N165256_06 CONFIDENTIA L
FGF117360
150combination with chemotherap y will be investigated in patients with NSCLC or with 
mesothelioma .
Section 4.3.2 Rationale for Evaluation of [COMPANY_004]3052230 Monotherapy
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Section [ADDRESS_471901] , specificall y amplification or 
overexpression of FGF ligand (s) and/or receptor(s).  Arm C will enroll subjects with 
deregulated FGF pathway  signaling (e.g. FGFR gene amplification, FGF ligand 
overexpression, etc.).  These subjects should have failed available standard therapi[INVESTIGATOR_377060] a cancer for which no standa rd therapi[INVESTIGATOR_377061] 4.3.3 Rationale for Endpoints
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Symptom assessments as measured by [CONTACT_377129] -meso were added to 
increase the understanding of the patient experien ce and perceptions .
Section 4.5.4 Pemetrexed and Cisplatin
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Section 4.5.4 Pemetrexed and Cisplatin
Subjects in Arm C will receive pre -treatment for pemetrexed and cisplatin 
accordin g to institutional standards. Pemetrexed according to the dose level being 
investigated (Table 5) will be administered intravenously over 10 minutes (or 
according to local clinical standards) on Day 1 of each 21 day treatment cycle 
followed 30 minutes late r by i.v. cisplatin infused over 2 hours.
Subjects will be hydrated and pre -medicated with folic acid and vitamin B12 
supplements in order to reduce the incidence and severity of hematologic and 
gastrointestinal toxicities as well as cutaneous hypersensitivity reactions as per 
institutional guidelines.  Recommendations for pre- medication are as follows:
• 1 -2 liters of fluid infused for 8 -12 hours prior to cisplatin dose
• 350 -1000  g folic acid, once daily, by [CONTACT_377130], during treatment, and for [ADDRESS_471902] dose of 
pemetrexed
• 1000 g vitamin B12 by [CONTACT_377131] (subsequent vitamin B12 
injections may be given on the same day as pemetrexed)
2013N165256_06 CONFIDENTIA L
FGF117360
151• 4 mg dexamethasone (or equivalent), twice daily, by [CONTACT_377132], 
the day of, and the day after pemetrexed administration   
Additional information can be found in the prescribing information for pemetr exed 
[Alimta Package Insert, 2012] and cisplatin [Platinol, 2010].
Section 4.7.2 Hematologic Toxicity Related to Chemotherapy
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough ) Added 
to last row of Modification I nstructions, Table 7
Arm C: Restart combination chemotherapy reduced by 1 level for the 
chemotherapy dose according to Table 5 .
Section 4.7.3 Non -hematologic Toxicity Related to Chemotherapy
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Table 8 Chemotherap y Dose Delay  and Modifications for Non- hematologic Toxicity
Adverse Event Action
Non-hematological, drug -related 
Grade 3 or 4 (except alopecia)Hold chemotherapy until recovery to Grade ≤1.
Arm A: Restart at dose levels reduced by 1 level for b oth agents 
according to Table 3.
Arm B: Restart docetaxel reduced by 1 level according to Table 4
Arm C: Restart combination chemotherapy reduced by 1 level 
for the chemotherapy dose according to Table 5
Exceptions
Grade 2 neurotoxicity Arm C: Withhold s tudy treatment until recovery to Grade 1; 
then resume treatment with cisplatin reduced by 50% of 
previous dose
Grade 3 or 4 Peripheral neuropathy
NeurotoxicityWithhold study treatment until patient recovers recovery to Grade 
1; then resume treatment at dose reduced by 2 levels according to 
Table 3 (Arm A) or Table 4 (Arm B). Permanently discontinue 
chemotherapy in Arm C . If treatment delay is more than 2 weeks, 
re-initiation of treatment should be agreed with the [COMPANY_004] study 
physician.
Mucositis, Grade 3 or 4 Arm C: Reduce pemetrexed only by 50% of previous dose
Serum creatinine <1.5 mg/100mL 
or BUN <25mg/100mLArm C: Hold chemotherapy until serum creatinine >1.5 
mg/100mL or BUN >25mg/100mL
Creatinine clearance <45 mL/min Arm C: Hold chemotherapy until c reatinine clearance ≥45 
mL/min
2013N165256_06 CONFIDENTIA L
FGF117360
152Section 5.1.2 Chemotherapeutic Agents
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Section 5.1.2 Paclitaxel + Carboplatin and Docetaxel Chemotherapeutic Agents
Paclitaxel, carboplatin, anddocetaxel, pemetrexed, and cisplatin will be sourced locally 
from commercial stock, except in countries where Regulatory Authorities mandate that 
the Sponsor must supply  all non -investigational product (I Ps) required for study  
participation. Investigators are responsible for ensuring that subjects receive supplies of 
paclitaxel, carboplatin, anddocetaxel, pemetrexed, and cisplatin for the entire duration 
of the study , as appropriate .  The contents of the label will be in accordance with all 
applicable regulat ory requirements.
Section 5.2 Preparation/Handling/Storage of [COMPANY_004]3052230
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Refer to the SPM (the FGF117360 Pharmacy Manual) for storage conditions.
Section 6.1 Screen Failures
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Section 6.1 Screen and Baseline Failures
Data for screen and base line failures....
2013N165256_06 CONFIDENTIA L
FGF117360
153Section 7.1 Time and Event Schedules
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Table 10. Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 
day 
F/U
D1 D8 D9 D15 D1 D8 D15 D1 D8 D15
Vital SignsArms A + B: Within [ADDRESS_471903] chemotherapy infusion 
and within 20 min before start of 
[COMPANY_004]3052230 infusion.
Arm C: Before start of 
[COMPANY_004]3052230 infusion. X X X X
Forced Vital Capacity Assess D1 of every odd cycle X X O
Tumor Tissue (fresh biopsy) for 
biomarker researchArm C only : (minimum of 6 
subjects). Predose sample +7 
days prior to C1D1. EOT sample 
only upon progression. X X X
Circulating Biomarkers Plasma sample collected predose 
(+7 days prior to C1D1) X X XArm C: D1 every cycle 1 
year, then D1 every 2 
cycles X
LCSS (Arms A and B); LCSS -
meso (Arm C)Must be administered first 
before any other tests or 
procedures. Study staff should 
check for completeness. X X X X X X
ARMS A, B, C: [COMPANY_004]3052230 30 minute infusion. X X X X X X X X X
ARM B: Do cetaxel [COMPANY_004]3052230 infused & 
observed 1 hr prior to 
docetaxel chemotherapy
infusions. X X X
ARM C: Pemetrexed + Cisplatin [COMPANY_004]3052230 infused & 
observed 1 hr prior to 
chemotherapy infusions. X X X
2013N165256_06 CONFIDENTIA L
FGF117360
154Table 10. Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 
day 
F/U
D1 D8 D9 D15 D1 D8 D15 D1 D8 D15
Table 11. FGF117360 Pharmacokineti c Sampling Schedule Limited PK Extensive PK Extensive PK Limited PK Extensive PK
Time When Window Arm A or Arm B Arm A Arm B Arm C Arm C
n=20pts in Arm A 
n=20pts in Arm B
each arm n>=10pts n>=10ptsRemaining 
patients n>= 6 10pts
Cycle 1 Day 1Prior to infusion of 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
End of infusion of 
[COMPANY_004]3052230Up to 5 min prior to end of 
infusion of [COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004] 3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
1hr after end of infusion of 
[COMPANY_004]3052230 10 min but after ECG[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
2hr after end of infusion of 
[COMPANY_004]3052230 or end of 
docetaxel infusion10 min or up to 5 min prior to 
end of docetaxel infusion[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
Cycle 1 Day 8Prior to infusion of 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052230[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
Cycle 1 Day 9(time relationship to tumor 
biopsy n ot infusion time) within 1 hr of tumor biopsy[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
Cycle 2 Day 1Prior to infusion of 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
End of in fusion of 
[COMPANY_004]3052230Up to 5 min prior to end of 
infusion of [COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
1 hr after start of 
paclitaxel infusion or end 
of docetaxel or 
pemetrexed infusion10 min for paclitaxel or up to 
5min prior to end of docetaxel 
infusion or up to 1 min prior 
to end of pemetrexed 
infusion[COMPANY_004]3052230 
PK
Paclitaxel PK[COMPANY_004]3052230 
PK
Docetaxel PK[COMPANY_004]3052230 PK
Pemetrexed PK
1 hr after end of 
pemetrexed infusion 20 min Pemetrexed PK
up to 5 min prior to end of Paclitaxel PK Docetaxel PK Pemetrexed PK
2013N165256_06 CONFIDENTIA L
FGF117360
155Table 10. Time and Events Schedule for FGF117360
ScreenCycle 1 Cycle 2 Additional CyclesEvery 4 
Cycles, 
D1 EOT30 
day 
F/U
D1 D8 D9 D15 D1 D8 D15 D1 D8 D15
End o f paclitaxel infusion 
or 2 hr after end of 
docetaxel or pemetrexed
infusionpaclitaxel infusion or 20 min 
for docetaxel and 
pemetrexed
2 hr after end of paclitaxel 
infusion or 5 hr after end 
of docetaxel or 
pemetrexed infusion 30 min(selected sites)
[COMPANY_004]3052230 
PK
Paclitaxel PK(selected sites)
[COMPANY_004]3052230 
PK
Docetaxel PK(selected sites)
[COMPANY_004]3052230 PK
Pemetrexed PK
Cycle 4 Day 1
Cycle 6 Day 1
Cycle 12 Day 1 Prior to infusion o f 
[COMPANY_004]3052230Up to 12 hr prior to infusion of 
[COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
Cycle 4 Day 1
End of infusion of 
[COMPANY_004]3052230Up to 5 min prior to end of 
infusion of [COMPANY_004]3052230 [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PKCycle 6 Day 1
Cycle 12 Day 1
EOT [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
30 days FUAt time of immunogenicity 
sample [COMPANY_004]3052230 PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK[COMPANY_004]3052230 
PK [COMPANY_004]3052230 PK
2013N165256_06 CONFIDENTIA L
FGF117360
156Section 7.2 7.2. Demographic/Medical History and Baseline Assessments
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
• LCSS for Arms A & B
• For Ar m C only LCSS (meso) and forced vital capacity
Section 7.2.1 Critical Baseline Assessments
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
. . .For Arm C, deregulation of FGF pathway  signaling pathway  may  be assessed locall y 
or centrally  (additional details will be in SPM). 
For Arm C, forced vital capacity will be assessed at screening.
Section 7.3.4 Forced Vital Capacity
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
7.3.4. Forced Vital Capacity
Forced vital capacity will be measured in Arm C at each scheduled disease 
assessment using standard methods (Refer to the SPM for details).
Section 7.3.8 Laboratory Assessments
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Table [ADDRESS_471904] of Clinical Laboratory  Tests
Blood urea nitrogen (BUN), Creatinine, Uric Acid, creatinine clearance
Section 7.4 Evaluation of Anti -cancer Activity
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
CT:  (second paragraph) For Arms A and B , RECIST 1.[ADDRESS_471905] 1.1. All measurements were added to obtain the 
total tumor measurement. The Image Acquisition Guidelines portion of the SPM
should be consulted for additional details on imaging protocols .
2013N165256_06 CONFIDENTIA L
FGF117360
157Brain Scan: In subjects with known brain metastases (criteria outlined in Section 3.2), a 
contrast -enhanced MRI (preferred) or CT of the brain must be obtained within [ADDRESS_471906] dose of the study  medication
Section 7.4.1 Evaluation of Response in Arm A and Arm B (RECIST 1.1)
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Section 7.4.1 Evaluation of Response Criteria in Arm A and Arm B (RECI ST 1.1)
Section Evaluation of Response in Arm C: Mesothelioma
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
7.4.2. Evaluation of Response in Arm C: Mesothelioma
[IP_ADDRESS]. Mesothelioma Tumor Imaging
Clinical trials of therap eutic agents in MPM may be compromised by [CONTACT_377133] [By[CONTACT_7943], 
2004; Tsao, 2011]. Malignant mesothelioma commonly grows as a rind and thus 
may not produce spherical lesions with bidime nsional, measurable diameters 
[By[CONTACT_7943], 2004]. Modification of RECIST criteria have been recommended to address 
the difficulties in measurement of lesions [By[CONTACT_7943], 2004; Tsao, 2011]. In subjects with 
mesothelioma, it is requested that disease assessments usin g both RECIST v1.[ADDRESS_471907] v1.1 criteria. 
Unidimensional measurements are added to produce the total tumor measurements 
(e.g., the sum of 6 pleural thickness measurements = on e univariate diameter).
Overall tips for measurement of mesothelioma by [CONTACT_100694] [Tsao, 2011]:
1. Larger lesions are easier and more accurate to measure. Choose the larger or 
thickest of the pleural disease to measure. Magnifying the image may make an 
easier measurement.
2. The short -axis diameter is defined as the shortest pathway from the tip of the 
tumor to the chest wall.
3. Ensure that that differentiation of normal chest wall from tumor is easy at 
the point of measurement
2013N165256_06 CONFIDENTIA L
FGF117360
1584. To ensure accuracy, all measurements must be performed electronically in 
the same window setting on consecutive studies. It is recommended that the “soft 
tissue” setting (not lung windows) be used, as it enables accurate pleural mass 
measurements with the electronic calipers and avoids the incorporation of chest wall 
or mediastinal fat within the calculations.
5. CT scan slices up to [ADDRESS_471908] wall/mediastinum.
9. Avoid measuring regions where the tumor infiltration obscures the interface 
of tumor to normal tissue. A good interface for measurement usually is one where 
the tumor abuts fat or an intact rib/vertebral body, as the density of the pleural 
tumor differs significantly from bone or fat and the difference can be easily 
observed. Avoid choosing an interface of tumor with muscle, as muscle and tumor 
have similar CT densities and are often difficult to distinguish when they abut one 
another.
10. Following the instructions in #5, choose three different axial slices, preferably 
above the level of the main bronchi and record two measure ments per slice, thus 
resulting in six separate measurements.
11. If any nodal, subcutaneous or other bidimensionally measurable lesions are 
available, they should undergo unidimensional measurements by [CONTACT_393] v1.1 and 
be added to the total obtained in #7 above.
Tips on Lymph Node Measurements:
Lymph nodes are considered as a separate organ to measure, and up to two lymph 
nodes can be measured per patient by [CONTACT_393] v1.1. For unidimensional lymph 
node measurements, use the short axis of the lymph node at bas eline and then at 
every followup scan. To be considered as pathologically enlarged and measurable at 
baseline, the lymph node short axis diameter should be ≥[ADDRESS_471909] for 
review. The slope of tumor growth prior to study entry and following treatment may 
be compared in subsequent analyses. Such comparisons may be important in 
evaluation of the clinical significance of subjects achieving a clinical response, 
particularly in those subjects achieving SD.
Section 7.4.3 Patient Reported Outcomes
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
7.4.3. Patient Reported Outcomes
The Lung Cancer Symptom Scale or the Lung Cancer Symptom Scale-
mesothelioma [LCSS ( -meso)] will be self- administered by [CONTACT_1766] (patient scales) 
and completed by [CONTACT_093] (observer scales) as indicated in the Time and 
Events schedule (Table 10). The LCSS( -meso) consists of nine (meso: eight) patient -
reported items (visual analogue scale with a range from 0 to100) and six observer 
reported it ems and is validated in lung cancer and in mesothelioma patients [Hollen, 
2006]. Using visual analogue scales, the patient scale measures the intensity of 
patient responses for appetite, fatigue, cough, dyspnea, hemoptysis, pain, and 
summary items symptoms of lung cancer, activity level and quality of life. An 
example questionnaire can be found in the SPM . The LCSS -meso was chosen 
because of its focus on disease -related symptoms, the possibility to combine the 
patient’s perception with the investigator’s co ntextual knowledge, its demonstrated 
concept and content validity, ease of application and minimal burden to patients. 
It is important that the LCSS patient scale is administered at the start of the clinic 
visit before any other study assessments are perf ormed.
Section 7.5.2 Pharmacokinetic Sample Analysis
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Concentrations of [COMPANY_004]3052230 and selected chemotherapy will be determined…
Section 7.7 Translational Research
REVI SED TEXT: (ne w text bold and underlined , deleted text in strikethrough)
7.7.1. Tumor Biomarker Anal ysis
[IP_ADDRESS]. Fresh Pre -and Post -dose Tumor Tissues
Pre and post dose tissues, as well as tissues collected at progression will be anal yzed for 
the appropriate protein an d/or RNA biomarkers of FGFR pathway  and 
proliferation/apoptosis (e.g. Ki67, CC3, etc).  Collected tissues may  also be used to 
2013N165256_06 CONFIDENTIA L
FGF117360
160analyze the protein and DNA markers of RTK/MAPK/PI 3K pathway  activation and 
cancer development.  Additional testing of DNA, RNA, o r protein biomarkers related to 
the function of [COMPANY_004]3052230 may  be done if ongoing research identifies or defines 
additional biomarkers for therap y failure or predictive and prognostic biomarkers. 
Paired pre -and post -dose fresh biopsies will be obtained f rom a minimum of 6 subjects 
with accessible tumors in Arm C.  These biopsies will be taken during the screening 
period, e.g., within 7 days prior to treatment (preferabl y pre -dose on day  1), and on Day  [ADDRESS_471910]  signaling (e.g. 
FGFR gene amplification) in tumor tissue. As part of the development and validation of 
this assay , addit ional measures to FGFR1 gene amplification will be collected to 
determine if these increase the discriminatory  potential of the assay  for future 
development of the IUO. Tumor alterations, such as FGFR1 gene amplification testing, 
will be conducted using a certified laboratory  (e.g. CLIA or appropriate certification) and 
validated laboratory  developed test (LDT) in a central laboratory . In addition, an 
exploratory  objective of this study  is to develop and further validate the deregulated FGF 
pathway  signalin g assay  towards an investigational use only  (IUO) assay  that can be used 
for future subject selection and for regulatory  approval and registration. The regulatory  
approved assay  will be used in the future to precisely  identify  the specific deregulated 
FGF signaling marker such as FGFR gene amplification or over expression, FGF ligand 
overexpression, etc., status in subjects who may benefit from treatment with 
[COMPANY_004]3052230. I t is essential that the required amount of tumor tissue is obtained in order 
to perfor m the FISH assay  for entry  into the study  in Arms A and B, explore other 
potential measures of FGF signaling pathway  deregulation, and complete the necessary  
equivalency  and precision testing requirements for the development of an IUO.
Collection of archiv al primary tumor tissue is required for all subjects (see Time and 
Events Table; Section 7.1;) ; if not available a fresh sample will be required. A formalin 
fixed paraffin embedded tumor block is requested or if not available, approximately  15 
sections wil l be needed. Details of the tumor biopsy  collection including amount, 
processing, storage, and shippi[INVESTIGATOR_377062].
In addition, these samples may  beArms A and B, a requirement for inclusion is 
evidence of FGFR1 gene amplif ication in tumor tissue as determined by a central 
laboratory (CLIA or appropriate certification) using a laboratory developed test .
2013N165256_06 CONFIDENTIA L
FGF117360
161In Arm C, FGF2 expression will be evaluated for the markers retrospectively by [CONTACT_377134] 2 are associated with response to 
[COMPANY_004]3052230
Any remaining tissue from this study may be used for:
• Development and validation of a potential IUO assay and companion 
diagnostic test, e.g., FGFR1 gene amplification by [CONTACT_377099]2 expression by 
[CONTACT_4658].
• Alternative biomarkers of FGF pathway signalling. 
• Biomarker research (protein, RNA and DNA) andstatus of RTK/PI 3K/AKT 
pathway s and cancer development and additional testing of DNA, RNA, or protein 
biomarkers related to the function of [COMPANY_004]3052230 if ongoing research identifies or 
defines additional predictive and prognostic biomarkers.
Samples will be collected as indicated It is essential that the required amount of 
tumor tissue is obtained in the Timeorder to perform the FISH assay for entry into 
the study in Arms A and Events Table (Section ). After determination B , explore other 
potential measures of FGF signaling pathway  alterations, tissue deregulation in all 
arms including Arm C, and complete the necessary equivalency and precision 
testing requirements for the development of an IUO and potential companion 
diagnostic test .
Tissue samples/sections will be retained for the further confirmation using the IUO 
validated assay  or potential companion diagnostic test , when available.  All samples 
will be retaine d for a maximum of [ADDRESS_471911] completes the trial.
Section [IP_ADDRESS] Plasma for Soluble Markers
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Clusters of markers (e.g. cy tokines and angiogenic factors [CAF]) circulating in the 
plasma have been found to correlate with tumor pathway  activation. Soluble 
mesotheline -related peptides (SMRP) have been shown to be clinical markers of 
MPM .... Therefore, a broad panel of CAF, including FGF ligand, and SMRP will be 
evaluated....
Section [IP_ADDRESS] Circulating cell free DNA (CFDNA) Analysis
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
...will be anal yzed for mutations in genes relevant to RTK/MAPK/PI 3K pathway  and 
cancer biology in cell free D NA...
Section 10.1.2 Male Subjects
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
2013N165256_06 CONFIDENTIA L
FGF117360
162For male subjects in Arm A and B , to prevent pregnancy  in a female partner…
For male subjects in Arm C, there are no contraception restrictions.
Section 11 Data Management
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Patient reported data will be collected via paper questionnaires and will be entered 
into the eCRF centrally. Data will be checked for completeness by [CONTACT_377135] -compliance will be 
noted.
Section 12.1 Considerations of statistical design
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
The sections below show the p lanned dose cohorts as well as the decision rules, by  [CONTACT_377105], specify ing the number of subjects with a confirmed objective response (according to 
RECI ST 1.1) needed for continuing enrolment, orstoppi[INVESTIGATOR_16589] , and stoppi[INVESTIGATOR_377063] .  The methodology  is based on the predictive probability  of success if enrolment 
continues to 30 subjects [Lee, 2008].  The predictive probability  design is similar to a 
Green -Dahlberg design in that it allows for earl y stoppi[INVESTIGATOR_16589] .  The differences 
are th atbutthe predictive probability design allows for evaluation of stoppi[INVESTIGATOR_377064] a minimum enrolment has been 
reached whereas the Green -Dahlberg design does this at only  two stages one fixed 
interim and that the predictive probabilities methodology  allows for stoppi[INVESTIGATOR_377065] . at the end of enrolment . While the two designs have similar ty pe I 
and ty pe II error rates, the probability  of early  termination is greater with the predic tive 
probability  design.  A randomized Phase II or Phase III study  may  be conducted based on 
the results from this study
Section 12.2 Hypotheses
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
No formal statistical h ypotheses ar e being tested during the dose escalation portions of 
Arms A, B, and B or for Arm C.  Anal ysis of the data obtained from the dose escalation 
parts of Arms A and B the study will be focused...
For the dose expansion portions of Arms A and B the study , hypothesized response 
rates...
Section 12.3.1 Arm A: [COMPANY_004]3052230 + Paclitaxel + Carboplatin
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
2013N165256_06 CONFIDENTIA L
FGF117360
163Starting with a cohort of [ADDRESS_471912] a t ype I error rate (α) of 0.15 and 88% power.  The trial is designed to 
stop earl y for efficacy when the predictive probability  of success if the trial were to 
continue to the total sample size of 30 is greater than or equal to 90%. 11 and 86% 
power .  The trial is stopped earl y for futility  if the predictive probability  of success is less 
than 0.1%.  The Bay esian prior used in determining the design was Beta (0.3, 0.7), a 
relativel y non -informative prior with a mean response rate of 30%.  Under the null 
hypothesis, the expected sample size is 22.724.2 subjects and probabilit y of earl y 
termination (PET) is 9483.5%. Under the alternative hy pothesis, the expected sample size 
is 1729.7 subjects and the probability of early termination PET is 94.69%.
Section 12.3.2 Arm B: [COMPANY_004]3052230 + Docetaxel
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
An initial dose escalation will be used to establish the MTD. Once the final dose is 
confirmed, at least 1214and up to [ADDRESS_471913] a t ype I error rate (α) of 0.09 07and 8179% power.  The trial is 
designed to stop earl y for efficacy when the predictive probability of success if the trial 
were to continue to the total sample size of 30 is greater than or equal t o 90%.   The trial 
is stopped earl y for futility if the predictive probability  of success is less than 0.1%.  The 
Bayesian prior used in determining the design was Beta (0.15, 0.85), a relatively non -
informative prior with a mean response rate of 15%.  Unde r the null hypothesis, the 
expected sample size is 24.0 subjects and probability of early termination is 84.5%. 
Under the alternative hypothesis, the expected sample size is 29.5 subjects and the 
probability of early termination is 12.2%.
Section 12. Arm C : [COMPANY_004]3052230 + Pemetrexed + Cisplatin
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
12.3.3. Arm C: [COMPANY_004]3052230 + Pemetrexed + Cisplatin
An initial dose escalation will be used to establish the MTD. Once the final dose is 
confir med, at least [ADDRESS_471914] line setting of malignant pleural mesothelioma [Vogelzang, 2003].
The null hypothesis is:
H0: p ≤40%
The alternative hypothesis is:
HA:p ≥60%
2013N165256_06 CONFIDENTIA L
FGF117360
164Starting with a cohort of [ADDRESS_471915] a type I error rate (α) of 0.10 and 82% power.  The trial is 
stopped early for futility if the predictive probability of success is less than 0.1%.  
The Bayesian prior used in determining the design was Beta (0. 5, 0.5), a relatively 
non-informative prior with a me an response rate of 50%.  Under the null hypothesis, 
the expected sample size is 23.1 subjects and probability  of earl y termination (PET) is 
92.386.4%. Under the alternative h ypothesis, the expected sample size is 19.129.5
subjects and the probability of e arly termination PET is 90.613.7%.
12.3.3. Arm C: [COMPANY_004]3052230
A sample size of [ADDRESS_471916] of 
the null hy pothesis HO:p ≤5% vs HA: p≥20% again using predictive probability  design. 
This arm will not stop for success, but will stop for futility  if no response s are observed in 
18 subjects.
Section 12.7 Interim Analysis
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
For each stud y arm, after the initial 12 ( Arms A and C) or 14 (Arm B) subjects have 
enrolled at the final dose, response data will be reviewed on an ongoing basis and the 
number of responses observed will be compared with the stoppi[INVESTIGATOR_377042] 4.2.1 ( Arm A), Section 4.2.2 (Arm B), and Section 4.2.3 . and Section (Arm C).   
The rules are also shown in a tabul ar format below :
TABLE 14: Deleted right hand column for stoppi[INVESTIGATOR_25492].
TABLE 15: Deleted right hand column for stoppi[INVESTIGATOR_25492]. Deleted top 2 rows for 
12 and 13 patients.
FIGURE 2 and FIGURE 3: Deleted figures because no longer stoppi[INVESTIGATOR_377066].
TABLE 16: Added new table for Arm C.
Section [IP_ADDRESS] Adverse Events
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
For the dose -escalation portions of Arms A and B the study , dose -limiting toxicities...
Section 12.8.3 P atient Reported Outcomes
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
12.8.3. Patient Reported Outcomes
Change from baseline scores in LCSS and LCSS -meso will be calculated for all 
scales and timepoints. 10mm in change from b aseline were previously identified as 
clinically meaningful (P. Hollen, personal communication). Associations with 
2013N165256_06 CONFIDENTIA L
FGF117360
165efficacy assessments and between patient reported and clinician reported 
symptomatic will be explored when warranted. Further details will be provided in 
the RAP.
Section 12.8.5. Pharmacokinetic/Pharmacodynamic Analyses
REVI SED TEXT: (new text bold and underlined , deleted text in strikethrough)
Where evidence of activity  is seen, linear and/or non -linear mixed effect models may  be 
fitted to the data to estimate PKPD PK/PD parameters of interest (e.g. slope, baseline 
(E0), location concentration for 50% of maximum effect (EC50) and maximum effect 
(Emax)).
Section 12.8.6 Tumor Kinetics Analysis
REVI SED TEXT: (new text bold and underlined , deleted t ext in strikethrough)
Data from allsome arms of the study ...
2013N165256_06 CONFIDENTIA L
FGF117360
166Amendment 2
Where the Amendment Applies
This amendment applies to all sites.
Summary of Amendment Changes with Rationale
Amendment No.2: Sponsor medical monitor information was updated, the inclusion 
criterion for FGFR gene amplification was modified, clarifications were made to the 
Time and Events Table, vital sign measurements, and permitted concomitant 
medications; and male contraceptive requirements were corrected.
List of Specific Changes
Change 1: Inclusion criterion for FGFR gene amplification modified.
Section3.2.1 Inclusion Criteria
PREVIOUS TEXT:
3.Availability  of archival tumor tissue required for assessment of deregulated FGF 
pathway  signaling e.g. FGFR1 amplification or FGF2 over exp ression status based on 
emerging [COMPANY_004]3052230 preclinical data), provided no sy stemic therapy  has been 
given since the biops y was obtained. If archival tissue is not available, a fresh biopsy  
is required. Please refer to Section [IP_ADDRESS].  In Arms A and B, su bjects will be 
prospectivel y screened for FGFR1 gene amplification using a FI SH assay . For 
inclusion in this study , a ratio of FGFR1/CEN 8 of > 2 will be required. FGFR1 gene 
amplification will determined by  [CONTACT_377136].
REVISED TEXT: ( new t ext underlined , deleted text in strikethrough)
3. Availability  of archival tumor tissue required for assessment of deregulated FGF 
pathway  signaling e.g. FGFR1 amplification or FGF2 over expression status based on 
emerging [COMPANY_004]3052230 preclinical data), pro vided no sy stemic therapy  has been given 
since the biopsy  was obtained . If archival tissue is not available, a fresh biopsy  is 
required. Please refer to Section [IP_ADDRESS].  I n Arms A and B, subjects will be 
prospectivel y screened for FGFR1 gene amplification using a FI SH assay  (note, local 
testing is permitted for pre- screening of subjects prior to central testing ). For 
inclusion in this study , based on the central laboratory testing, FGFR1 gene 
amplification must meet one of the following criteria: a ratio o f FGFR1/CEN 8 of ≥2; 
or average number of FGFR1 signals per tumor nucleus of ≥6; or the percentage 
of tumor nuclei containing  ≥5 FGFR1 signals is ≥50%. FGFR1 gene amplification 
will determined by  [CONTACT_377136].
2013N165256_06 CONFIDENTIA L
FGF117360
167Change 2: Clarification for sta ge of disease and chemotherapy in Arm A.
Protocol Synopsis, Section3.2.1 Inclusion Criteria
PREVIOUS TEXT:
2.Histologicall y or c ytologically  confirmed diagnosis:
Arms A and B: Stage IV squamous NSCL C...
Arm A: Subjects who have received no prior therapy  for Stage IV disease....
Arm B: Subjects who have ... Stage IV disease...
Arm C: Subjects who have ... Stage IV disease...
REVISED TEXT: ( new text underlined , deleted text in strikethrough)
2.Histologicall y or c ytologically  confirmed diagnosis:
Arms A and B:Stage IV or recurrent metastatic squamous NSCL C...
Arm A: Subjects who have received no prior therapy for Stage IV or recurrent 
metastatic disease....
Arm B: Subjects who have ... Stage IV or recurrent metastatic disease...
Arm C: Subjects who have ... Stage IV or recurrent metastatic disease...
PREVIOUS TEXT:
2. Arm A: Subjects who have received no prior therapy for Stage IV disease. Note, to 
avoid an y undue delay  of initiating sy stemic chemotherapy  for these subjects with 
newly  diagnosed metastatic dis ease, it is allowed to initiate the first cycle of 
chemotherap y while the subject is still in screening for the present study . The first 
dose of [COMPANY_004]3052230 should then be given no later than the day  of the second cy cle 
of chemotherap y.
REVISED TEXT: ( new t ext underlined , deleted text in strikethrough)
2. Arm A: Subjects who have received no prior therapy  for Stage IV or recurrent 
metastatic disease . Note, to avoid any  undue delay  of initiating s ystemic 
chemotherap y for these subjects with newly  diagnosed me tastatic disease, it is 
allowed to initiate the first cy cle of chemotherap y whilst the subject is still in 
screening for the present study while eligibility for the study is still being 
determined, as long as the first dose of [COMPANY_004]3052230 is given no later than 
Cycle 2 Day 1 of chemotherapy.
2013N165256_06 CONFIDENTIA L
FGF117360
168Section 4.2.1 Arm A
PREVIOUS TEXT:
Arm A: Screening procedure for subjects on chemotherap y
To avoid any undue delay in initiating s ystemic chemotherap y for subjects with newly 
diagnosed Stage IV disease, the first cy cle of chemotherapy  may  be initiated while 
subjects are still in screening for the present study.  
REVISED TEXT: ( new text underlined , deleted text in strikethrough)
Arm A: Screening procedure for subjects on chemotherap y
To avoid an y undue delay in initiatin g systemic chemotherap y for subjects with newly 
diagnosed Stage IV or recurrent metastatic disease, the first cy cle of chemotherapy  
may be initiated while subjects are still in screening determination of eligibility is being 
completed for the present study .
Change 3: Other clarifications to Inclusion/Exclusion criteria.
Section3.2.1 Inclusion Criteria
10. Added footonotes for hemoglobin (a) and serum total bilirubin (b):
a. Subjects should meet criteria in the absence of hematopoetic g rowth factors 
or transfusions.
b. If the serum total bilirubin is elevated at screening but the direct bilirubin is 
≤ULN then the subject may be allowed to enter study .
Section3.2.2 Exclusion Criteria
PREVIOUS TEXT:
10. Symptomatic leptomeningeal or brain metastases or spi[INVESTIGATOR_110638].
NOTE: Subjects previously  treated for these conditions that have had stable CNS disease 
(verified with consecutive imaging studies) for >[ADDRESS_471917] -procedure complications. I n addition , subjects 
treated or currently  taking enz yme-inducing anticonvulsant are allowed on study .
REVISED TEXT: ( new text underlined , deleted text in strikethrough)
10.Symptomatic leptomeningeal or brain metastases or spi[INVESTIGATOR_13377].
NOTE: Subjects pre viously treated for these conditions are eligible if they meet 
both of the criteria below:
2013N165256_06 CONFIDENTIA L
FGF117360
169(1) have had stable CNS disease for at least 4 weeks after local therapy as 
assessed by [CONTACT_9661] (contrast enhanced magnetic resonance imaging (MRI) or 
computed tomography (CT)), and
(2) are asymptomatic and off corticosteroids, or are on stable dose of 
corticosteroids for at least 4 weeks prior to Day 1.
Change 4: Clarifications to preparation of [COMPANY_004]3052230, Time and Events 
Table, vital sign measurements, permitted c oncomitant medications.
Section 5.2 Preparation/Handling/Storage of [COMPANY_004]3052230
Added to end of paragraph on Preparation:
Please refer to SPM for recommended IV supplies.
Section 7.1 Time and Events Table (footnotes)
PREVIOUS TEXT:
Visit Window Must occur within the window specified. D=day
Physical exam, weight, and height (baseline onl y) Complete phy sical exam at 
screening. Abbreviated disease -oriented phy sical exam subsequently .
Ophthalmologic Exam To be performed by [CONTACT_15922].
Vital Signs Within -20/+10mins of [COMPANY_004]3052230 i.v. Arm A: -10mins of i.V. 
start
Hematology  and Chemistry See Table 11 for anal ytes. In addition Arm A: additional 
cycles D8 while dosing on paclitaxel + carboplatin only
Circulating Biomarkers Plasma sample collected predose. 
Blood sample for PGx Collect only  if PGx informed consent has been signed. 
Brain Scan within 8 weeks of C1D1
Bone Scan within 12 weeks of C1D1
ARM A: Paclitaxel + Carboplatin [COMPANY_004]3052230 infused & observed 1 hr prior to 
chemotherap y doses.
REVISED TE XT: ( new text underlined , deleted text in strikethrough)
Visit Window Tissue prescreen for Arms A and B within 60 day s and all 
other screening assessments within 30 day s of C1D1. Visit windows of ±2 day s during 
study  through EOT, +7 day s for F/U. Cy cle 1 Day 9 assessments for Arm C only .
2013N165256_06 CONFIDENTIA L
FGF117360
170Physical exam, weight, and height (baseline onl y) Not needed C1D1 if screening 
assessments within prior [ADDRESS_471918].
Vital Signs Arms A + B: Within [ADDRESS_471919] chemotherapy 
infusion and within 20 min before start of [COMPANY_004]3052230 infusion. Arm C: Before 
start of [COMPANY_004]3052230 infusion
Hematolog y and Chemistry Not needed C1D1 if screening assessments within prior 
72 hrs . See Table 11 for anal ytes. In addition Arm A: additional cy cles D8 while dosing 
on paclitaxel + carboplatin only
Circulating Biomarkers Plasma sample collected predose (+7 days prior to C1D1 )
Blood sample for PGx Collect any time on study but only  if PGx informed consent has 
been signed; preferred on C1D1 after dosing.
Brain Scan within 35 day s of C1D1
Bone Scan within 4 weeks of C1D1
ARM A: Paclitaxel + Carboplatin [COMPANY_004]3052230 i nfused & observed 1 hr prior to 
chemotherap y doses. May start chemotherapy during screening period, see inclusion 
#2
Section 7.3.3 Vital Signs
PREVIOUS TEXT:
Vital sign measurements will include sy stolic and diastolic blood pressure, temperature, 
respi[INVESTIGATOR_377067].  Vital signs should be measured after resting for at least 5 
minutes … . Refer to the SPM for details regarding measurement of vital signs.
REVISED TEXT: ( new text underlined , deleted text in strikethrough)
Vital sign measurements wi ll include sy stolic and diastolic blood pressure, temperature, 
respi[INVESTIGATOR_352363].  All vital sign measurements will be obtained after the 
subject has rested for at least 5 minutes .... Whenever blood pressure and heart rate 
are measured at th e same nominal time as a blood draw, the blood pressure and 
heart rate will be prior to the blood draw . Refer to the SPM for details regarding 
measurement of vital signs
Section 7.3.6 Ophthalmologic Examinations
PREVIOUS TEXT:
These exams will be performed by [CONTACT_377137]...
2013N165256_06 CONFIDENTIA L
FGF117360
171REVISED TEXT: ( new text underlined , deleted text in strikethrough)
These exams will be performed by  [CONTACT_377138]...
Section 9.1 Permitted Medications
PREVIOUS TEXT:
Subjects should receive full supportive care during the stud y, including transfusion of 
blood and blood products, and treatment with antibiotics, antiemetics, antidiarrheals, and 
analgesics, as appropriate.
REVISED TEXT: ( new text underlined , deleted text in strikethrough)
Subjects should receive full supportive care during the stud y, including transfusion of 
blood and blood products, and treatment with antibiotics, antiemetics, antidiarrheals, and 
analgesics, as appropriate. Pre-medication for chemotherapy is allo wed per 
institutional guidelines.
Change 3: Correction of contraceptive requirements.
Section 3.2.1 Inclusion Criteria
PREVIOUS TEXT:
6. Women of childbearing potential must have a negative serum pregnancy  test within 
[ADDRESS_471920], to allow for clearance of any altered sperm.
REVISED TEXT: ( new text underlined , deleted text in strikethrough
6. Women of childbearing potential must have a negative serum pregnanc y test within [ADDRESS_471921]
7. For Arm A and B : Men with a female partner of childbearing potential must have 
either had a prior vasectomy  or agree to use effective contraception as described in 
Section 10.1.[ADDRESS_471922] , to allow for clearance of an y 
altered sperm. Arm C: No male contraception restrictions .
Section 10.1.2
PREVIOUS TEXT:
To prevent pregnancy  in a female partner or to prevent exposure of any  partner to the 
study  treatment from a male subject’s semen, male subjects must use one of the followi ng 
contraceptive methods until 4weeks after the last dose of [COMPANY_004]3052230 or [ADDRESS_471923]…
REVISED TEXT: ( new text underlined , deleted text in strikethrough)
For male subjects in Arm A and B , to prevent p regnancy  in a female partner or to 
prevent exposure of an y partner to the study treatment from a male subject’s semen, male 
subjects must use one of the following contraceptive methods until 4weeks after the last 
dose of [COMPANY_004]3052230 or [ADDRESS_471924]
For male subjects in Arm C, there are no contraception restrictions.
2013N165256_06 CONFIDENTIA L
FGF117360
173Amendment 1
Where the Amendment Applies
This amendment is applicable to [LOCATION_006] site(s) only .  
Summary of Amendment Changes with Rationale
Amend ment No.1: This amendment modified contraceptive practice and adjusted QTc 
stoppi[INVESTIGATOR_377068].  
List of Specific Changes
Change 1: Contraception Guidelines
RATIONALE FOR CHANGE:
The protocol has been clarified to r eflect the SPC for paclitaxel, carboplatin, and 
docetaxel which recommend using effective contraception methods for a period of 
6months.  I n addition, the protocol has been clarified regarding the contraception timing 
for [COMPANY_004]3052230 to allow [ADDRESS_471925] -therap y of [COMPANY_004]3052230 given there are no genotoxicity  
concerns.
Section 3.2.1 Inclusion Crite ria:
PREVIOUS TEXT
6. Women of childbearing potential must have a negative serum pregnancy test within [ADDRESS_471926] dose of study  treatment.
7. For Arms A and B: Men with a female partner of childbearing potential must have 
either had a prior vasectomy  or agree to use effective contraception as described in 
Section 10.1.[ADDRESS_471927] dose of study  
treatment [and for at least [ADDRESS_471928] dose of chemotherap y given in this study ] 
to allow for clearance of any altered sperm. Arm C: No male contraception restrictions.
REVISED TEXT: ( new text underlined , deleted text in strikethrough )
6. Women of childbearing potential must have a negative serum pregnancy test within [ADDRESS_471929] .
7.    For Arms A and B: Men with a female partner of childbearing potential must have 
either had a prior vasectomy  or agree to use effective contrac eption as described in 
Section 10.1.[ADDRESS_471930] dose of study  
2013N165256_06 CONFIDENTIA L
FGF117360
174treatment [and for at least [ADDRESS_471931] dose of [COMPANY_004]3052230, whichever is lates t,to allow for clearance of 
any altered sperm. Arm C: No male contraception restrictions.
Section 7.3.8 Pregnancy Testing and Reporting :
PREVIOUS TEXT
If a female subject is of childbearing potential, she must have a serum -HCG pregnancy 
test performed w ithin [ADDRESS_471932] dose of study  treatments.
REVISED TEXT: ( new text underlined , deleted text in strikethrough )
If a female subject is of childbearing potential, she must have a serum -HCG pregnancy 
test performed wi thin [ADDRESS_471933].
Section 10.1.1 Female Subjects
Moved to end of section:
PREVIOUS TEXT
Complete abstine nce from sexual intercourse for [ADDRESS_471934] dose of study  
treatment.
REVISED TEXT: ( new text underlined , deleted text in strikethrough )
Complete abstinence from sexual intercourse or contraception must be practiced for 
14days prior to first dose of study  treatment, through the dosing period, and for at least 
[ADDRESS_471935]’s semen, male 
subjects m ust use one of the following contraceptive methods…..
For subject in Arm C, there are no restrictions.
2013N165256_06 CONFIDENTIA L
FGF117360
175REVISED TEXT: ( new text underlined , deleted text in strikethrough )
For subjects on Arm A and B, To prevent pregnancy  in a female partner or to prevent 
exposure of an y partner to the study  treatment from a male subject’s semen, male 
subjects must use one of the following contraceptive methods until 4weeks after the 
last dose of [COMPANY_004]3052230 or [ADDRESS_471936] …..
For subject in Arm C, there are no restrictions.
Change 2: QTc stoppi[INVESTIGATOR_377069]:
Country  Specific Requirements previously  specified the QTc stoppi[INVESTIGATOR_377070] 
500msec for [LOCATION_009].  The QTc stoppi[INVESTIGATOR_377071] s pecific appendix have 
been modified to include [LOCATION_006] along for [LOCATION_009] for the QTc stoppi[INVESTIGATOR_377072].  
Section 4.7.2, QTc Stoppi[INVESTIGATOR_377073], please refer to Appendix 7 for the French specific QTc 
stoppi[INVESTIGATOR_3418].
REVISED TEXT (new text underlined , deleted text in strikethrough ):
For subjects recruited in [LOCATION_009] or the [LOCATION_006] , please refer to Appendix 7 for the French 
country specific QTc stoppi[INVESTIGATOR_3418].
15.8 Appendix 7: Country Specific Requirements
PREVIOUS TEXT
[LOCATION_009]:
French Specific QTc Stoppi[INVESTIGATOR_2121]:
In line with local requirements, a French subject that meets the criteria QTc1 below will 
have stud y treatment withheld...
REVISED TEXT (new text underlined , deleted text i n strikethrough ):
[LOCATION_009] or [LOCATION_006] :
French or [LOCATION_006] Specific QTc Stoppi[INVESTIGATOR_2121]:
2013N165256_06 CONFIDENTIA L
FGF117360
176In line with local requirements, French subjects that meet the criteria QTc1 below will 
have study  treatment [COMPANY_004]3502230 withheld:
QTcB > [ADDRESS_471937] study treatment withheld :
QTc > 500 msec
1Based on average corrected QT (QTc) interval value of triplicate electrocardiograms 
(ECGs) to include manual over -read. For example, if an ECG demonstrate s a prolonged 
QT interval, obtain [ADDRESS_471938] study  treatment
[COMPANY_004]3502230 withheld.
QT interval (corrected for HR) ≥500 msec; [COMPANY_004]3502230 will be permanently 
discontinued.
QTc interval increase from baseline ≥ 60 msec and maximum QTc  < 500 msec; 
[COMPANY_004]3502230 may be restarted at a reduced dose level after discussion with the 
medical monitor once the QTc returns to baseline.  If QTc prolongation meeting 
stoppi[INVESTIGATOR_377074] -challenge, [COMPANY_004]3502230 must be permanently 
discontinued .
If the QTc prolongation resolves to Grade [ADDRESS_471939] will benefit from further treatment